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Abstract
Asthma has been understood to affect the airways in a spatially heterogeneous manner for over
six decades.

Computational models of the asthmatic lung have suggested that airway

abnormalities are diffusely and randomly distributed throughout the lung, however these
mechanisms have been challenging to measure in vivo using current clinical tools. Pulmonary
structure and function are still clinically characterized by the forced expiratory volume in onesecond (FEV1) – a global measurement of airflow obstruction that is unable to capture the
underlying regional heterogeneity that may be responsible for symptoms and disease
worsening. In contrast, pulmonary magnetic resonance imaging (MRI) provides a way to
visualize and quantify regional heterogeneity in vivo, and preliminary MRI studies in patients
suggest that airway abnormalities in asthma are spatially persistent and not random. Despite
these disruptive results, imaging has played a limited clinical role because the etiology of
ventilation heterogeneity in asthma and its long-term pattern remain poorly understood.
Accordingly, the objective of this thesis was to develop a deeper understanding of the
pulmonary structure and function of asthma using functional MRI in conjunction with
structural computed tomography (CT) and oscillometry, to provide a foundation for imaging
to guide disease phenotyping, personalized treatment and prediction of disease worsening. We
first evaluated the biomechanics of ventilation heterogeneity and showed that MRI and
oscillometry explained biomechanical differences between asthma and other forms of airways
disease. We then evaluated the long-term spatial and temporal nature of airway and ventilation
abnormalities in patients with asthma. In nonidentical twins, we observed a spatially-matched
CT airway and MRI ventilation abnormality that persisted for seven-years; we estimated the
probability of an identical defect occurring in time and space to be 1 in 130,000. In unrelated
asthmatics, ventilation defects were spatially-persistent over 6.5-years and uniquely predicted
longitudinal bronchodilator reversibility. Finally, we investigated the entire CT airway tree
and showed that airways were truncated in severe asthma related to thickened airway walls and
worse MRI ventilation heterogeneity. Together, these results advance our understanding of
asthma as a non-random disease and support the use of MRI ventilation to guide clinical
phenotyping and treatment decisions.

ii

Keywords
Asthma, Airways, Chronic Obstructive Pulmonary Disease, Computed Tomography,
Hyperpolarized Noble Gas MRI, Pulmonary Imaging, Pulmonary Structure-function,
Ventilation Heterogeneity

iii

Summary for Lay Audience
Asthma is a chronic lung disease that causes the air a person breathes in to unevenly spread
throughout their lungs. The causes of this are still not well-known because the current tools to
measure lung function cannot locate where inside the lungs the air does not go. To better
understand this, computer models have been created and showed that asthma lung
abnormalities are randomly spread throughout the whole lungs, but magnetic resonance
imaging (MRI) of the lung showed that abnormalities stay in the same lung locations over time
and are not random. Despite these new results, MRI of the lungs is not used often for asthma
patients because the causes of MRI measurements and how they change over long periods of
time are not known. This thesis measured lung structure and function in asthma using
functional MRI and structural computed tomography (CT) imaging to better understand how
and why air unevenly spreads throughout the lungs in patients with asthma and create a new
way to guide asthma treatments to help air spread more evenly. First, we evaluated lung
biomechanics and saw different biomechanical measurements in patients with asthma
compared to different lung diseases and healthy people. We then evaluated MRI and CT lung
abnormalities twice over 6-7 years in two different groups of patients. Twins with asthma had
a lung abnormality in the exact same location that stayed the same after 7 years. We calculated
the chances of an identical abnormality like this occurring in two people to be 1-in-130,000,
or less likely than the chances of someone being struck by lightning. In a larger group of nonrelated asthma patients, MRI and CT abnormalities remained in the same lung locations over
6.5 years and MRI abnormalities predicted future asthma worsening. Finally, we evaluated all
airways we could see on CT images and saw that patients with severe asthma had less airways
and this was related to thicker airway walls and worse lung function. Together, these results
provide a better understanding of lung structure-function in asthma that are not random and
support the use of MRI to guide patient-specific treatment.
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CHAPTER 1
1

INTRODUCTION

Asthma is a chronic airways disease; for over 2500 years, airway abnormalities in asthma
have been understood to be distributed randomly throughout the lung. There is now
evidence to suggest that asthma is regionally heterogeneous and not random. In this thesis,
the structure and function of asthma are studied using pulmonary magnetic resonance
imaging (MRI) and computed tomography (CT) to develop a deeper understanding of the
asthmatic lung.

1.1 Motivation and Overview
Asthma is a chronic respiratory disease that affects approximately 300 million people in
the world.1 Worldwide prevalence rates of asthma have been consistently increasing over
the last 20 years and this estimate is expected to increase to 400 million by 2025.1 In
Canada, asthma prevalence has increased 67% since 2000 and currently affects 3.8 million
people (10.8%).2 As shown in Figure 1-1, asthma is the most common chronic respiratory
disease in Canada, accounting for 78% of all cases.3 Asthma affects people of all ages,
although prevalence rates are highest for those younger than 20 years old and prevalence
rates drop until age 65 and older, after which the rates begin to increase.4

Figure 1-1 Prevalence of asthma in Canada
Left: Proportion of all respiratory diseases. Data from the Public Health Agency of Canada,
Life and Breath: Respiratory Disease in Canada (2007).3
Right: Asthma prevalence by age. Data from Public Health Agency of Canada, A Trend
Analysis of the Health of Canadians from a Healthy Living and Chronic Disease
Perspective (2016).4

1

Because of its high prevalence and chronicity, asthma poses a large burden on the economy
and healthcare system. The number of patients hospitalized annually for asthma is greater
than that of heart failure and diabetes and approximately 16% of these patients will
experience a repeat hospitalization within one year of initial admission (Figure 1-2).5 In
contrast to other chronic diseases however, hospitalizations related to asthma are most
common for patients younger than 20 years of age.5 In Ontario alone, asthma care cost
approximately $1.8 billion in 2011 and is estimated to grow to $97 billion in the next 20
years.6

Figure 1-2 Hospitalizations for chronic diseases in Canada
Left: Repeat hospitalizations after first admission. Right: Hospitalizations by age groups.
Data from Canadian Institute for Health Information (CIHI) Health Indicators 2008.5
Notably from Figure 1-1 and Figure 1-2, chronic obstructive pulmonary disease (COPD)
is the second most common respiratory disease in Canada3 and accounts for the greatest
total number of hospitalizations, especially for people aged 60 and older.5 COPD is even
more costly than asthma, costing approximately $3.9 billion in Ontario in 2011.6
Moreover, in the next 20 years, the economic burden of COPD is expected to rise to $311
billion.6 Together, asthma and COPD affect over 5 million people in Canada2 and 500
million people in the world,7 and contribute to the third leading cause of death worldwide.8
Although often recognized as distinct chronic respiratory diseases, asthma and COPD have
also been regarded by some as heterogeneous and overlapping conditions. Despite the
traditional idea that COPD is caused by tobacco smoke and largely preventable, asthma is
also a risk factor for development of COPD independent of tobacco smoking.9,10
Epidemiological studies suggest that 10% of patients with asthma will progressively
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develop persistent airflow obstruction and COPD in their lifetime11,12 and these patients
utilize more healthcare resources13 and experience more hospitalizations14 than those with
COPD alone. These alarming findings highlight the need for a deeper understanding of
pathophysiology, treatment and management of chronic respiratory disease.
Since its first description over 2500 years ago,15 asthma has been idealized as a diffuse
airways disease with variable symptoms and airflow limitation. Substantive research has
generated new knowledge that has driven a paradigm shift in the understanding of these
concepts. The notion of ventilation heterogeneity in asthma was first introduced over 60
years ago using inert gas washout16,17 and nuclear medicine imaging techniques.18,19
Currently however, airflow limitation and its response to treatment or progression over
time are monitored using the forced expiratory volume in one second (FEV1) – a simple
and inexpensive spirometry measurement of airflow obstruction. FEV1 provides only a
global measurement of lung function that is unable to capture the regional heterogeneity of
airway abnormalities that may be responsible for symptoms and disease worsening.
Computational modeling studies have suggested that the regional heterogeneity in asthma
can be described by randomly distributed airway abnormalities throughout the whole
lung,20,21 however these mechanisms have been challenging to measure in vivo using
current clinical tools. As a result, asthma is still regarded as a random disease and
treatments are geared towards all airways and not individualized. Moreover, inhaled
therapies are not effective in all patients with asthma for various reasons such as poor
regional drug distribution or drug resistance, but spirometry is not able to identify the
reasons that cause lack of treatment efficacy.
Pulmonary functional magnetic resonance imaging (MRI) using inhaled noble gases
provides a means to directly visualize and quantify regional gas distribution in vivo.
Preliminary MRI findings in asthma demonstrate focal ventilation abnormalities that are
spatially persistent over time.22,23 These disruptive results contradict in silico results and
suggest that asthmatic airway abnormalities may not be random, yet pulmonary imaging
has played a limited role in asthma research and clinical care because the etiology of
ventilation heterogeneity and its long-term pattern remains poorly understood. In contrast,
imaging has played a large role in developing an understanding of the pulmonary structure-
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function relationships in COPD owing to multiple large cohort studies that have
incorporated imaging using x-ray computed tomography (CT)24-27 and inhaled gas MRI.28
Whereas COPD is characterized by persistent and progressive airflow limitation, overlap
between asthma and COPD exists11,12,29 and there is something to be learned from the
imaging results in COPD. Pulmonary imaging has the potential to uncover the structural
mechanisms and physiological relevance of regional ventilation heterogeneity in asthma
and accordingly, this thesis focuses on the investigation of the pulmonary imaging
structure-function relationships in asthma to develop a deeper understanding of the
asthmatic lung. Armed with such an understanding, we have the potential to guide
treatment decisions and regional therapies, predict disease worsening, and improve patient
outcomes.
In this Chapter, the relevant background information is provided to motivate the original
research presented in Chapters 2-5. A general overview of typical pulmonary structure
and function is first provided (1.2), followed by the pathophysiology of asthma and COPD
(1.3) and a brief description of current knowledge of asthma-COPD overlap. Clinical tools
to measure pulmonary function are then described including the expected measurement
deviations for asthma and COPD (1.4) as well as clinical assessments for characterizing
each (1.5). The current state of imaging techniques is subsequently described in the context
of imaging biomarkers to measure and understand pulmonary structure and function in
asthma and COPD (1.6). Finally, the specific hypotheses and objectives of the work
presented in this thesis are introduced (1.7).

4

1.2 Respiratory Structure and Function
The primary function of the respiratory system is gas exchange. The respiratory system
comprises the nasal and oral cavities, pharynx, larynx, airways, lungs, chest wall and
diaphragm; in this section, the structure and function of the airways and alveoli within the
lungs are presented. The airways serve as conduits for the movement of air to the alveoli
where gas exchange occurs across the alveolar-capillary interface. The overall function of
the airways and alveoli is to deliver oxygen and remove carbon dioxide from the
bloodstream by the process of ventilation.

1.2.1 Airways: Conducting and Respiratory Zones
Inhaled air first enters the respiratory system through the nasal or oral passages and then
moves through the pharynx followed by the larynx, collectively known as the upper
airways. Below the larynx, and as shown in Figure 1-3, the lower airways are grouped
into the conducting and respiratory zones based on their structural and functional
characteristics. The conducting zone acts as a conduit to carry air to the respiratory zone
where gas exchange occurs. In general, each airway starting from the trachea continuously
bifurcates into two daughter branches until the alveolar sacs at generation 23.
Conducting Zone
The conducting zone comprises the first 16 airway generations from the trachea (generation
0) to the terminal bronchioles (generation 16).30 The trachea is a long tube lined with
cartilage and muscle that connects the upper airways directly to the lungs and
asymmetrically bifurcates into the left and right main bronchi to supply each lung. The
main bronchi divide into the lobar bronchi that supply the five lung lobes – the upper,
middle and lower lobes in the right lung and upper and lower lobes in the left lung. Lobar
bronchi subsequently divide into segmental bronchi, which supply air to the 19
bronchopulmonary segments that are anatomically and functionally distinct. Figure 1-3
shows the anatomical labels for the airways from the trachea to the segmental level. The
airways are not individually named beyond the segmental bronchi. From here, the airways
become narrower, shorter and more numerous as they branch to supply all areas of the
lungs. The airways from the trachea up to the small bronchi at generation 11 are lined with
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cartilage to maintain patency. Smooth muscle is interleaved with cartilage beginning in
the lobar and segmental bronchi and is typically circumferentially wrapped around the
airway walls.

At the 12th generation, the airways become embedded in the lung

parenchyma and are lined with smooth muscle only, relying on the elastic forces to tether
the airways open.31 The conducting zone ends at the terminal bronchioles, where the
number of airways has increased more rapidly than the calibre diminished such that the
total cross-sectional area exponentially increases. As the name suggests, the conducting
zone conducts and humidifies air to the distal lung. These airways do not participate in gas
exchange and are thus known as the anatomic deadspace – approximately 150 mL of air
remains in the conducting airways during each breath.30
Respiratory Zone
The respiratory zone begins at the respiratory bronchioles (generation 17) and includes the
remaining distal airways up to the alveolar sacs (generation 23). Compared with the
conducting zone, the airways in the respiratory zone change little in diameter as they
branch. As shown in Figure 1-3, the respiratory bronchioles are the point where the
airways begin to be lined with alveoli to facilitate gas exchange. There are increasingly
more alveoli in the airway walls as the respiratory bronchioles branch and increase in
airway generation. The alveolar ducts directly follow the respiratory bronchioles and have
no airway walls but are completely lined with alveoli. The respiratory zone and entire
airway tree terminate at the alveolar sacs, which are completely surrounded by alveoli to
maximize surface area available for gas exchange. Although the distance from the first
respiratory bronchiole to the most distal alveolus is only a few millimetres, the respiratory
zone accounts for approximately 2.5-3.0 L of lung volume at rest30 because of its millions
of airways.
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Figure 1-3 Airway tree schematic and airway labels
Top: The human airway tree consists of the conducting zone (generations 0-16) and
respiratory zone (generations 17-23); corresponding airway generation, number, diameter
and cross-sectional area are shown. Adapted from West & Luks, Respiratory Physiology:
The Essentials, Tenth Edition30 and Weibel et al, Morphometry of the Human Lung.32
Bottom: Segmental airway labels. Based on Boyden, Segmental Anatomy of the Lung33
and adapted from Tschirren et al, IEEE Trans Med Imaging (2005).34
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1.2.2 Alveoli: Site of Gas Exchange
The alveoli are the direct site of gas exchange at the terminal ends of the airway tree on the
respiratory bronchioles, alveolar ducts and alveolar sacs. On average, there are 480 million
alveoli in the human lung (range 274-790 million depending on height and lung volume of
the individual),35 each with a diameter of approximately 200 m.30 Pulmonary capillaries
wrap around each alveolus to create the blood-gas interface between the alveolar
epithelium and capillary endothelium. Oxygen and carbon dioxide are exchanged across
the blood-gas interface by passive diffusion according to Fick’s law – the amount of gas
that moves across the membrane is proportional to its area and inversely proportional to its
thickness.30 The blood-gas interface is extremely thin (0.2-0.3 m)36 and, together with
the large alveolar surface area (50-100 m2),30 this makes the lung well-suited for efficient
exchange of oxygen and carbon dioxide.

1.2.3 Ventilation
The process by which air travels to and from the alveoli is known as ventilation. Pressure
gradients between the external environment and the alveoli drive airflow from the upper
airways to the alveoli by bulk flow.30 Inspiration is actively initiated when the diaphragm
and intercostal muscles contract, causing the alveolar pressure to decrease below that of
the environment and air to flow into the lungs. Expiration occurs passively when the
muscles relax and alveolar pressure increases beyond that of the environment, driving the
gas out of the lungs. The lung and chest wall are elastic and will tend to return to their
equilibrium positions via elastic recoil after being actively expanded during inspiration.
Ventilation is expressed as the volume of air that is exchanged between the external
environment and body as a function of time in Equation 1-1:
Equation 1-1

Total ventilation [L/minute] = Breathing rate [/min] ∙VT [L]

The total volume of air inhaled with each breath, known as tidal volume (VT), is 0.5 L on
average. The ventilation rate for healthy adults is 12-20 breaths/minute – assuming a rate
of 15 breaths per minute, the total ventilation would be 7.5 L/min. However, as described
previously, not all inhaled gas reaches the alveoli and participates in gas exchange because
of the 150 mL of deadspace (VD) in the conducting zone. Thus, Equation 1-1 represents
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total ventilation to the entire lung. It is important to determine the amount of fresh air
participating in gas exchange, known as the alveolar ventilation as in Equation 1-2:
Equation 1-2

Alveolar ventilation [L/min] = Breathing rate [/min] ∙ (VT-VD) [L]

In the same way as previously, assuming a breathing rate of 15 breaths per minute, the
alveolar ventilation would be 5.25 L/min. Although 7.5 L of air enters the lungs every
minute, only 5.25 L reaches the alveoli.

1.3 Pathophysiology of Asthma and COPD
Asthma and COPD are both obstructive lung diseases characterized by expiratory airflow
limitation. Though once recognized as distinct disease entities, new understandings and
definitions in the last 20 years acknowledge overlap of asthma and COPD and highlight
similarities and differences between the two. Importantly, the airway and parenchymal
abnormalities within an individual patient are regionally heterogeneous in both asthma and
COPD. Here, the underlying pathophysiologies of the respiratory system in asthma and
COPD are first presented as distinct entities, followed by a description of overlap between
asthma and COPD.

1.3.1 Asthma
Asthma is characterized by variable airflow limitation that results in intermittent symptoms
of shortness of breath, wheeze, cough and chest tightness.37 Pathophysiology of asthma is
confined to the airways and derives from a complex interplay of structural and
inflammatory changes that lead to airway wall thickening and edema, airway
hyperresponsiveness, mucus hypersecretion and ultimately, luminal narrowing.

This

phenomenon is shown in Figure 1-4 – compared with a healthy airway, the asthmatic
airway wall is markedly thickened and encroaches on the airway lumen.38 Structural
airway changes include goblet cell hyperplasia,39 subepithelial fibrosis,40 angiogenesis,41
submucosal gland hyperplasia and hypersecretion,42 and smooth muscle hypertrophy and
hyperplasia,43 collectively known as airway remodeling.

Airway remodeling and

inflammation together lead to thickening of the airway wall and subsequent airflow
obstruction via bronchoconstriction by smooth muscle and luminal obstruction by mucus
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and debris. Airway inflammation in asthma involves the interactions of many immune
cells, however is predominantly eosinophilic.38 Eosinophil levels are increased in both the
airway wall and lumen,44 and contribute to wall thickening and luminal plugging, trigger
bronchoconstriction and mucus secretion, and may also play a role in driving the
remodeling process.45 Bronchoconstriction occurs when the smooth muscle in the airway
walls contracts and narrows the airway lumen; bronchoconstriction may be further
exaggerated in airway hyperresponsiveness to various stimuli or irritants, such as allergens
or exercise. Ultimately, narrowed and obstructed airway lumens increase the resistance to
airflow in asthmatic airways and restricts airflow into and out of the lung. Although the
lung parenchyma is spared in asthma, airway abnormalities affect the entire bronchial tree
including large and small airways.46 It is important to note that asthma is a heterogeneous
condition and the relative contributions of each underlying component may be different
between patients.
There is no one single cause of asthma, but rather a number of host and environmental
factors are thought to contribute to its development.47 The causes of asthma are beyond
the scope of this thesis, however briefly, host factors may include genetic variants,48 family
history of asthma49 or sex,50 whereas environmental factors may include allergen
sensitization,51 respiratory viruses52 and air pollution.53 Onset of asthma commonly begins
in childhood, but may occur at any age. Airflow obstruction in asthma is conventionally
recognized as reversible with bronchodilator treatment, however may become persistent
over time.29

1.3.2 COPD
In contrast to asthma, COPD is characterized by persistent airflow limitation and symptoms
of shortness of breath, cough and sputum production.54 COPD arises from chronic
inflammation that, as shown in Figure 1-4, affects both the airways and lung parenchyma.
Notably, inflammation in COPD consists primarily of neutrophils and macrophages.55 The
mechanisms of airflow obstruction in COPD are associated with airway remodeling which
increases resistance to airflow,56,57 and parenchymal damage that reduces the lung’s elastic
recoil force.58 Structural airway remodeling in COPD occurs primarily in the small
conducting airways59 (generations 4-16 with diameter <2 mm) and causes bronchial wall
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thickening by submucosal gland hypertrophy60 and connective tissue deposition.42
Inflammatory infiltrates also trigger mucus hypersecretion, which can lead to luminal
plugging as is seen in the COPD-afflicted airway in Figure 1-4.

Figure 1-4 Airway and parenchymal pathophysiology in asthma and COPD
Top: Compared with healthy airways where the wall is thin and lumen is patent, asthmatic
airway shows thickened airway wall via increased smooth muscle mass, muscle
constriction and inflammation. In COPD, airway walls are inflamed and thickened with
inflammatory exudate of mucus and cells partially occluding the lumen. Healthy and
COPD airway histology adapted from Hogg, Lancet (2004).59 Asthma airway histology
adapted from Saetta & Turato, Eur Respir J (2001).38
Bottom: Healthy lung parenchyma shows in-tact alveoli, whereas in COPD, alveolar walls
are destroyed and airspaces are enlarged. There is no parenchymal disease in asthma.
Parenchymal histology adapted from Woods et al, Magn Reson Med (2006).61
Permissions to reproduce all images are provided in Appendix A.
Emphysema refers to destruction of the lung parenchyma within the respiratory zone. This
loss of tissue reduces the elasticity of the lung tissue such that the lungs are unable to
completely empty and become hyperinflated. Emphysema also contributes to loss of
tethering forces holding the small airways open and in severe cases, obliterates terminal
airways causing reduced total airway cross-sectional area. Emphysema can be divided into
different types based on where along the respiratory zone the damage occurs.62,63 Most
relevant to this thesis is centrilobular emphysema, which results from the destruction of the
respiratory bronchioles while preserving the alveolar ducts and sacs and is the pattern most
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commonly observed in COPD caused by cigarette smoking.59 Regardless of the type of
emphysematous lung damage, the airspaces become permanently enlarged, reducing the
surface area of the lung available for gas exchange. Most patients with COPD will have
some combination of both airways disease and emphysema, while few patients have
extremes of one or the other.64
Tobacco cigarette smoking has been recognized as the main cause of and largest risk factor
for COPD development, however it is well understood now that only approximately 20%
of smokers will develop COPD and up to 30% of patients with COPD are life-long neversmokers.65,66

A number of other host and environmental factors have now been

identified,67 including genetic variants,68,69 suboptimal lung development in childhood,70
occupational exposures,71 air pollution,72 childhood respiratory infections,73 as well as lifelong asthma.9 Onset of COPD typically occurs after age 40,54 however may occur earlier
in life due to genetic conditions such as alpha-one antitrypsin deficiency.

1.3.3 Asthma-COPD Overlap
The two previous sections describe the extremes of asthma and COPD that are easily
identified. Consistent with this idea, asthma and COPD are often treated as unique
conditions with separate and distinct pathophysiologies.74 Some argue though that the two
are heterogeneous and overlapping conditions with common origins and clinical
expressions. This idea was originally proposed in 1961 and is known as the Dutch
hypothesis.75 Although loosely defined, it is acknowledged now that 15-45% of patients
with obstructive lung disease will exhibit some overlap of both asthma and COPD.76,77
Despite the high prevalence, no prospective studies have been conducted to evaluate this
group of patients; patients with overlapping features are often excluded from respective
asthma and COPD trials78,79 and very little is known to date about the pathogenesis of
asthma-COPD overlap. The most recent consensus guidelines suggest key features of
asthma-COPD overlap to be persistent airflow limitation in symptomatic patients over the
age of 40, documented history of asthma in childhood or early adulthood and significant
exposure to cigarette or biomass smoke,79 however this definition is still not standardized.
It is well-known now that asthma is a risk factor for COPD development9,10 and that up to
10% of asthmatics will progressively develop irreversible airflow limitation or COPD.11,12

12

1.4 Clinical Tools to Measure Pulmonary Function
Objective measures of pulmonary function, collectively known as pulmonary function
tests, play an important role in the diagnosis and monitoring of patients with asthma and
COPD. Importantly, pulmonary function tests are simple, inexpensive and relatively quick
to perform. There are a number of tools currently available, each serving a unique purpose
to measure different aspects of lung disease. In this section, the clinical tools used to
measure pulmonary function relevant to the original work presented in this thesis and their
corresponding measurements are introduced. The measurement deviations in the context
of asthma and COPD are also discussed.

1.4.1 Spirometry
Spirometry measures volume and airflow from the lungs as air is inhaled and exhaled as a
function of time80 and is the most commonly reported pulmonary function test. Spirometry
has been extensively standardized by international societies and these criteria are widely
implemented.80 Figure 1-5 shows an example of a handheld spirometer used to measure
airflow at the mouth and a corresponding volume-time curve. The patient holds the
spirometer while seated in the upright position with nose clips on and makes a tight seal
around the mouthpiece with their lips. After 3-4 tidal breaths, the patient is instructed to
inhale completely and then fully and forcefully exhale until their lungs are completely
empty. Airflow is measured at the mouth over the entire maneuver to calculate exhaled
volumes, as shown in Figure 1-5. The volume of air expired during the first second is the
forced expiratory volume in one second (FEV1), whereas the volume of air expired over
the entire exhalation maneuver is the forced vital capacity (FVC). FEV1 and FVC are
measured in litres and are commonly expressed as a percentage of a predicted value using
reference equations based on the patient’s age, sex, height and ethnicity.81 The ratio of
FEV1 to FVC (FEV1/FVC) is also commonly reported.
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Figure 1-5 Handheld spirometer and typical volume-time curve
Handheld spirometer records volume-time curve to measure the forced expiratory volume
in one second (FEV1) and forced vital capacity (FVC).
Expiratory airflow becomes limited in both asthma and COPD due to luminal narrowing
and airway obstruction. In asthma, FEV1, FVC and FEV1/FVC may be reduced because
of airway smooth muscle thickening and constriction, inflammation or intraluminal
plugging. In COPD, FEV1, FVC and FEV1/FVC may be reduced because of airway
inflammation, intraluminal plugging or collapsed airways. In both cases, FVC may also
be reduced because of premature airway closure during forced expiration. FEV1 and
FEV1/FVC are important diagnostic and classification markers of COPD and this is
described in more detail in section 1.5.4.

1.4.2 Plethysmography
Lung Volumes and Capacities
Plethysmography measures changes in volume in the body and accordingly, can be used to
measure lung volumes and capacities.

Figure 1-6 shows a common whole-body

plethysmograph and corresponding volume-time curve. The lung volumes and capacities
measured are also shown on the volume-time curve. Tidal volume (VT) is the total volume
of gas inhaled and exhaled during normal tidal breathing. Functional residual capacity
(FRC) is the volume of gas in the lungs after exhalation during normal tidal breathing and
residual volume (RV) is the volume of gas in the lungs after a complete exhalation.
Inspiratory reserve volume (IRV) is the volume of gas maximally inhaled from the top of
normal inhalation during normal tidal breathing, whereas expiratory reserve volume (ERV)
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is the volume of gas maximally exhaled from the end of a normal exhalation during tidal
breathing. Inspiratory capacity (IC) is the volume of gas inhaled from the end of a normal
exhalation during tidal breathing and vital capacity (VC) is the volume of gas inhaled from
end of a complete exhalation. Finally, total lung capacity (TLC) is the volume of gas in
the lungs at end full inhalation. Although many of these volumes and capacities can also
be measured using simple spirometry, plethysmography is required to determine FRC, RV
and TLC.

Figure 1-6 Whole-body plethysmograph and typical volume-time curve
Whole-body plethysmograph measures lung capacities and volumes.
During testing, patients are seated upright inside the plethysmograph with nose clips on
and their hands on their cheeks; the chamber is sealed to create an airtight closed system
with known interior volume. After 3-4 tidal breaths, the mouthpiece is closed by a shutter
at end tidal expiration and the patient is instructed to perform a series of gentle pants for 23 seconds against the closed shutter. Once the shutter reopens and following a few tidal
breaths, the patient is instructed to inhale fully and then passively exhale fully. During the
panting maneuver, the lungs expand causing the pressure and volume inside the lungs to
decrease and increase, respectively. In turn, the pressure within the sealed chamber
increases and the volume within the box decreases to accommodate the new volume of the
patient’s lungs. The pressure within the box and at the mouth are measured and in this
way, plethysmography directly measures FRC using Boyle’s Law relating pressure and
volume in an isothermal environment.82 VT, IRV, ERV, IC and VC are determined from
the spirometry-like maneuver performed after the shutter is re-opened.

RV is then

calculated as FRC minus ERV, and TLC as the sum of FRC and IC. It is important to note
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that body plethysmography is just one option to measure FRC; nitrogen washout or helium
dilution techniques may also be used and the lung volumes measured by each technique
are standardized,82 however the work in this thesis employs plethysmography. Similar to
spirometry, lung volumes can be expressed as a percent of a predicted value based on the
patient’s age, sex, height and ethnicity.83
Gas trapping in both asthma and COPD causes RV, FRC and TLC to increase. The ratio
of RV to TLC (RV/TLC) is often expressed as an indication for gas trapping. In asthma,
gas trapping may be due to increased smooth muscle and inflammation that cause
narrowing of the airway lumen, particularly in the small airways. In COPD, small airways
inflammation may cause gas trapping, and loss of elastic recoil from emphysematous tissue
destruction may also contribute to increased RV, FRC and TLC.
Airways Resistance
In general, resistance is defined as the ratio of driving pressure to flow; thus, in the context
the lungs, airways resistance (Raw) is the ratio of the difference between alveolar and mouth
pressure and the flow rate measured at the mouth as shown in Equation 1-3:

Equation 1-3

Raw [cmH2 O∙s/L]=

Alveolar pressure - Mouth pressure [cmH2 O]
Flow rate (V̇ ) [L/s]

Similar to the panting maneuver described previously for the measurement of lung
volumes, a panting maneuver is also performed to measure airways resistance, this time
with additional open-shutter panting prior to closed-shutter panting. Although flow rate
may be directly measured at the mouth, alveolar pressure is not directly available during
the panting maneuver. Instead, the pressure differential is inferred from the box pressure
and the inverse slope of the pressure-flow plot is known as specific airways resistance
(sRaw), a corrected index for airways resistance regardless of lung volume.
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As shown in Equation 1-4, Raw is then derived from sRaw normalized to FRC:
Equation 1-4

Raw [cmH2 O∙s/L]=

sRaw [cmH2 O∙s]
FRC [L]

Predictive reference equations exist for Raw based on patient age, sex, height and
ethnicity.84,85 Resistance of the airways is directly related to the luminal diameter of the
branches. Raw is especially increased in asthma due to increased smooth muscle and
inflammation that cause narrowing of the airway lumen. Parenchymal pathologies in
COPD typically do not influence Raw, however small airways inflammation in COPD can
lead to narrowing of the airway lumen and increase Raw.

1.4.3 Diffusing Capacity of the Lung
The efficiency of gas exchange within the lungs can be determined using the single-breath
carbon monoxide uptake technique86 to measure the diffusing capacity of the lung for
carbon monoxide (DLCO), which provides an indirect measure of oxygen diffusion across
the alveolar membrane. Carbon monoxide is used instead of oxygen because its uptake in
the pulmonary capillaries is diffusion-limited only – oxygen, on the other hand, is limited
by diffusion and perfusion.

Because of its binding affinity for hemoglobin that is

approximately 210-times greater than that of oxygen and the use of an extremely low
concentration of carbon monoxide that does not cause complete saturation of hemoglobin,
the pressure of carbon monoxide in the pulmonary capillary remains constant over time.87
Patients are again seated upright with nose clips on; after four tidal breaths, patients are
instructed to exhale completely to RV, then to rapidly inhale a test gas mixture to TLC and
hold their breath at TLC for 8-10 seconds before exhalation. The test gas contains a
mixture of 0.3% carbon monoxide, 21% oxygen, a balance of nitrogen and a tracer gas.
During the breath-hold at TLC, the carbon monoxide diffuses across the alveolar-capillary
membrane into the blood. The first 150 mL of exhaled gas is discarded to account for
anatomical dead space within the lungs, after which a discrete sample of alveolar gas is
analyzed by comparing the concentrations of carbon monoxide in the exhaled sample to
that of the inhaled gas. DLCO then is the conductance (flow normalized to pressure) of
carbon monoxide from the inspired test gas to the bloodstream and is measured in units of
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mLmin-1mmHg. DLCO may also expressed be as a percent of a predicted value based on
the patient’s age, sex, height and ethnicity.88 Notably, the tracer gas also serves to measure
the initial alveolar carbon monoxide concentration and the alveolar volume from which the
carbon monoxide uptake is occurring. The tracer gas must be one that is insoluble,
biologically inert and has a diffusivity similar to that of carbon monoxide so as not to
interfere with the measurement of carbon monoxide concentration; typical tracer gases are
neon (0.5%) or helium (10%).
The capacity of the lung to exchange gas across the alveolar-capillary interface, and thus
the DLCO measurement, is dependent on a number of structural and functional factors that
reflect a variety of physiological conditions. For the purposes of this thesis, DLCO is
measured to determine the effective alveolar-capillary surface area available for gas
exchange within the lung. In patients with COPD, DLCO may be reduced due to decreased
surface area of the alveolar-capillary membrane caused by emphysematous tissue
destruction. DLCO is not commonly measured in asthma because of the nature of its
pathophysiology that does not impact the pulmonary parenchyma.

1.4.4 Oscillometry
First developed over 60 years ago,89,90 oscillometry is an emerging pulmonary function test
that measures lung biomechanics. Oscillometry views the lungs as a linear dynamic
system, which allows the lungs to be considered from a systems analysis perspective
(inputs converted to outputs) and treated as an electrical circuit. Some background
information on the mechanical properties of the lungs is first required to understand the
basis of oscillometry.
As described previously in section 1.2.3, the respiratory system functions through the
mechanical expansion and contraction of the thoracic cavity, which alters the pressure
inside the lungs and results in airflow. The key to oscillometry is respiratory system
impedance (Zrs) – the quantity that directly relates pressure and airflow in the lungs and
reflects how difficult it is for air to flow through the airways.91 By applying airflow at a
known rate (input) and measuring pressure over time (output) at the mouth, impedance can
be calculated. All pulmonary function measurements previously described in this thesis
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are viewed in the time domain (ie, lung volume over time). When considering the lungs
as a linear dynamic system,91 in the time domain, inputs are converted to outputs by
convolution, which is a computationally expensive and challenging task. By taking the
Fourier transform of the pressure and flow signals to convert to the frequency domain, the
relationship between pressure (P) and airflow (V̇) is reduced to multiplication and the
impedance calculation becomes computationally simpler as shown in Equation 1-5:
Equation 1-5

P(f) [cmH2 O]=Zrs (f) [cmH2 O∙s/L] ∙ V̇ (f) [L/s]

Airflows are applied at the mouth using small-amplitude pressure oscillations that contain
multiple frequencies at once to determine impedance over a frequency range. Pressure is
measured at the mouth for each of the frequencies in the signal, and the impedance is
subsequently calculated over the same frequency range.
Again in contrast to the other pulmonary function tests described previously, which
measure only the magnitude of pressure, flow and volume, impedance describes the
relationship for both magnitude and phase between pressure and flow and is therefore a
complex number. As shown in Equation 1-6, respiratory system resistance (Rrs) is the inphase or real component of impedance, whereas reactance (Xrs) is the out-of-phase or
imaginary component:
Equation 1-6

Zrs (f) [cmH2 O∙s/L] = Rrs (f) + iXrs (f)

Resistance and reactance are the intrinsic properties of the respiratory system that
determine how it responds to input, or airflow in this case. Taken together, oscillometry
measures respiratory system resistance and reactance over a frequency range. A common
handheld oscillometer and corresponding impedance-frequency curve are shown in Figure
1-7. While seated in the upright position with nose clips on and hands on their cheeks, the
patient performs normal tidal breathing into the mouthpiece on the handheld device for 16
seconds as the pressure oscillations are superimposed over the normal breathing pattern.
The patient is instructed to use their hands to support the cheeks and upper airways to avoid
shunting of the applied oscillations in the upper airways and force the applied oscillations
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to travel to the lungs. The applied oscillations typically begin at 4-5 Hz to avoid overlap
with the patient’s normal breathing pattern, which is typically 0.5 Hz or less.91

Figure 1-7 Handheld oscillometer and impedance-frequency curve
Handheld oscillometer measures respiratory system impedance, including resistance and
reactance, over 5-37 Hz frequency range.
The impedance-frequency curve in Figure 1-7 is that of a healthy person without
respiratory disease. Resistance is always positive and normally not frequency dependent.
Analogous to airways resistance measured by plethysmography described previously,
oscillometry-measured resistance is related to airway lumen calibre. Reactance always
begins negative at low frequencies, and is frequency-dependent such that it crosses zero at
some frequency and becomes positive. Reactance is related to elastic properties of the
lung, but the exact property measured depends on the frequency at which the measurement
is made; at low frequencies, reactance is negative and reflects tissue elastance, whereas at
higher frequencies, reactance is positive and reflects tissue inertance. The point at which
reactance equals zero is the resonant frequency (fres) – here, elastic and inertive forces are
equal and overall impedance is completely resistive. The area under the reactance curve
may also be integrated up to fres and this value is known as the reactance area (AX).92
In asthma and COPD, oscillometry-derived resistance may increase as a result of airway
obstruction for the same reasons as outlined previously for plethysmography-derived
resistance. The resistance-frequency curve may be elevated at low frequencies causing it
to become frequency-dependent (scooped shape), with or without additional increases
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across all frequencies (upwards shift). The frequency-dependent nature of resistance
reflects heterogeneous airway obstruction and is often attributed to increased resistance in
the small airways; this enhanced sensitivity to small airways disease93 demonstrates the
major advantage of oscillometry over plethysmography-derived airways resistance and
other pulmonary function tests. The frequency-dependence of resistance is quantified as
the resistance at 5 Hz minus the resistance at 19 Hz (R5-19). Reactance may also be
increased as a result of inflammation in the small airways that causes reduced elasticity of
the lungs in both asthma and COPD. In emphysematous COPD, reactance may increase
because of loss of elastic recoil of the parenchyma. In all cases, the reactance curve will
typically become more negative at low frequencies (downward shift) and fres may also
increase, both of which subsequently cause AX to increase.
Oscillometry has recently gained clinical traction because, compared with the pulmonary
function tests described previously, it requires minimal coaching and patient effort.
Reference values exist for oscillometry measurements94 but the current equations were
developed based only on Caucasian adults in European countries. The Global Health
Initiative is currently developing global reference values for oscillometry which will be
similar to that of spirometry, plethysmography and DLCO. There are multiple commercially
available oscillometers, however in contrast with spirometry and plethysmography,
oscillometry techniques and devices are not yet well standardized. There exists many
variations in the functions used to generate the oscillations as well as the frequency ranges
used. Oscillometry is an overarching term to include the forced oscillation technique and
impulse oscillometry, which differ by the way the oscillations are generated. The work in
this thesis employs the forced oscillation technique over a frequency range of 5-37 Hz. It
is important to note that here, ‘forced’ describes the forcing function used to generate the
oscillations, not a forced exhalation maneuver as is performed during spirometry.

1.5 Clinical Assessments to Characterize Asthma and COPD
The tools outlined above, particularly spirometry, can be used to assess features of asthma
and COPD to provide characterization towards certain phenotypes and classify disease
severity. Validated questionnaires have also been developed to sensitively probe patientreported outcomes.
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1.5.1 Bronchodilator Reversibility
Reversible airflow limitation is a key feature of asthma. The goal of reversibility testing
is to determine whether a patient’s lung function improves with bronchodilator treatment,
which is assessed using spirometry before and after bronchodilator administration. The
most common regimen to evaluate bronchodilator reversibility is using a short-acting betaagonist (SABA) such as salbutamol. Following baseline spirometry, four separate 100 g
doses of aerosolized salbutamol are administered and spirometry is repeated after 15
minutes. Salbutamol acts directly on smooth muscle receptors in the airway wall to relieve
muscle constriction and dilate the airway lumen. A total dose of 400 g and wait time of
15 minutes are used and standardized to ensure that the response is high enough on the
salbutamol dose-response curve.95 Reversibility is assessed by evaluating the difference
between pre- and post-bronchodilator FEV1 or FVC in absolute volume and as a percent of
baseline measurements. Clinically relevant bronchodilator response is defined as an
improvement in FEV1 or FVC of 200 mL and 12% from baseline.95 These thresholds were
chosen to be confidently greater than the error in spirometry measurements; changes less
than 150 mL or 8% are likely to be within the normal measurement variability.96,97 Patients
are also instructed to withhold their prescribed bronchodilator medications prior to
reversibility testing.
Spirometry is the test of choice for confirming bronchodilator reversibility, although
changes in plethysmography- and oscillometry-derived metrics also typically respond to
bronchodilator.

Airflow limitation in COPD is generally regarded as incompletely

reversible; pulmonary function tests in COPD are typically performed post-bronchodilator
only.

1.5.2 Airway Hyperresponsiveness
Airway hyperresponsiveness is another common feature of asthma, and is defined as
increased sensitivity of the airways to inhaled stimuli.98 Methacholine challenge testing is
the most commonly performed method for the assessment of airway hyperresponsiveness
in patients and standardized guidelines are published.99 Methacholine is nebulized and
inhaled by the patient, after which it directly stimulates airway smooth muscle to contract
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and cause bronchoconstriction and a decrease in FEV1; increasing methacholine doses are
inhaled until FEV1 decreases by 20%. In this way, methacholine challenge testing creates
an ideal, controlled environment to simulate an asthma attack. Baseline spirometry is first
performed to determine pre-challenge FEV1 and the target decrease in FEV1. Saline diluent
or a methacholine dose of 0.03 mg/mL is then administered, and after nebulization,
spirometry is repeated. If FEV1 has not decreased by 20%, the next highest concentration
of methacholine is administered and this process is repeated until FEV1 has decreased at
least 20% or the 16 mg/mL maximum methacholine dose has been administered. Similar
to reversibility testing, patients are again instructed to withhold their prescribed asthma
medications prior to completing methacholine challenge testing according to guidelines.99
The provocative concentration required to decrease FEV1 by 20% (PC20) is the primary
outcome measurement from methacholine challenge testing and is estimated according to
Equation 1-7:
Equation 1-7 PC20 [mg/mL]= antilog [log C1 +

( log C2 - log C1 )(20-R1 )
]
R2 -R1

C and R are the methacholine concentration and percent decrease in FEV1 from baseline,
respectively, and the 1 and 2 subscripts represent the second-to-last and last measurements,
respectively. PC20 greater than 16 mg/mL indicates normal airway hyperresponsiveness,
whereas PC20 less than 4 mg/mL indicates abnormal airway hyperresponsiveness. PC20
between 4-16 mg/mL is recognized as borderline hyperresponsiveness and is more
challenging to interpret.99
Although methacholine challenge testing for airway hyperresponsiveness is sensitive for
asthma, it is not specific.99 This means that the lack of airway hyperresponsiveness (PC20
> 16 mg/mL) can help to exclude asthma, but the presence of airway hyperresponsiveness
(PC20 < 4 mg/mL) is not always perfectly indicative of asthma.37
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1.5.3 Questionnaires
Questionnaires are important clinical tools to evaluate a patient’s perception of their
respiratory disease. The asthma control questionnaire (ACQ)100 evaluates asthma control
during the previous week using five symptom-related questions (night awakening,
symptoms on awakening, activity limitation, shortness of breath and wheezing), as well as
questions for daily bronchodilator use and pre-bronchodilator FEV1. Each question is
scored on a scale of 0-6 and the total score is calculated as a mean the individual question
scores; all seven questions may be used for the ACQ-7, or abbreviated versions101 may be
used to omit pre-bronchodilator FEV1 (ACQ-6) or both pre-bronchodilator FEV1 and daily
bronchodilator use (ACQ-5). The primary goal of asthma care is to achieve and maintain
asthma control, which refers to the extent to which a patient’s asthma symptoms can be
reduced or eliminated by treatment.102 Accordingly, the ACQ is widely used as a clinical
trial endpoint.103,104 Total scores range from 0 to 6, where 0 reflects total control and 6
reflects severely uncontrolled. The minimal clinically important difference for ACQ is
0.5.101
The asthma quality of life questionnaire (AQLQ),105 as the name suggests, probes asthmarelated quality-of-life during the previous two weeks. The AQLQ consists of 32 questions
related to symptoms, activity limitation, emotional function and exposure to environmental
stimuli. Each question is scored on Likert scale from 1 for totally limited/limited a very
great deal/limited all of the time/severely limited to 7 for limited none of the time/not at all
limited, depending on the question. Total AQLQ score is calculated as the mean of all 32
question; total scores close to 1 represent poor asthma quality-of-life and scores close 7
represent very good quality-of-life. AQLQ score is also commonly used as a clinical trial
endpoint104 and its minimal clinically important difference is 0.5.106
It is important to acknowledge that there are a number of variations of questionnaires
designed to probe asthma control and quality-of-life – ACQ and AQLQ are employed in
this thesis, although they are not the only options. It is also worth acknowledging the St.
George’s Respiratory Questionnaire (SGRQ),107 which measures the impact of respiratory
disease on an individual’s overall health, daily activities and perceived well-being, is
mostly commonly used for patients with COPD.
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1.5.4 Disease Severity
Asthma
Asthma severity is determined by the type and amount of treatment required to control
symptoms and prevent exacerbations. Asthma therapies can be grouped into three main
types: controllers, relievers and add-ons.37 Controller medications are used to continuously
reduce airway inflammation, control symptoms and reduce exacerbations. Controller
therapy is typically in the form of inhaled corticosteroids (ICS), with or without long-acting
beta-agonist (LABA) combination. As shown in Table 1-1, it is the daily dose of controller
ICS which forms the basis of asthma severity classification. The Global Initiative for
Asthma (GINA) defines ‘treatment steps’ based on the required daily dose of ICS (low,
medium, high), from as-needed, reliever-only use for very mild asthma at treatment step 1
to daily high dose for very severe asthma at treatment step 5.37 Reliever therapies are
provided to all patients for as-needed acute symptom relief, and are now also in the form
of ICS-LABA combination.

Add-on therapies are considered when symptoms and

exacerbations persist despite optimized treatment with ICS-LABA, and take many forms
from bronchodilator to anti-inflammatory actions.
Table 1-1 GINA criteria for asthma severity classification
ICS/ICS-LABA Use
GINA Step 1
Very Mild
As needed
GINA Step 2
Mild
Daily low dose ICS
GINA Step 3
Moderate
Daily low dose ICS-LABA
GINA Step 4
Severe
Daily medium dose ICS-LABA
GINA Step 5
Very Severe
Daily high dose ICS-LABA
Adapted from GINA Global Strategy for Asthma Management and Prevention
2019 report37
COPD
COPD severity criteria are comparatively more straightforward. Spirometry thresholds are
used to both diagnose and stratify COPD severity according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines.54 Post-bronchodilator FEV1/FVC
less than 0.70 is the diagnostic criteria for COPD, and disease severity is subsequently
stratified from mild (GOLD I) to very severe (GOLD IV) based on FEV1 percent predicted
(%pred). Table 1-2 shows the FEV1 thresholds that define each level of COPD severity.
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Table 1-2 GOLD criteria for COPD severity classification
FEV1/FVC < 0.70
GOLD I
Mild
FEV1 ≥ 80%pred
GOLD II
Moderate
50% ≤ FEV1 < 80%pred
GOLD III
Severe
30% ≤ FEV1 < 50%pred
GOLD IV
Very Severe
FEV1 < 30%pred
Adapted from GOLD Global Strategy for the Diagnosis, Management,
and Prevention of Chronic Obstructive Pulmonary Disease 2019 report.54

1.6 Imaging of Pulmonary Structure and Function
The pulmonary function tests described previously in section 1.4 provide rapid,
inexpensive measurements that are well understood. Unfortunately, these measurements
cannot inform on regional disease heterogeneity,108,109 are weakly predictive of early
disease and disease progression,24,110 and are insensitive to the small airways.111,112
Pulmonary imaging, on the other hand, provides regional structural and functional
measurements of lung disease that are sensitive to the entire bronchial tree. With respect
to the lungs and this thesis, planar x-ray, x-ray computed tomography (CT), nuclear
medicine and magnetic resonance imaging (MRI) are reviewed here.

1.6.1 Planar X-ray
Planar x-ray imaging, as the name suggests, uses x-ray radiation to generate twodimensional images of the body. Since its advent in 1895 by Wilhelm Röntgen, planar xray has become the most common method to image the chest and lung disease because of
its low cost, low radiation dose, short acquisition window and ease of access. Planar x-ray
images (also known as radiographs) are produced by positioning the patient between an xray source and detector that are directly opposite each other. While the patient holds their
breath, x-rays are passed through the thorax and are differentially attenuated by different
anatomical structures. The detector measures the relative attenuation of the x-rays after
they exit the body and generates a two-dimensional projection image that is a superposition
of all anatomy along the x-ray path. Image contrast is thus generated by the relative
attenuation of x-rays across the body; high-attenuating structures, such as bone, appear
bright on an x-ray image, whereas low-attenuating structures, such as lung parenchyma,
appear dark. Images of the thorax are typically acquired while the patient stands upright
for anterior-posterior or lateral projections, or both. The radiation dose associated with
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planar chest x-rays is on the order of 0.01 mSv,113 or 0.6% that of the average annual
background radiation in Toronto, Canada.114
Lung volume abnormalities on planar x-ray are commonly assessed by the shape of the
lungs.

Hyperinflation is detected by elongated lung volumes and flattening of the

diaphragm in asthma115-117 and COPD,118 especially in severe emphysema.119 Bronchial
wall thickening or plugging may also be evident on chest x-ray in patients with
asthma.115,117 Lung abnormalities typically need to be quite severe in order to be detectable
by chest x-ray; in fact, chest x-ray imaging in the clinical care of asthma and COPD often
serves to rule out alternative causes of respiratory-related symptoms such as shortness of
breath. Moreover, the two-dimensional projection nature of planar x-ray images has
motivated the development of three-dimensional x-ray approaches to capture depth and
tomographic information.

1.6.2 X-ray Computed Tomography
X-ray computed tomography (CT) imaging also leverages the body’s x-ray attenuating
properties, however it does so in a three-dimensional manner. CT was first developed in
the 1970s and continuous improvements in acquisition speeds and image quality since have
made CT the modality of choice for the evaluation of lung disease. Multi-detector
technology now allows for sub-millimetre isotropic imaging of the entire lung volume in a
single breath-hold, permitting multi-planar and three-dimensional reconstructions.
1.6.2.1 Conventional CT
CT images are produced using an x-ray source and detector array that are positioned
opposite one another and rotate around the patient acquiring multiple x-ray projection
images at different angles. As the x-ray source and detector rotate, the scanner bed with
the patient laying supine passes through the imaging components of the system to acquire
axial images of the entire thorax as the patient holds their breath. The projections are then
reconstructed into a three-dimensional volumetric image, typically using filtered back
projection or iterative reconstruction techniques.120
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Each voxel in the reconstructed image is represented by a measurement of the tissue density
relative to that of water, known as Hounsfield units (HU)121 according to Equation 1-8:

Equation 1-8

Hounsfield unit [HU]= (

μtissue -μwater
) ∙1000
μwater

where  represents the linear attenuation coefficient for the tissue of interest or water. The
attenuation of water is normalized to 0 HU, and it follows that the HU of air is -1000, lowattenuating structures such as the lung parenchyma have HU near -800, and highattenuating structures such as bone have HU near +1000. The typical radiation dose
associated with clinical chest CT protocols is much greater than that of planar x-ray at 7-8
mSv.122 Low-dose research CT protocols have been established with doses on the order of
1.6 mSv,24,25,27 or roughly equivalent to the average annual background radiation in
Toronto, Canada.114 Advanced image reconstruction methods have more recently been
developed to achieve ultra-low-doses on the order of 0.1-0.4 mSv,123,124 however such
techniques have not yet been widely implemented clinically.125 CT images of the lungs
may be acquired after inspiratory or expiratory maneuvers, depending on the evaluation of
interest.
In patients with asthma and COPD, CT is commonly used to assess structure of the airways,
lung parenchyma and pulmonary vessels; this thesis primarily focuses on airway and
parenchymal measurements. Figure 1-8 shows inspiratory CT images in the coronal plane
for comparison between a healthy control and patients with asthma and COPD. Airway
findings on CT include bronchial wall thickening, bronchial dilation, luminal narrowing,
bronchiectasis, mucous plugging, atelectasis or mosaic lung attenuation, whereas
parenchymal abnormalities are reflected in focal regions of low attenuation. In Figure 1-8,
airway wall thickening is evident in the asthmatic patient, and a narrow window highlights
regions of low attenuation in the patient with COPD. CT evaluation of lung disease has
been revolutionized by the application of computational analysis to generate quantitative
CT imaging biomarkers, collectively known as quantitative CT.126 A number of software
platforms are commercially available for quantitative CT analysis – Pulmonary
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Workstation 2.0, Apollo and VIDAVision are examples from VIDA Diagnostics Inc.
(Coralville, IA, USA) which have been approved for clinical use.

Figure 1-8 Inspiratory coronal CT with corresponding airway trees
Top: CT images in typical lung window (W) and level (L) used to visualize structural
airway and parenchymal abnormalities.
Middle: CT images with narrow window to highlight low attenuating areas. Compared with
healthy participant, COPD participant shows regions with low x-ray attenuation indicative
of parenchymal disease and airspace enlargement, whereas parenchyma in asthmatic
participant appears normal.
Bottom: Three-dimensional airway reconstructions show fewer CT-resolved airways in
asthma and COPD.
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Airways
Semi- and fully-automated approaches have been developed to segment the large airways
in three dimensions. Such techniques take advantage of the cylindrical shape of the airways
and the inherent contrast between the air within the airway lumen and highly vascularized
airway wall. In an inspiratory CT image, airways can typically be resolved and segmented
up to the tenth generation and reliably measured up to the fifth and sixth generations.127
Figure 1-8 also shows three-dimensional airway reconstructions for each patient. Large
airway morphology is measured using metrics analogous to those used in histology, such
as airway wall area percent and wall thickness, as shown in in Equation 1-9 and Equation
1-10 respectively:

Equation 1-9

Airway wall area [mm2 ]
Wall area percent [%]=
∙100
Total area [mm2 ]

Equation 1-10

Wall thickness [mm]=Outer diameter - Inner diameter [mm]

The large airways in asthma have been extensively evaluated using CT. Asthmatics show
greater wall thickness compared with healthy controls128-134 and wall thickness increases
with increasing disease severity.129,135,136 Wall thickness in asthma is directly related to
airway

remodeling

on

pathology131,136,137

and

correlates

with

airway

obstruction130,131,134,136,138 and airway hyperresponsiveness.133,136,139 Airway wall thickness
on CT also decreases in response to inhaled corticosteroid treatment132,140,141 and bronchial
thermoplasty.142 Beyond airway morphology, a quantitative scoring system has been
developed to measure the burden of intraluminal airway plugging, and in patients with
asthma, a high plug score was associated with worse airflow obstruction and airway
eosinophilia.143

Evaluation of the large airways in COPD using CT has been less

straightforward. Although early CT work observed narrowed airway lumens and fewer
peripheral airways in patients with COPD compared with never-smokers controls144-146 and
relationships between airway wall thickness and airflow obstruction,145,147-149 more recent
work by Smith and colleagues demonstrated thinner airway walls relative to controls when
comparing spatially-matched airways.150 These recent results highlight the importance of
airway sampling technique when reporting and comparing quantitative CT airway
measurements in patients with COPD. In contrast, the total number of airways visible and
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segmented on CT may be quantified as total airway count (TAC).151 Airway count was
first investigated in patients with COPD and was shown to be reduced with greater
emphysematous destruction in the right upper lobe,151 and in following was shown to be
decreased relative to never-smoking controls in the whole lung and before the onset of
emphysema.152 Overall, the common quantitative CT airway measurements at the disposal
of clinical and research studies include lumen diameter, lumen area (LA), wall area percent
(WA%), wall thickness (WT), total airway count (TAC), square root of wall area of a
hypothetical airway of internal perimeter 10 mm (Pi10), and airway circularity.
As described previously in section 1.3, the small airways (<2 mm diameter) play an
important role in the pathogenesis of both asthma and COPD. Although the small airways
are beyond the spatial resolution limits of CT, small airways disease can be indirectly
assessed via air trapping on expiratory CT. Air trapping appears as mosaic attenuation,
which is defined as variable lung attenuation that results in a heterogeneous appearance of
the lung parenchyma.153 Automated thresholds are applied to the lung density histogram
and air trapping is quantified as the relative area of the lung with Hounsfield units less than
-856 (RA856)154 – -856 HU is chosen because it is the attenuation value of normally inflated
lung, thus the lungs at end expiration contain less air and should have higher attenuation
than -856 HU.155 In asthma, air trapping is elevated compared with healthy controls156,157
and

related

to

disease

severity,158

airflow

obstruction138,154,156

and

airway

hyperresponsiveness.154 CT air trapping has been shown to be sensitive to treatment effects
with inhaled corticosteroids,159,160 bronchial thermoplasty142 and montelukast, a
leukotriene receptor antagonist.161

In COPD, CT air trapping is related to airflow

obstruction,162,163 however it can be difficult to distinguish from emphysema using a simple
threshold.155 For this reason, expiratory CT is not commonly assessed alone in COPD, but
rather in conjunction with inspiratory CT using image registration techniques as described
subsequently.
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Parenchyma
The parenchyma is assessed for emphysema also using densitometric thresholds on
inspiratory CT. The key feature of emphysema on CT is decreased lung density,164 and
regions of low attenuation in a COPD participant compared with the healthy and asthma
participants are highlighted using a narrow window in Figure 1-8. Similar to that of air
trapping on expiratory CT, automated thresholds are applied to the lung density histogram
to quantify the extent of emphysema on inspiratory CT. Thresholds ranging from -910 to
-970 HU165-167 or the 15th percentile of the density histogram (HU15 or PD15)168 have been
validated against histology. The relative area of the lung less than -950 HU provides the
best balance of sensitivity and specificity and is therefore most commonly used.155
Emphysema is considered present when RA950 is greater than 6.8%.167 Unsurprisingly,
RA950 is typically less than 6.8% in asthma. In COPD, RA950 is elevated and shows good
agreement with manual emphysema scores by radiologists169 and is related to airflow
obstruction.170
Beyond single image sets at inspiration or expiration, novel quantitative CT methods and
biomarkers have been developed by co-registering inspiratory and expiratory images. As
alluded to previously, this is particularly useful for patients with COPD to distinguish
emphysematous regions from regions of air trapping and this forms the basis of parametric
response mapping171 and disease probability measure.172 Parametric response mapping
uses the density thresholds previously described for emphysema and air trapping on
inspiratory and expiratory CT, respectively, to classify lung tissue into normal,
emphysematous or gas-trapped regions on a voxel-wise basis. Disease probability measure
uses the same fundamental principles, however instead of using single thresholds, it uses a
probability of each category based on normalized densities at inspiration and expiration on
a continuous scale. The non-emphysematous air trapping category has been termed
‘functional small airway disease’, and together, these categories make up the primary
imaging phenotypes of COPD that are well-recognized and widely implemented in COPD
research.173 Ostridge and colleagues directly compared parametric response mapping and
disease probability measure and observed good agreement between the two methods.174
This study also demonstrated relationships between disease probability measure air
trapping and oscillometry measures of small airways disease,174 providing physiological
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validation for the air trapping measurement. Parametric response mapping has been
extensively applied in COPD to sensitively identify regions of gas trapping,175-177 and these
regions were recently validated against pathology as measure of small airways disease in
severe COPD.178 Preliminary work in asthma has demonstrated an increase in regions of
parametric response map gas trapping in patients with severe asthma compared with
nonsevere asthma and controls,179 however given its dependence on emphysema, the
technique has not been widely applied in asthma studies. Alternatively, the air volume
change and amount of deformation between inspiratory and expiratory CT images may be
quantified180 and these quantitative CT metrics show differing volume changes and tissue
deformations between asthmatics and healthy controls.181 Choi and colleagues used a
combination of airway and parenchymal measurements to develop quantitative CT clusters
of asthma patients,182 providing for the first time, quantitative imaging phenotypes of
asthma. The same authors subsequently used similar methods to compare quantitative CT
phenotypes of asthma and COPD patients.183
1.6.2.2 Dual-energy CT
The previous section summarizes the rich structural CT measurements of the lung, with the
exception of some that indirectly represent pulmonary function.

Direct functional

assessments of the lungs are also possible using CT with inhaled contrasts and advanced
CT techniques.

Functional CT imaging of the lungs was first performed using a

conventional-CT-like acquisition with inhaled xenon-133 (133Xe) to measure regional
ventilation. After a wash-in period, regions ventilated with

133

Xe have increased CT

density compared with non-ventilated regions.184 The poor xenon enhancement associated
with this technique limited its application though and has motivated xenon ventilation
imaging using a dual-energy CT approach. Although first introduced in the 1970s,185 dualenergy CT has only recently been applied to measure regional ventilation using

133

Xe.186

Compared with conventional CT, dual-energy CT acquires two separate images at different
x-ray tube voltages, one each at a high and low energy. Moreover, dual-source technology
enables simultaneous acquisition of these two images; as the name suggests, dual-source
systems are equipped with two x-ray sources and two corresponding detectors oriented 90
from each other that simultaneously rotate around the patient. The real advantage of dual-
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energy CT over conventional methods is that it is sensitive to both tissue attenuation in HU
and chemical composition of the lung. Regional gas distribution is generated using threematerial decomposition based on attenuation differences at different energy levels to
differentiate inhaled xenon from the lung parenchyma and air.187 Following a wash-in
period where patients breathe a mixture of xenon and oxygen for 2-3 minutes, static
ventilation images may be acquired during an inspiratory breath-hold or dynamic images
may be acquired during wash-in and wash-out phases.188 The average radiation dose
associated with dual-energy CT is approximately 3 mSv for static acquisitions and 8 mSv
for dynamic acquisitions.187
As expected, xenon ventilation on dual-energy CT is homogeneous in healthy controls.188
In patients with asthma, dual-energy CT shows ventilation abnormalities189,190 that are
associated with thicker airway walls also measured using CT,189 sensitive to bronchodilator
treatment190,191 and related to asthma symptoms.192,193

In COPD, dual-energy CT

demonstrates structural and ventilation abnormalities related to airways disease and
emphysema.194 Another study used xenon ventilation dual-energy CT to classify areas of
normal, air trapped and emphysematous tissue in patients with COPD,195 similar to that
described previously for parametric response mapping.
The wealth and utility of structural and functional information from all CT methods is clear,
yet the application of quantitative CT is still limited beyond the research setting. Dualenergy CT in particular is limited due to the high concentrations of inhaled xenon required
to provide adequate contrast that may cause respiratory depression. Even using low-dose
conventional CT protocols, the risks stemming from ionizing radiation exposure limits the
use of CT in serial studies of treatment response or longitudinal monitoring, especially in
children and young adults with chronic lung disease.

1.6.3 Nuclear Medicine
Nuclear medicine imaging techniques employ radioactive tracers to measure lung function,
and are used to measure ventilation, perfusion and ventilation-perfusion mismatch. As it
is most relevant to this thesis, this section specifically focuses on nuclear medicine
measurements of pulmonary ventilation. It is important to note that nuclear medicine
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imaging methods alone only provide functional information and must be combined with
other modalities to obtain structure-function relationships.
1.6.3.1 Scintigraphy
Scintigraphy measures gamma radiation to form a two-dimensional projection image of
radioactivity in the body. While the patient lays supine, radionuclide tracers are either
injected or inhaled and once inside the body, undergo radioactive decay and emit gamma
rays. The gamma rays are detected by gamma cameras around the patient which convert
the absorbed energy into an electrical signal to form an image.

Regions of high

radionuclide content appear as hot spots on the image.
Tracers may be radioactive themselves or labeled with a radionuclide. Evaluation of
regional ventilation is typically performed used radioactive gases, radioactively-labeled
aerosols or Technegas.196 Common radioactive tracer gases are

133

Xe and krypton-81m

(81mKr) and the radionuclide technetium-99m (99mTc) is used to label
triamine pentaacetate (DTPA) aerosol and Technegas.

99m

Tc-diethylene-

Early research and clinical

applications most commonly employed inhaled 133Xe, however Technegas distribution in
the lungs is similar to 133Xe and is actually is favoured now because its deposition remains
stable for more than 20 minutes.197
Although the primary pulmonary application of scintigraphy is diagnosis of pulmonary
embolism,198 scintigraphy was the first method to regionally identify ventilation
abnormalities in patients with asthma in the 1960s18,19 and studies identifying the same in
COPD followed shortly thereafter.199,200

In patients with asthma, the effects of

methacholine-201 and histamine-induced202 bronchoconstriction on regional ventilation
distribution were also demonstrated using scintigraphy. Similar to planar x-ray, the twodimensional nature of scintigraphy has motivated the development of three-dimensional
approaches.
1.6.3.2 Single Photon Emission Computed Tomography
By the late 1990s, nuclear medicine studies of the lung transitioned to single photon
emission computed tomography (SPECT) for three-dimensional imaging. Analogous to
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planar x-ray and CT, SPECT offers a three-dimensional tomographic approach to image
gamma radiation.196 The same radionuclide tracers may be used for SPECT, and twodimensional scintigraphy projections are acquired at multiple angles around the patient and
reconstructed to form three-dimensional image. The radiation exposure associated with
SPECT is dependent on the radionuclide used, though a typical ventilation-perfusion study
using

99m

Tc is approximately 2-3 mSv.196 Hybrid SPECT/CT systems are available for

simultaneous structure-function imaging.203
Physiological studies have employed SPECT to measure airway closure204 and predictably
have shown increased ventilation abnormalities in asthma relative to controls205 and
demonstrated bronchoconstrictive response to methacholine.206

In COPD, SPECT

demonstrated increased ventilation abnormalities compared with control participants207
and has been used to determine severity of airflow obstruction208 and the degree of
ventilation within emphysematous bullae.209 Beyond ventilation imaging, SPECT lends
itself to the investigation of regional deposition of inhaled aerosols when labelled with
99m

Tc to evaluate the delivery efficacy of inhaled treatments.210,211

1.6.3.3 Positron Emission Tomography
Positron emission tomography (PET) imaging also offers three-dimensional information,
however in contrast to SPECT, PET uses positron-emitting isotopes to form images of
metabolic activity. A radionuclide is either injected or inhaled and once inside the body,
begins to decay and emits a positron. The positron will only travel a short distance before
colliding with an electron and undergoing annihilation – this process produces two gamma
photons of equal energy that are emitted 180 from each other and detected coincidentally
using gamma cameras oriented circumferentially around the patient. The source particle
is subsequently spatially located along the straight line between the two detector elements,
and all detected sources are reconstructed into a volumetric image.212 Hybrid PET/CT213
and PET/MRI214 systems are available for simultaneous structure-function imaging,
however applications of each are not common for the study of asthma and COPD.
Although PET imaging is less common than scintigraphy and SPECT for pulmonary
applications, pulmonary ventilation has been assessed using nitrogen-13 (13NN), either as
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a bolus injection or inhaled aerosol.

13

NN is not soluble in blood or tissue and is eliminated

exclusively in the lungs;212 when injected, it travels to the lungs, crosses the alveolar
membrane to the airspaces and is eliminated from the body by ventilation. Accordingly,
well-ventilated lung regions will quickly wash out the tracer whereas unventilated regions
retain the tracer because of gas trapping. Alternatively, when inhaled, 13NN does not reach
poorly-ventilated lung regions.212 The primary studies employing

13

NN PET in asthma

have studied the effects of methacholine on regional ventilation and observed regions of
poor ventilation following bronchoconstriction.20,215 In COPD, 13NN PET was observed
to be sensitive to airways disease versus emphysematous phenotypes.216 Because of the
short half-life (approximately 10 minutes) and rapid elimination of 13NN from the body,
the radiation dose associated with 13NN PET ventilation-perfusion studies is quite low at
approximately 0.2 mSv.212 Although beyond the scope of this thesis, it is worth noting that
fluorine-18-fluorodeoxyglucose (18F-FDG) PET has been suggested as a biomarker for
pulmonary inflammation,217,218 however future work is required to determine its utility in
asthma and COPD.
Although SPECT and PET offer three-dimensional imaging (versus scintigraphy) and
functional information, both methods are inherently limited by low spatial resolution and
still carry risk due to the radiation exposure. SPECT is further affected by motion artifacts
owing to long acquisition times, and PET relies on cyclotrons for the production of
radioisotopes that make it less widely available. SPECT and PET have unique applications
for physiological studies of ventilation, perfusion and ventilation-perfusion mismatch,
however remain research tools for asthma and COPD.

1.6.4 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) uses non-ionizing radiofrequency waves to generate
images by manipulating magnetic spins of different nuclei in the body. Conventional MRI
leverages the nuclear spins of protons (1H) and provides excellent soft tissue contrast based
on proton density of the tissue of interest. Radiofrequency waves excite the nuclei and the
image is acquired as the nuclei relax and resultant signal decays back to equilibrium. A
range of MRI methods currently available to obtain structural and functional information
of the lungs are described here.
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1.6.4.1 Conventional 1H MRI
MRI examinations of the chest and lungs make up 2% of all examinations worldwide.219
MRI of the lungs is challenging technically because of the inherent properties of the lung
compared with, for example, the brain. The tissue density of the lungs is approximately
0.1 g/cm3, which contributes to extremely low 1H signal intensity.220 For context, the
density of the lungs is approximately 10% that of the brain.221 Moreover, the same reasons
that make the lung so efficient for gas exchange pose additional challenges for lung MRI;
the 480 million alveoli and 100 m2 of air tissue-interfaces in the lung further degrade the
pulmonary MRI signal by creating local magnetic field inhomogeneities, or susceptibility
artifacts.222,223 This causes extremely rapid signal dephasing and decay (0.4-0.9 ms),
making it challenging to acquire sufficient signal to generate contrast within the lungs using
conventional sequences. Finally, pulmonary MRI is highly impacted by artifacts from
cardiac and respiratory motion. Together, these factors contribute to low pulmonary MRI
signal such that the lungs appear as dark signal voids, as shown in Figure 1-9 and making
it challenging to differentiate between health and disease.

Figure 1-9 1H MRI of the lungs
Top row: Conventional 1H shows structural information and differences are
indistinguishable between healthy participant and those with asthma and COPD.
Bottom row: UTE 1H MRI shows more structural information, where regions of low signal
intensity are visible in asthma and COPD participants compared with healthy participant.
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The obvious safety advantage of MRI over CT and nuclear medicine has motivated the
development and of novel methods to overcome these technical challenges in order to
achieve increased pulmonary MRI signal and obtain structural information. Ultra-short
echo time (UTE) MRI methods do so by reducing time between radiofrequency excitation
and data acquisition to acquire signal from lung tissue before it decays.220 UTE 1H images
are shown in Figure 1-9, demonstrating enhanced signal within lung parenchyma in
comparison to conventional 1H.

UTE MRI is particularly useful for evaluating

parenchymal diseases – using a free-breathing approach in conjunction with respiratory
gating, Ohno and colleagues demonstrated comparable visualization of pulmonary
anatomy using UTE MRI versus CT in a variety of parenchymal diseases.224 In COPD, a
multi-volume breath-hold approach showed strong relationships with CT measurements of
emphysema225 and similar work in asthma showed decreased parenchymal signal intensity
in asthma compared with healthy controls.226 These preliminary results highlight the
potential for UTE MRI in patients with asthma and COPD and developments are ongoing
to achieve increased parenchymal signal using more rapid acquisition times. Although
anatomical 1H MRI of the lung is developing rapidly, it does not provide information
beyond that of a low-dose CT so the field has pushed towards pulmonary functional MRI.
1.6.4.2 Inhaled Gas MRI
MRI of inhaled fluorinated and hyperpolarized gases has been used extensively over the
last 25 years to evaluate regional lung structure and function in patients with lung disease.
Using specialized multi-nuclear hardware and pulse sequences, the gases are imaged
directly once inhaled by the patient. Although the gases are not endogenous and provide
excellent contrast in that way, intrapulmonary tracer gases have low spin density at thermal
equilibrium that generates three orders of magnitude less MRI signal than that of solid
tissue or fluids in the body. Each gas requires different techniques to improve the spin
density and MR visibility, and have their own respective advantages and disadvantages
that lend themselves to different applications. In all cases, anatomical 1H is typically also
acquired to provide matched anatomical information.
Of the inhaled gas MRI applications, inhaled fluorinated gas MRI was the first to be
proposed in 1984,227 although it was not evaluated in humans until 2008.228 Fluorinated
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gas MRI is enabled using inhaled sulfur hexafluoride (SF6), hexafluoroethane (C2F6),
tetrafluoromethane (CF6), perfluoropropane (PFP; C3F8) or octafluorobutane (C4F8), all of
which are non-toxic and contain multiple fluorine-19 (19F) nuclei to increase the spin
density. Moreover, 19F has a rapid signal relaxation time that allows for extensive signal
averaging to improve image signal-to-noise. Importantly,

19

F is naturally abundant and

does not require hyperpolarization, so the associated costs for 19F MRI are lower than that
of hyperpolarized gases. Dedicated 19F radiofrequency coils are generally desired but not
required; the gyromagnetic ratio of 19F is close to that of 1H (40.052 MHz/T) so 19F can be
imaged using conventional 1H hardware, however at the cost of reduced image quality due
to slight off-resonance effects. Patients are instructed to breathe the fluorinated gas mixed
with oxygen for 5-7 breaths to reach steady state concentration of 19F in the lungs, after
which images may be acquired in a static breath-hold or during the wash-in and wash-out
of the contrast gas.

19

F MRI shows homogeneous ventilation in healthy volunteers229,230

and a visual increase in heterogeneity of gas distribution in patients with asthma230 and
COPD230,231 compared with healthy controls. These studies demonstrate that sufficient and
clinically relevant signal may be achieved using 19F MRI, however it still suffers from low
spatial resolution that has limited its widespread application in asthma and COPD.
On the other hand, hyperpolarized gas MRI provides images of pulmonary structure and
function with high spatial and temporal resolution. Hyperpolarized gas MRI is enabled
using noble gases helium-3 (3He) or xenon-129 (129Xe) which, as the name suggests, are
hyperpolarized to increase their spin densities.232 In contrast to 19F, signal averaging cannot
be performed because 3He and 129Xe have long signal relaxation times. The technique was
originally discovered using

129

Xe when Albert and colleagues recognized that the

polarization of the nuclei could be increased by approximately 100,000 times and provided
the first

129

Xe MR image of excised mouse lungs in 1994.233 For both 3He and

129

Xe,

hyperpolarization is achieved via spin-exchange optical pumping234 whereby a circularly
polarized laser is used to bombard a glass cell housing rubidium and the noble gas. The
circularly polarized light, with wavelength corresponding to the transition energy of
rubidium, is absorbed by and polarizes the rubidium. Subsequent collisions between
polarized rubidium and the noble gas transfer angular momentum to the noble gas,
effectively increasing the nuclear-spin polarization of the noble gas and improving its MR
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signal. The cell itself is housed inside Helmholtz coils to maintain a constant magnetic
field and minimize the rate at which the polarized noble gas atoms decay back to thermal
equilibrium. A single inhalation of up to 1.0 L of hyperpolarized gas is sufficient to
generate high resolution static breath-hold MR images.
129

Following Albert and colleagues’ initial results using

Xe,233 the field quickly

transitioned to 3He235 because of its three-fold greater gyromagnetic ratio (32.434 MHz/T
for 3He versus 11.777 MHz/T for

129

Xe) and greater achievable polarization levels with

simpler turn-key systems (30-40% for 3He versus 8-25% for 129Xe). This meant that greater
MRI signal and thus image quality could be achieved using small volumes of polarized
3

He. The field was entirely dominated by 3He until recently when the global shortage and

high cost of 3He236 pushed researchers back towards

129

Xe.237,238 As a result,

129

Xe

polarizer technology has significantly advanced to achieve polarization to the same order
as 3He.239-241 Differences have been observed between the results produced by 3He and
129

Xe which are further discussed later on, however importantly, both have excellent safety

and tolerability in healthy participants and patients with respiratory disease.242-244

129

Xe

MRI is now approved for clinical use in the United Kingdom and positive phase III clinical
trial results for 129Xe MRI against gold-standard 133Xe scintigraphy just completed this year
will support clinical approval in the United States later in 2020.245 These methods allow
for measurement of regional ventilation, lung microstructure and gas exchange. It is
important to note that both 3He and

129

Xe MRI require dedicated multi-nuclear MR

systems, radiofrequency coils and hyperpolarizers. In the grand scheme of inhaled gas
MRI, hyperpolarized gas applications are much more predominant than fluorinated gas;
the remainder of this section is dedicated to hyperpolarized gas imaging of the lung.
Ventilation Imaging
Imaging the spin density of hyperpolarized gases provides a visualization of the regional
distribution of inhaled 3He or

129

Xe in the lungs, highlighting regions that do and do not

ventilate well. Figure 1-10 demonstrates regional distribution of hyperpolarized 3He
(cyan) and 129Xe (purple) in a healthy volunteer and participants with asthma and COPD.
Compared with the healthy volunteer, where ventilation is homogeneous throughout, 3He
and

129

Xe show visually obvious ventilation heterogeneity in asthma and COPD. Noble
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gas ventilation images are co-registered to anatomical 1H (grey-scale) to delineate regions
of hyperpolarized gas signal void, which are termed ventilation defects. Early work by
Altes and colleagues demonstrated good agreement between 3He MRI and

133

Xe

scintigraphy ventilation images.246 Notably, when comparing paired 3He and 129Xe images,
both remain homogenous in the healthy volunteer, but

129

Xe ventilation is more

heterogeneous than 3He in the asthma and COPD participants with larger and more
numerous defects. These results have been observed systematically in asthma247 and
COPD248,249 and suggest that 129Xe is more sensitive to lung abnormalities than 3He. It is
important to note that the images shown in Figure 1-10 were acquired after a single static
inhalation of hyperpolarized gas; dynamic wash-in and wash-out investigations have been
carried out,250,251 however single, static inhalations remain the most commonly employed
method.

Figure 1-10 Hyperpolarized 3He and 129Xe MRI
3
He (cyan) and 129Xe (purple) MRI co-registered to anatomical 1H (grey-scale) show
homogeneous ventilation for healthy participant and ventilation heterogeneity for asthma
and COPD participants. In asthma and COPD, 129Xe MRI ventilation is visually more
heterogeneous than 3He.
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The extent of ventilation abnormalities was initially quantified using visual scoring and
manual segmentation, however semi-automated252-254 and automated255,256 approaches are
now widely used.

Quantitative MRI biomarkers include the ventilated volume,257

ventilation coefficient of variation,258 ventilation defect volume259,260 and ventilation defect
percent.252,253,257,261

Second-order texture features of MRI signal have also been

quantified.262 VDP is the most widely disseminated biomarker to date, owing to its robust
reproducibility23,259 and well-established relationships with clinical indices.248,263 VDP is
calculated as the ventilation defect volume normalized (VDV) to the thoracic cavity
volume (TCV)252 as shown in Equation 1-11:
Equation 1-11

Ventilation defect percent [%]=

Ventilation defect volume [mL]
∙100
Thoracic cavity volume [mL]

In asthma, and as shown in Figure 1-10, ventilation is typically more heterogeneous than
healthy controls,258,263-265 although not all asthmatics have ventilation defects.264,266
Asthmatics with defects tend to be older,266 and ventilation defects increase with increasing
disease severity,263,267 are related to airflow obstruction22,260,263,266 and related to
plethysmography airways resistance.265 By lung lobe, one study showed a predominance
of defects in the right upper and middle lobes in patients with asthma.267 Ventilation
defects increase in size and number following methacholine-265,268 and exercise-induced268270

bronchoconstriction, and partially or completely resolve with bronchodilation.247,264,268

Investigations of the short-term temporal nature of ventilation defects in asthma
demonstrated persistence in the same spatial locations for same-day,23,264 7-14 day,271 and
up 1.5-year repeat evaluations.22,23 Repeat methacholine challenges also revealed the same
regions of lung affected by bronchoconstriction for up to 1.5 years.22 Although long-term
investigations have not yet been undertaken, these MRI findings refute the idea of diffuse
and random airway abnormalities in asthma and suggest the importance of regional
heterogeneity within the asthmatic lung.272 Moreover, ventilation defects are unique
predictors of asthma control273 and exacerbations,274 suggesting an important role for MRI
ventilation defects as an indicator of patient outcomes.
Ventilation defects in asthma may arise from any of the underlying airway pathologies
introduced in section 1.3.1 and the pathology has been investigated using a number of
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different approaches. Using CT airway measurements, ventilation defects have been
shown to be quantitatively and spatially related to abnormally remodeled large airways266
and intraluminal plugging by mucus and cellular debris.275 Fain and colleagues also
demonstrated the contribution of small airways to ventilation defects via spatial
correlations with regions of air trapping on expiratory CT260 and relationships with
oscillometry small airways resistance further suggest the role of small airways in
ventilation defects in asthma.276

Using a more invasive approach, a preliminary

investigation of image-guided bronchoscopic biopsies in regions of ventilation defects
demonstrated increased goblet cell hyperplasia and squamous metaplasia in regions of
defects versus well-ventilated regions in the same participants.277 With respect to airway
inflammation, ventilation defects have been shown to be related to fractional exhaled nitric
oxide,265 neutrophils in bronchoalveolar lavage260 and sputum eosinophils.278

In

conjunction with sputum measurements and pre- and post-bronchodilator evaluations, MRI
can distinguish regions with inflammatory versus non-inflammatory contributions to
ventilation heterogeneity.278 With an understanding of the pathophysiology, it follows that
ventilation defect response to treatment has been demonstrated with montelukast,270
bronchial thermoplasty279 and dupilumab.280 Preliminary results of a randomized control
trial for MRI-guided bronchial thermoplasty demonstrated non-inferior results compared
with the conventional whole-lung approach,281 and larger-scale image-guided studies are
ongoing.282
Many similar results have been observed in patients with COPD. Ventilation is also more
heterogeneous in COPD compared with healthy controls,248,259,283 and ventilation defects
increase with increasing COPD severity259,284 and are related to airflow obstruction.248,283
In milder disease, ventilation defects are more predominant in the basal lung and the
distribution becomes more homogeneous in more severe disease.285 Repeatability of
ventilation defects in COPD has been observed on same-day and 7-day evaluations,259
which is in agreement with the understanding of persistent airflow obstruction in COPD.
Regional and quantitative improvements in ventilation defects have however been
observed following bronchodilation in the absence of spirometric improvement,286
suggesting the increased sensitivity of MRI ventilation abnormalities to bronchodilation in
COPD.

Importantly, ventilation defects are related to COPD symptoms and exercise
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limitation287 and are predictive of COPD exacerbations.288 Pathologically, ventilation
defects are spatially and quantitatively related to CT measurements of emphysema289 and
comparison with CT parametric response maps revealed that ventilation defects in mild
COPD are related to air trapping and small airways disease, whereas in severe COPD,
defects are more related to emphysema.284
The sensitivity and safety of MRI provide a unique opportunity to evaluate the natural
progression of lung diseases. The progressive nature of COPD was evaluated in a
preliminary longitudinal study in 15 participants with COPD, which demonstrated that
MRI ventilation significantly worsened after two years in the absence of FEV1 changes.290
In a larger cohort study evaluating spirometry, CT and MRI over three years, only MRI
ventilation biomarkers significantly predicted disease worsening in mild-moderate
COPD.291 In comparison in asthma, MRI ventilation abnormalities have only been studied
over a longitudinal period of up to 1.5 years.22,23 With the novel understanding of a
progressive phenotype of asthma and progression to COPD, longitudinal studies are
required to better understand asthma disease progression, and previous results in
COPD290,291 suggest MRI ventilation biomarkers may be sensitive to early disease changes.
Diffusion-weighted Imaging
Diffusion-weighted hyperpolarized gas MRI leverages the self-diffusion of the inhaled
gases to measure the lung microstructure.292 The random Brownian motion of the noble
gas atoms reflects the restricted diffusion of the gases within the airways and airspaces and
is quantified as apparent diffusion coefficients (ADC). The diffusion time interval is a
surrogate of airspace size or dimension such that increased ADC reflects a greater mean
square displacement of the gas molecule, which typically occurs in enlarged airspaces in
the case of emphysema. ADC were first evaluated using 3He, which were validated against
histology61 and shown to be highly reproducible in vivo.259,293 3He ADC were subsequently
used to validate

129

Xe ADC.294 Owing to the respective pathophysiologies, diffusion-

weighted MRI is commonly evaluated in COPD but not asthma.
Limited studies in asthma show conflicting evidence; some studies have shown elevated
ADC compared with healthy controls295,296 whereas another observed no difference.265
ADC has however been shown to increase following methacholine-induced
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bronchoconstriction and subsequently decrease with bronchodilation.265

The

methacholine-induced increase in ADC was suggested to be due to gas trapping,265 and a
more recent study demonstrated direct relationships between elevated ADC in asthma and
CT-measured gas trapping.296
In COPD, ADC are certainly elevated relative to healthy controls248,297,298 and as expected,
are related to CT measurements of emphysema.248,299,300 ADC are also related to airflow
obstruction297,299 and diffusing capacity of the lung.294 In a 3He-129Xe comparative study,
ADC were used to explain the differences between 3He and 129Xe ventilation defects, which
was ultimately determined to be related to emphysema.289 The use of ADC in COPD
phenotyping has also been described in a preliminary investigation,301 similar to that for
CT described previously. It is important to acknowledge however that ADC measurements
are limited to those regions that ventilate in a single breath-hold and therefore may be
unable to probe the most diseased regions.
Dissolved-phase Imaging
129

Xe is especially advantageous because, unlike 3He, it is soluble in biological tissue and

can probe the efficiency of gas exchange.302,303 The so-called dissolved phase refers to
xenon dissolved in the alveolar-capillary membrane and red blood cells within the
pulmonary capillaries – once dissolved,

129

Xe exhibits a chemical shift from the gaseous

state that can be resolved as three distinct nuclear MR peaks: 1) gas, 2) tissue barrier plus
plasma, and 3) red blood cell. The gas state reflects the spin density imaging described
previously and has the largest measurable signal. The tissue barrier plus plasma signal
represents

129

Xe dissolved in the alveolar-capillary membrane and blood plasma. The

tissue barrier and plasma themselves have indistinguishable chemical shifts and together
combine for the second largest signal approximately 197 ppm from the gas state.304 Once
uptaken into the red blood cells,

129

Xe exhibits an additional chemical shift of

approximately 20 ppm beyond the tissue-plasma peak, creating the third and smallest peak.
All three compartments may be imaged simultaneously within a single breath-hold of
129

Xe303 to quantify gas exchange on a regional level.305 Each peak may be quantified as a

defect percent on its own analogous to VDP, or ratios between the peaks may also
expressed, for example tissue-to-gas, red blood cell-to-gas, or red blood cell-to-tissue.306

46

The primary applications of dissolved-phase imaging have been in diseases of pulmonary
fibrosis, with limited application to date in asthma and COPD. In the first evaluation of
asthma and COPD using

129

Xe dissolved-phase MRI, Qing and colleagues observed

reduced red blood cell-to-tissue ratio in COPD and increased variance in the red blood cellto-tissue ratio in asthma, both compared with healthy controls.306 Additional preliminary
work has observed greater improvements in

129

Xe barrier and red blood cell biomarkers

compared with ventilation following dual bronchodilator therapy307 and also identified
phenotypes of gas exchange in patients with COPD.308

Although there are limited

applications of dissolved phase imaging to date in obstructive lung disease, there is
enormous opportunity for

129

Xe dissolved phase to better understand pathophysiology,

evaluate and determine new disease phenotypes, and evaluate treatment response. Similar
to ADC, dissolved-phase measurements are also limited to those regions that ventilate in a
single breath-hold.
1.6.4.3 Functional 1H MRI
Fourier decomposition MRI (FDMRI) is a free-breathing 1H approach that permits
simultaneous ventilation and perfusion imaging of the lung.309 As the patient tidally
breathes, a time series of 1H images are acquired and subsequently deformably coregistered to a reference image frame. The reference image is usually chosen as one at
mid-position between end-inspiration and end-expiration. In the registered image, the
signal intensity oscillates over time due to the mechanical compression and expansion of
the lung tissue during breathing. Fast Fourier transforms of the signal oscillations in each
voxel generate the ‘signal intensity’ of the ventilation map using the first ventilation
harmonic, which corresponds to the respiratory rate. Example FDMR ventilation images
are shown in Figure 1-11 for healthy, asthmatic and COPD participants. The same process
may be performed at the cardiac rate to generate perfusion maps.309
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Figure 1-11 Functional 1H FDMRI
FDMRI ventilation maps (magenta) generated from free-breathing 1H MRI co-registered
to anatomical 1H (grey-scale) show homogeneous ventilation for healthy participant and
ventilation heterogeneity for asthma and COPD participants.
FDMRI sensitively detects ventilation abnormalities in both asthma310 and COPD311 that
show strong agreement with 3He static ventilation abnormalities. FDMRI may however
exhibit a small bias towards smaller ventilation defect abnormalities than 3He, likely owing
to the different time constants for lung filling during the image acquisition time (2 minutes
FDMRI versus 12 seconds 3He).310 Kaireit and colleagues also demonstrated strong
agreement between FDMRI and dynamic washout

19

F MRI ventilation abnormalities in

patients with COPD.312 In a randomized control trial, a similar variation of FDMRI313
showed ventilation improvements in patients with COPD following dual bronchodilator
therapy.314
Although FDMRI requires advanced post-processing to generate functional maps, it
eliminates the need for additional hardware and contrast agents, and enables functional
ventilation maps on any MRI system using conventional 1H sequences and coils. A rapid,
automated pipeline was recently developed315 to facilitate wider translation of this
technique.

1.7 Thesis Hypotheses and Objectives
The underlying structure-function determinants of ventilation heterogeneity in asthma are
not well understood. In silico models suggest that asthmatic airway abnormalities are
random, whereas early in vivo MRI results suggest airway abnormalities in asthma are not
random. Instead, MRI findings reveal focal ventilation abnormalities that persist for up to
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1.5 years.22,23 There is enormous potential for pulmonary imaging to provide a better
understanding of the mechanisms and physiological relevance of ventilation heterogeneity
in asthma. Accordingly, the overarching objective of this thesis was to exploit sensitive
pulmonary imaging measurements to better understand the structure and function of the
asthmatic lung that drive ventilation heterogeneity and provide a foundation for imaging
to guide disease phenotyping, predict disease worsening, and deliver personalized asthma
treatment. The hypotheses and objectives specific to each chapter of this thesis are
described below.
We first wanted to better understand the structural biomechanics of ventilation
heterogeneity in asthma compared with that of COPD and if these differences could be
explained by oscillometry and MRI ventilation defects. We hypothesized that oscillometry
measurements of resistance and reactance exhibit different relationships with MRI
ventilation defects in participants with asthma and COPD. The objective of Chapter 2
was therefore to evaluate and compare hyperpolarized 3He MRI and oscillometry in
participants with asthma versus those with COPD, never-smokers without asthma and exsmokers without COPD.
We next wanted to understand the long-term spatial and temporal nature of airway and
ventilation abnormalities in asthma. Based on previous work that showed that ventilation
abnormalities are spatially persistent for up to 1.5 years, we hypothesized that MRI
ventilation defects and CT airway abnormalities in asthma are spatially and quantitatively
persistent for longer than 1.5 years. In Chapter 3, our objective was to evaluate and
compare CT airway and MRI ventilation abnormalities in nonidentical twins over a period
7 years.
Building on this, we further evaluated the long-term structure-function relationships in
asthma in a group of unrelated asthma patients. We also wanted to determine the role for
MRI in predicting disease worsening and we hypothesized that ventilation defects are
predictive of future bronchodilator reversibility. In Chapter 4, we conducted a proof-ofconcept study in 11 mild-to-moderate asthmatics over 6.5 years with the objective to
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investigate the long-term pattern of ventilation defects and to identify predictors of
longitudinal bronchodilator reversibility after 6.5 years.
Finally, based on previous work in COPD, we wondered whether the airway tree appears
truncated on CT in patients with asthma. Due to the nature of airway remodeling in asthma,
we hypothesized that CT airway count is reduced in patients with severe asthma compared
to those with mild-to-moderate asthma, and that this reduction is associated with thickened
airway walls and worse lung function. Accordingly, the objective of Chapter 5 was to
measure CT total airway count in patients with asthma across a range of severities and
evaluate relationships with asthma severity, airway morphology, pulmonary function, and
MRI ventilation.
In Chapter 6, I provide an overview and summary of the important observations and
conclusions from Chapters 2-5. I also discuss the study specific and general limitations
for these studies and suggest some potential solutions. I conclude my thesis with an outline
of future studies that can build on the work presented here.
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CHAPTER 2
2

OSCILLOMETRY AND PULMONARY MAGNETIC
RESONANCE IMAGING IN ASTHMA AND COPD

To better understand the biomechanical impacts of asthma and how this compares to
COPD, we evaluated and compared oscillometry and MRI ventilation defects in
participants with asthma and COPD as well as never-smokers without asthma and exsmokers without COPD.
The contents of this chapter were previously published in the journal Physiological
Reports: RL Eddy, A Westcott, GN Maksym, G Parraga, RJ Dandurand. Oscillometry and
Pulmonary Magnetic Resonance Imaging in Asthma and COPD. Physiol Rep.
2019;7(1):e13955. This article is available under the terms of the Creative Commons
Attribution License.

2.1 Introduction
First developed over 60 years ago,1 oscillometry has re-emerged as a way to generate
clinical measurements in patients with obstructive lung disease because minimal coaching
and patient effort is required. Moreover, oscillometry is well-tolerated in young and old
patients across disease severities2 and is sensitive to small airway abnormalities.3
Oscillometry also provides a non-invasive way4 to reveal lung pathologies that result in
ventilation heterogeneity5-7 by directly measuring resistance and reactance as functions of
frequency. It is well established that in asthma, respiratory-system resistance responds to
bronchodilator inhalation8-11 and is frequency-dependent.12-14 The frequency dependence
of resistance has also been observed in patients with chronic obstructive pulmonary disease
(COPD),15 in whom low frequency resistance also diminishes after bronchodilation.8,9
In patients with asthma and COPD, reactance is more negative at low frequencies.16 The
area under the reactance curve can be quantified as the reactance area (AX)17 which is
determined by the reactance value measured at the lowest frequency, the resonant
frequency, and the shape of the low frequency reactance curve. AX measurements correlate
strongly with the frequency dependence of resistance18 and in asthmatics, AX detects
bronchodilator8 and bronchial challenge19 responses in the absence of low frequency
reactance changes. Furthermore, AX has been suggested as a useful tool for early disease
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screening and monitoring in COPD, and may be more sensitive to therapy response than
the frequency dependence of resistance.20
X-ray computed tomography (CT) airway measurements were previously shown to be
related to oscillometry measurements of resistance in asthma21 and COPD.22 Quantitative
CT measurements of emphysema have also been shown to be related to oscillometrymeasured reactance in COPD22 and there are differences in the relationships between CT
measurements and respiratory impedance in different COPD phenotypes.23 Magnetic
resonance imaging (MRI) using inhaled noble gases was also recently used to discern the
relationships between low frequency resistance and elastance as well as the frequency
dependence of resistance with MRI signal intensity coefficients of variation.24 Another
study showed a relationship between MRI ventilation defect percent (VDP) and the
frequency-dependence of resistance in COPD patients.25
While these previous results are intriguing, no large-scale, controlled study has investigated
a diversity of patients across a spectrum of disease severities to ascertain the relationships
between experimental oscillometry measurements and imaging biomarkers of airway and
parenchymal disease. This is important because in patients with asthma and COPD, airway
and parenchymal abnormalities both contribute to symptomatic derangements in lung
function and poor exercise capacity. In recent years, there has been modest clinical support
for experimental impedance measurements as a way to evaluate patients.20,26 Accordingly,
our objective was to investigate the relationships between oscillometry measurements
including resistance, reactance and the frequency dependence of resistance as well as AX
with MRI ventilation defect measurements across a wide variety of patients. In contrast
with previous investigations,24,25,27 here we evaluated participants with asthma and those
with COPD (with and without emphysema) as well as control groups of never-smokers
without asthma and ex-smokers without COPD.
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2.2 Materials and Methods
2.2.1 Study Participants and Design
We evaluated never-smokers aged 60 to 90 years, asthmatics aged 18 to 70 years and exsmokers with and without COPD aged 50 to 90 years who provided written informed
consent to study protocols approved by the local research ethics board and Health Canada
and registered (NCT02483403, NCT02279329, NCT02351141 https://clinicaltrials.gov).
All subjects underwent a single three-hour study visit including spirometry,
plethysmography, oscillometry and MRI.
evaluated and results published.25

Some of these subjects were previously

Never-smokers performed all testing without

administration of a short-acting bronchodilator. Participants with asthma and all exsmokers performed all testing after administration of a short-acting bronchodilator. In
addition, all ex-smokers underwent post-bronchodilator thoracic CT. Post-bronchodilator
testing was performed 20 minutes after administration of four inhaled doses of 100 μg
Novo-Salbutamol HFA (Teva Novopharm Ltd., Toronto, ON, Canada) through a
pressurized metered-dose inhaler using an AeroChamber Plus spacer (Trudell Medical
International, London, ON, Canada).

2.2.2 Pulmonary Function Tests
Spirometry and plethysmography were performed using a MedGraphics Elite Series
plethysmograph (MGC Diagnostics Corporation, St. Paul, MN, USA). Spirometry was
performed according to American Thoracic Society (ATS)/European Respiratory Society
(ERS) guidelines28 to measure the forced expiratory volume in one second (FEV1), forced
vital capacity (FVC) and FEV1/FVC, while plethysmography was performed to measure
lung volumes and airways resistance (Raw). For never-smokers and all ex-smokers, the
diffusing capacity of the lung for carbon monoxide (DLCO) was also measured using a
stand-alone gas analyzer attached to the plethysmograph. For post-bronchodilator testing
in asthma, ex-smoker and COPD subgroups, participants withheld short-acting β-agonists
for 6 hours, long-acting β-agonists for 12 hours and long-acting muscarinic antagonists for
24 hours before their study visit.
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2.2.3 Oscillometry
Oscillometry was performed using the tremoFlo C-100 Airwave Oscillometry System
(Thorasys, Montreal, QC, Canada) with the non-harmonic composite airwaves in the adult
frequency range consisting of 5, 11, 13, 17, 19, 23, 29, 31 and 37 Hz to measure total
respiratory system resistance at 5 Hz (R5), frequency-dependence of resistance as R at 5
Hz minus R at 19 Hz (R5-19), reactance at 5 Hz (X5), resonant frequency (fres) and AX. AX
was calculated by integrating the reactance curve from 5 Hz to fres and when fres was greater
than 37 Hz, the reactance curve was truncated at 37 Hz and integrated up to that point.
Participants were seated comfortably with legs uncrossed and supported their chin and
cheeks with their hands to limit upper airway shunt. Oscillometry measurements were
acquired over 16 seconds and repeated for three acceptable and repeatable tests, as judged
by a coefficient of variation in resistance at 5 Hz (CVR5) of < 15%. Artefacts were
automatically identified and removed by the manufacturer’s automated algorithms.
Calibration of the oscillometry unit was performed daily using the vendor-provided
nominal 2 cmH2Os/L reference test load.

2.2.4 Image Acquisition and Analysis
All subjects underwent anatomical proton (1H) followed by hyperpolarized 3He static
ventilation MRI (within five minutes) using a whole body 3T system (MR750 Discovery,
General Electric Healthcare, Milwaukee, WI) with broadband imaging capability as
previously described.29 3He gas was polarized to 30-40% polarization (HeliSpin; Polarean
Inc., Durham, NC, USA) and diluted with N2 gas to 25% 3He by volume. Subjects were
positioned supine in the scanner with their arms above their head and instructed to inhale
1.0 L of gas (100% N2 for 1H MRI, 3He/N2 mixture for 3He MRI) from functional residual
capacity (FRC) and coronal images were acquired in 8-15 seconds under breath-hold
conditions. For all image acquisition, FRC was assumed to be the lung volume at end tidal
expiration.
Hyperpolarized 3He MR images were analyzed using in-house segmentation software as
previously described.30 Briefly, a single user placed seeds on the 1H and 3He images to
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label the lung and the surrounding background tissue and image registration and
segmentation were completed automatically. 3He images were segmented into five clusters
of signal intensity using three-dimensional k-means clustering,31 and the ventilation defect
percent (VDP) was quantified as the ventilation defect volume normalized to the thoracic
cavity volume.
Ex-smoker participants were transported from the MRI suite to the CT suite by wheelchair
to avoid exercise-induced dilatation of the airways. Thoracic CT volumes were acquired
within ten minutes of completion of MRI using a 64-slice LightSpeed VCT system
(General Electric Healthcare) as previously described32 under breath-hold conditions after
full inspiration. The total effective dose for each CT scan was 1.8 mSv as calculated using
the manufacturer’s settings and the ImPACT patient dosimetry calculator (based on the
UK Health Protection Agency NRPB-SR250 software).
Thoracic CT images were analyzed using Pulmonary Workstation 2.0 (VIDA Diagnostics
Inc., Coralville, IA, USA) to quantify emphysema using the relative area of the lung < 950 Hounsfield units (RA950). An RA950 threshold of 6.8% was used to stratify COPD
subjects with and without CT evidence of emphysema.33

2.2.5 Statistical Analysis
Data were tested for normality using the Shapiro-Wilk test using IBM SPSS Statistics 25.0
(IBM Corporation, Armonk, NY, USA) and when not normally distributed, non-parametric
statistics were performed. One-way ANOVA and Kruskal-Wallis H test were performed
for group-wise differences with post-hoc least significant difference and Holm-Bonferroni
correction to adjust for multiple comparisons and Fisher’s exact test was used for
categorical variables using SPSS. Univariate relationships were evaluated using Pearson
correlations (r) for normally distributed data and Spearman correlations (ρ) when the data
were not normally distributed using GraphPad Prism 7.00 (GraphPad Software, La Jolla,
CA, USA). Multivariable models were generated in SPSS using the enter approach to
determine the contributions of R5, R5-19, X5 and AX to VDP using age, sex and body mass
index (BMI) as covariates for four separate models: (1) all subjects, (2) never-smokers and
ex-smokers with and without COPD, (3) ex-smokers with and without COPD, and (4)
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asthmatics only. Results were considered statistically significant when the probability of
making a Type I error was less than 5% (p<0.05).

2.3 Results
We evaluated 175 participants including 42 elderly never-smokers (74±7 years), 49
participants with asthma (48±12 years; n=14 treatment steps 1-2, n=35 treatment steps 3-4
as per the Global Initiative for Asthma [GINA] guidelines34), 28 ex-smokers without
COPD (70±9 years) and 56 ex-smokers with COPD (73±9 years; n=18 mild [GOLD I],
n=22 moderate [GOLD II], n=16 severe [GOLD III-IV]). Table 2-1 shows demographic,
pulmonary function test and imaging measurements for never-smokers, asthma
participants, ex-smokers and COPD participants and between-group differences are shown
in Figure 2-1 for select data. We note that for 10 participants, fres was greater than 37 Hz
(n=1 asthma, n=9 COPD).

Participants with COPD had significantly worse post-

bronchodilator pulmonary function than never-smoker and ex-smoker participants,
whereas participants with asthma did not have significantly different post-bronchodilator
oscillometry measurements than never-smokers and ex-smokers.
significant differences between never-smoker and ex-smoker subgroups.
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There were no

Table 2-1 Participant demographics
Parameter
Mean (±SD)
Age years
Male n (%)
BMI kg/m2
FEV1 %pred
FVC %pred
FEV1/FVC %
RV %pred
TLC %pred
RV/TLC %pred
DLCO %pred
Raw %pred
R5 cmH2Os/L
R5-19 cmH2Os/L
X5 cmH2Os/L
fres Hz✝
AX cmH2O/L
VDP %

Never-smokers
Asthma
(n=42)
(n=49)
74 (7)
48 (13)
21 (50)
19 (39)
27 (4)
28 (5)
107 (18)
77 (21)
103 (15)
88 (15)
77 (6)
69 (13)
98 (22)
121 (33)
100 (13)
102 (15)
96 (17)
118 (23)
90 (16)
83 (38)
105 (51)
3.59 (1.68)
4.25 (1.49)
0.54 (0.76)
0.82 (0.87)
-1.41 (0.88)
-1.86 (1.26)
19.77 (7.40)
19.53 (6.86)
12.94 (14.94) 14.38 (14.90)
3 (2)
5 (6)

Ex-smokers
(n=28)
70 (9)
16 (57)
31 (4)
102 (19)
95 (19)
80 (6)
100 (21)
96 (13)
104 (16)
87 (17)
65 (24)
3.32 (1.12)
0.36 (0.54)
-1.42 (0.72)
20.20 (5.78)
9.79 (7.57)
5 (4)

COPD
(n=56)
73 (9)
36 (64)
26 (4)
68 (27)
92 (21)
53 (12)
148 (47)
113 (18)
129 (26)
61 (23)
117 (49)
3.64 (1.23)
0.96 (0.79)
-2.41 (1.57)
23.66 (7.67)
23.30 (19.96)
19 (12)

Sig diff*
(p)
<0.0001
0.1
<0.0001
<0.0001
0.002
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.7
0.001
0.001
0.001
0.008
<0.0001

SD=standard deviation; Sig diff=significance of difference; BMI=body mass index;
FEV1=forced expiratory volume in one second; %pred=percent predicted; FVC=forced vital
capacity; RV=residual volume; TLC=total lung capacity; DLCO=diffusing capacity of the lung
for carbon monoxide; Raw=airways resistance; R5=respiratory system resistance at 5 Hz; R519=frequency dependence of resistance; X5=respiratory system reactance at 5 Hz; fres=resonant
frequency; AX=reactance area; VDP=ventilation defect percent.
Pre-bronchodilator values shown for never-smokers and post-bronchodilator values shown for
asthmatics, ex-smokers and COPD subjects.
*Significance of difference calculated using one-way ANOVA for parametric variables and
Kruskal-Wallis H test for non-parametric variables; significant values are bolded.
✝
n=42 for never-smokers, n=48 for asthma, n=28 for ex-smokers, n=47 for COPD; fres> 37 Hz
for remaining subjects.
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Figure 2-1 Pulmonary function test and MRI VDP measurements
A) Significantly lower FEV1 in asthma and COPD compared to never-smokers and exsmokers. B) Significantly greater RV/TLC in asthma and COPD compared to neversmokers and ex-smokers. C) Significantly greater Raw in asthma as compared to exsmokers and COPD subjects and significantly greater Raw in COPD as compared to never
and ex-smokers. D) Significantly greater VDP in COPD as compared to all other
subgroups. E) R5 not significantly different between all subgroups. F) Significantly greater
R5-19, and, G) Significantly more negative X5, and, H) significantly greater AX in COPD as
compared to never- and ex-smokers.
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Figure 2-2 shows

3

He MRI ventilation defects and oscillometry plots for two

representative participants in each group: one with low (normal) VDP and one with greater
(abnormal) VDP. For participants with asthma and COPD, worse ventilation heterogeneity
qualitatively reflected increased frequency dependence of resistance and reactance as well
as greater AX. Increased ventilation heterogeneity in never-smokers and ex-smokers
without COPD, however, did not reflect qualitatively apparent changes in oscillometry. As
shown quantitatively in Figure 2-3, in asthma and COPD participants, post-bronchodilator
VDP was significantly related to R5-19, X5 and AX, but not R5. For never-smokers, VDP
was significantly negatively related to R5 only and there were no relationships in exsmokers (not shown).
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Figure 2-2 Relationships between MRI ventilation heterogeneity and impedance
measurements in representative subjects
Centre slice coronal static ventilation 3He MRI (cyan) co-registered to anatomical 1H (greyscale) and corresponding oscillometry plots for two representative asthma, COPD, neversmokers and ex-smokers.
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Figure 2-3 Quantitative relationships between MRI VDP and impedance measurements
A) VDP was not significantly related to R5 in asthma nor in COPD subjects. B) VDP was
significantly related to R5-19 , and, C) X5 and, D) AX in asthma and COPD participants.
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Table 2-2 shows multivariable models that predict VDP from oscillometric parameters R5,
R5-19, X5 and AX. R5 (β=-0.22, p=0.01) and X5 (β=-0.34, p=0.03) significantly added to the
prediction of VDP for all subjects (Model 1: R=0.63, R2=0.39, p<0.0001). For neversmokers and ex-smokers with and without COPD, R5 (β=-0.48, p=0.001), R5-19 (β=0.35,
p=0.03) and X5 (β=-0.41, p=0.03) significantly added to the prediction of VDP (Model 2:
R=0.66, R2=0.44, p<0.0001), whereas for only ex-smokers with and without COPD, the
overall model was significant (Model 3: R=0.62, R2=0.38, p<0.0001) but none of the
oscillometry parameters significantly added to the model. The overall model was also
significant for asthmatic participants only (Model 4: R=0.65, R2=0.43, p=0.001) but none
of the oscillometry parameters significantly added to the model.
Table 2-2 Multivariable models to predict VDP from oscillometry
Unstandardized
Variable
B
Standard Error
MODEL 1: All subjects, n=175 (R=0.63; R2=0.39, p<0.0001)
R5
-1.98
0.77
R5-19
1.81
1.61
X5
-2.75
1.26
AX
0.13
0.11

Standardized
β

p

-0.22
0.15
-0.34
0.21

0.01
0.3
0.03
0.2

MODEL 2: Never-smokers, ex-smokers with and without COPD, n=126 (R=0.66, R2=0.44,
p<0.0001)
R5
-3.96
1.17
-0.48
0.001
R5-19
5.14
2.35
0.35
0.03
X5
-3.55
1.63
-0.41
0.03
AX
0.10
0.13
0.15
0.5
MODEL 3: Ex-smokers with and without COPD, n=84 (R=0.62; R2=0.38, p<0.0001)
R5
-2.95
1.93
-0.29
0.1
R5-19
6.24
3.41
0.39
0.07
X5
-1.16
2.20
-0.14
0.6
AX
0.18
0.17
0.27
0.3
MODEL 4: Asthma only, n=49 (R=0.65, R2=0.43, p=0.001)
R5
-1.28
0.84
R5-19
3.33
1.85
X5
1.15
1.36
AX
0.14
0.13

-0.20
0.49
0.24
0.36

0.1
0.08
0.4
0.3

VDP=ventilation defect percent; R5=resistance at 5 Hz; R5-19=resistance at 5 Hz minus
resistance at 19 Hz; X5=reactance at 5 Hz; AX=reactance area.
Covariates: age, sex, BMI
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Of the 56 COPD participants evaluated, 33 had CT evidence of emphysema (RA950 ≥
6.8%33) and 23 had no CT evidence of emphysema (RA950 < 6.8%). VDP was not
significantly related to R5 regardless of the presence of emphysema, but VDP was related
to Ax in COPD with (ρ=0.39, p=0.02) and without emphysema (ρ=0.43, p=0.04). VDP
and R5-19 were significantly related in COPD subjects without emphysema only (ρ=0.54,
p=0.008), and significantly related to X5 in COPD subjects with emphysema only (ρ=-0.36,
p=0.04). There was no CT evidence of emphysema (all RA950 < 6.8%) in ex-smokers
without spirometry evidence of airflow limitation based on GOLD criteria of FEV1/FVC <
0.7.35

2.4 Discussion
We evaluated oscillometry and hyperpolarized

3

He MRI measurements in a relatively

large group of patients with asthma and COPD as well as two control groups and made
four important observations: 1) in asthma and COPD participants, VDP was significantly
but weakly correlated with R5-19, X5 and AX, but not R5, 2) in COPD patients without
emphysema, VDP was related only to R5-19 and AX, and only X5 and AX in COPD patients
with emphysema, 3) in an ex-smoker control group, there were no significant relationships
while in never-smokers, only VDP and R5 were related, and, 4) AX was weakly related to
VDP in all subgroups with airflow obstruction, demonstrating its sensitivity to airflow
obstruction but not specificity to type of obstruction.
The relationship between oscillometry and MRI VDP with quality-of-life measurements
was previously investigated in 100 patients25 and this previous work was in agreement with
our observations. The fact that there were no significant relationships between VDP and
oscillometry in the control subgroups except for R5 and VDP in never-smokers is also
congruent with previous results.25 Based on this previous work, our results were not
unexpected. R5 reflects the resistance of the entire respiratory system including all airways
(and not the just the small airways or the larger airways) and this may explain why
significant relationships with VDP were not present. R5 was also not significantly different
between the four subgroups, whereas R5-19, X5, AX as well as plethysmography-measured
airways resistance (Raw) were. This suggests that R5 is not sensitive to the differences in
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resistance in our patient population and this could be because much of the resistance in
these patients may be due to the peripheral airways and this effect is overshadowed in the
R5 signal. Oscillometry measurements that reflect the heterogeneity of airway narrowing
(R5-19) as well as X5 and AX36,37 were all related to VDP in asthma and all COPD patients,
and none of these relationships were detected in never- or ex-smokers. Notably, ventilation
defects in severe COPD were previously shown to be related to both emphysema and small
airways disease38,39 so the negative relationship between VDP and X5 in COPD was not
surprising. This was not previously observed25 perhaps due to the current study’s larger
sample size across all grades of COPD severity. It has been shown in experimental studies
in humans and animals however, that the major influence of heterogeneity is its impact on
resistance and elastance between 0.1 – 5 Hz,40-42 whereas our system is limited to 5 Hz and
above. We are thus only capturing the ‘tail-end’ of the impact of heterogeneities using R519

and this may explain the weak correlations observed.

To better understand how oscillometry and MRI VDP measurements are related and may
explain the biomechanical impact of obstructive lung disease in patients, we generated
multivariable models. We were surprised to observe that R5 significantly contributed to
the models with all subjects (Model 1) and in never-smokers and ex-smokers with and
without COPD (Model 2). R5 did not significantly contribute to the models in ex-smokers
with and without COPD (Model 3) or in asthmatics (Model 4). Based on these differences
it is possible that the R5 results were being driven by the never-smoker subgroup in whom
there is no airflow obstruction. There were no significant coefficients in Model 3 and 4
which may be due to the smaller subgroup sizes which limited power to detect significant
contributions. However, R5-19 has the greatest relative influence on VDP in Models 3 and
4 which did not include the never-smoker group.
COPD patients can be phenotyped based on the presence of airways disease and
emphysema43 and these phenotypes also reflect differences in lung biomechanics and
function.23 We observed differences in the relationships between VDP and oscillometry
measurements in COPD patients with and without emphysema, although it is likely that all
COPD patients had airways disease too. The fact that X5 and AX were related to VDP in
emphysematous COPD patients suggests that X5 and AX may reflect parenchymal stiffness
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or derecruitment, resulting in ventilation defects. In contrast, in COPD patients with little
or no emphysema, VDP was related to AX and R5-19 indicative of heterogeneous airway
narrowing largely in the periphery, which was in agreement with previous work.2 The
different behaviours of R5-19 and X5 in COPD patients with and without emphysema
suggests that X5 measures a different component that is independent of heterogeneous
airway obstruction associated with R5-19.5 However, AX was weakly significantly related
to VDP in patients with and without emphysema, and this suggests that it is non-specific
to the type of obstruction (either airways disease or emphysema) in COPD patients.
Emphysematous and airways disease phenotypes may be best identified by appropriate use
of R5-19 and X5. In COPD patients, it is also important to acknowledge that airways disease
and emphysema phenotypes are typically observed in combination,44 so future
examinations should also evaluate mixed phenotypes which were not evaluated here.
AX was originally developed to improve the signal-to-noise ratio of respiratory system
reactance compared to reactance values at a single frequency.17 Table 2-3 provides an
overview of the advantages and limitations of oscillometry measurements of obstructive
lung disease including AX. It is clear that AX is sensitive to airflow obstruction, however
it is non-specific to the type of obstruction and cannot distinguish airway constriction from
lung recruitment or parenchymal stiffening. R5-19 on the other hand is known to reflect
obstruction in the distal airways12 whereas X5 is known to reflect elastic components of the
lung. Moreover, AX and the frequency dependence of resistance may depend on the
number and choice of harmonics in the forcing waveform making them variable in different
settings. For AX, the largest influence is the first harmonic since this is where the most of
the area is located, and different commercially available devices start at different
frequencies anywhere from 4 Hz for adults up to 8 Hz for children. Our data also
demonstrated that for COPD participants with markedly abnormal AX greater than 50
cmH2O/L, VDP values ranged from 5% to 45% (Figure 3D) and this suggests that AX is
weakly related to inter-subject VDP differences. We note that AX did not significantly
contribute to VDP in any of the multivariable models. The multiple correlation coefficients
ranged from 0.62-0.66 with R2=0.39-0.44, so together, the oscillometry parameters
contributed to no more than 44% of the variability in VDP regardless of subgroup.
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Table 2-3 Advantages and limitations of oscillometry measurements
Advantages
Limitations
Frequency Dependence of Resistance (R5-19)
+ Signal averaging minimizes noise and
- Variable in different settings
potential artefacts
+ Differentiates proximal from distal
obstruction
+ Detects mild/early obstruction
Reactance at 5 Hz (X5)
+ Reflects elastic components
+ Reflects peripheral airway disease

- More noise
- Non-specific to obstruction versus
restriction

Reactance Area (AX)
+ Sensitive to obstruction
+ Signal averaging minimizes noise and
potential artefacts
+ Units of cmH2O/L, similar to
compliance
+ Sensitive to intra-subject response to
therapy or provocation

- Non-specific to type of obstruction
- Variable in different settings
- When fres is undefined, Ax value is
user-defined (hence variable between
different devices)
- Weakly related to inter-subject
differences

We also recognize a number of other study limitations. Hyperpolarized 3He MRI is
unlikely to be clinically used because of the vanishing global quantities and exorbitant cost
of 3He.45

129

Xe MRI is more sensitive to airway obstruction,38,46 less costly and therefore,

more feasible for clinical examinations so it will be important to compare oscillometry and
129

Xe MRI measurements in patients. Moreover, shunting of the oscillatory waves to the

upper airways reduces sensitivity to obstruction despite firm cheek-holding.47 This means
that in patients with obstruction, impedance may be underestimated, which may have also
limited the correlation strengths observed here. We note that the never-smoker control
group studied here underwent testing without inhaled bronchodilators whereas asthmatics,
ex-smokers and COPD ex-smokers were evaluated post-bronchodilator. We previously
showed that there was no post-bronchodilator MRI ventilation response in elderly neversmokers48 with ventilation abnormalities, so we expect no confounding effects due to the
lack of post-bronchodilator measurements in this subgroup. Finally, we also acknowledge
positional differences in the oscillometry (seated upright) and MRI measurements (supine).
Respiratory system resistance is increased in the supine position compared to upright49,50
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and the presence of emphysema also causes large upright to supine AX variability,51 which
may also explain why the relationships observed here were weak to moderate.
To our knowledge, this is the largest controlled evaluation of oscillometry and functional
MRI undertaken in patients and healthy volunteers. The pattern of significant relationships
for VDP with R5-19 and X5 was different between the different disease subgroups (i.e.,
COPD with and without emphysema, asthma). On the other hand, the relationship of AX
with VDP was similar across disease subgroups, suggesting that AX is a sensitive but not
specific measurement of obstruction. The different relationships for MRI VDP with R5-19
and X5 may reflect airway and parenchymal disease-specific biomechanical abnormalities
that lead to ventilation defects.
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CHAPTER 3
3

NONIDENTICAL
TWINS
WITH
ASTHMA:
SPATIALLY-MATCHED CT AIRWAY AND MRI
VENTILATION ABNORMALITIES

To better understand the long-term spatial and temporal nature of ventilation
heterogeneity in asthma, we evaluated and compared CT airway and MRI ventilation
abnormalities in nonidentical twins. We compared these measurements between the twins
over two visits separated by seven years and estimated the probability of the twins having
the same MRI ventilation abnormality.
The contents of this chapter were previously published in the journal Chest: RL Eddy, AM
Matheson, S Svenningsen, D Knipping, C Licskai, DG McCormack, G Parraga.
Nonidentical Twins with Asthma: Spatially-matched CT Airway and MRI Ventilation
Abnormalities. Chest. 2019;156(6):e111-6. This article is available under the terms of the
Creative Commons CC-BY-NC-ND License.

3.1 Introduction
We report magnetic resonance (MR) and x-ray computed tomography (CT) imaging
findings for female adult non-identical twins with moderate asthma who recounted a
similar clinical history and symptoms of asthma since childhood, or about 40 years. In
both 48-year-old women, there were spatially identical MRI ventilation defects and the
same abnormal subsegmental airway, both of which remained persistently abnormal in the
same spatial location over a period of seven years.
In patients with asthma, chronic cough, dyspnea and wheeze as well as acute
bronchoconstrictive worsening can be directly related to abnormal airway smooth muscle,1
luminal inflammation and mucus plugging,2 and airway wall remodeling.3 Pulmonary
functional MRI has recently revealed that asthma may be expressed in a spatially
heterogeneous manner, leading to MRI quantifiable ventilation heterogeneity4,5 and
ventilation defects that are both spatially and temporally persistent.6,7 Importantly and
across a number of different research centres, pulmonary functional MRI has shown that
in patients with asthma, ventilation abnormalities do not appear to be stochastic, nor
diffusely homogeneous.6 Such MRI findings contradict in silico modeling studies that
predict randomly distributed ventilation defects in patients with asthma.8,9
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3.2 Case
As part of a longitudinal asthma study (clinicaltrials.gov NCT02351141, ethics board#
103516), we prospectively followed female twins for two study visits between January
2010 and March 2017 using hyperpolarized 3He MRI, thoracic CT and pulmonary function
tests. Both twins were never-smokers (tobacco and cannabis) and attended separate
baseline visits, each reporting a longstanding diagnosis of moderate asthma according to
the Global Initiative for Asthma (GINA) treatment step criteria.10 Their clinical histories
were similar; they reported that both parents were heavy tobacco smokers within the family
home and both father and mother had a clinical history of airways disease. They both lived
within 25 km of each other and their original family home during their lifetime. Neither
twin reported occupational exposures or risk; they worked as healthcare (Twin1) and
daycare (Twin2) providers for most of their working lives. The twins had been
independently prescribed 400 mcg daily dose budesonide combined with formoterol
(Twin1, 200/6 mcg 2-puffs od; Twin2, 200/6 mcg 1-puff bid), by different asthma
specialist care providers for the past decade. During the seven-year follow-up period,
asthma medications remained the same and there were no asthma exacerbations reported.
They both reported weak-to-moderate controller medication adherence, although both
exhibited audible wheeze, shortness of breath and reported significant exercise limitation.
Both twins had airways hyperreactivity, with a provocative concentration of methacholine
resulting in a 20% decrease in FEV1 (PC20) of 0.08 mg/mL for Twin1 and 0.07 mg/mL for
Twin2 at the baseline visit. They also demonstrated bronchodilator reversibility according
to ATS/ERS guidelines11 over the follow-up period (Twin1, ΔFEV1=260 mL, 14%; Twin2,
ΔFEV1=220 mL, 15%). FEV1 did not change over the follow-up period for both twins
(+30 mL for Twin1, +130 mL for Twin2; less than the minimal clinically important
different for FEV1 in asthma12,13) and they both reported adequate asthma control (asthma
control questionnaire score [ACQ] <1.0).
Figure 1 shows pre-bronchodilator hyperpolarized 3He MRI at baseline (V1) and followup (V2), seven-years later. MR ventilation images provided in Figure 1 shows that for both
twins there was a spatially identical, focal ventilation defect at baseline; the same left upper
lobe ventilation abnormality also persisted at follow-up in both twins. We co-registered
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the follow-up MRI ventilation to the patient’s thoracic CT and generated three-dimensional
airway trees (Figure 1, right panel) in order to reveal the specific airways that corresponded
to the persistent MRI ventilation defects in each patient. The posterior branch of the left
upper lobe apico-posterior bronchopulmonary segment (LB2) was abnormally remodeled
and at follow-up, the subsegmental airway wall-area-percent was 71% for Twin1 and 75%
for Twin 2 (both of which are markedly abnormal based on the literature14,15). Inset panels
provide two-dimensional coronal CT airway subsegments which show that LB2 was not
visible distally (due to airway termination or closure) to the same extent in Twin2 as in
Twin1.
We also co-registered the airway trees to directly compare the twins’ overall tree, as shown
in Figure 2. The bulk airway anatomy was similar, with differences mainly in branching
angles. Notably, Twin2 had less airways overall than Twin1 (total airway count 166 versus
202), and this is reflected in the number of airways by airway tree generation distal to LB2
and RB1. Wall-area-percent at the generation of the LB2 airway spatially-related to the
persistent ventilation defect (indicated by * in Figure 2), was increased relative to RB1 (as
a comparator) in both twins.
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Figure 3-1 Spatially-matched MRI ventilation defects and CT airways for twins with
asthma
Tables show spirometry and MRI ventilation defect percent (VDP) at both visits, as well
as CT total airway count (TAC) and asthma control questionnaire (ACQ-7) score at visit
2. 3He MRI ventilation (cyan) co-registered to anatomical 1H (grey-scale) for the twins at
two study visits with yellow arrows showing spatially similar ventilation defects between
the twins and over time. Follow-up 3D MRI ventilation on right co-registered to CT and
3D airway tree shows spatial relationship between left upper lobe apico-posterior
segmental airway leading to similar defect, with inset showing airway segment on CT.
White arrows show spatially persistent airways in 3D and in 2D CT inset.
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Figure 3-2 Co-registered CT airway trees
Co-registered airway trees for Twin1 (dark blue) and Twin2 (light blue) show similar bulk
airway anatomy. Airway trees were registered to align LB2 and comparator RB1 (zoomed,
white arrows) and corresponding number of airway branches (n) and mean wall area
percent (WA%) by airway tree generation are shown for both segments. Stars (*) in the
table indicate generation of abnormally remodeled LB2 airway that corresponds to the
spatially persistent defect between the twins.
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3.3 Discussion
A number of MRI investigations of asthma point to gas distribution abnormalities that are
spatially and temporally persistent, suggestive of ventilation heterogeneity that is spatially
non-random and preserved over time. We wondered about the likelihood of twins with
asthma having identical MRI ventilation defects that could be identified as related to
abnormal airways measured using CT; we also wondered if such abnormalities might also
persist after a long-period of time in asthma patients with relatively stable disease.
If we assume that ventilation abnormalities are randomly distributed, to estimate the
probability of two participants with asthma having the same segmental ventilation defect
over a relatively long period of time, we considered the 19 anatomically and functionally
distinct bronchopulmonary segments and made the following assumptions: 1) both patients
with asthma would report at least one ventilation defect and no more than one defect per
bronchopulmonary segment (ie., >0 and <19 ventilation defects),16 and, 2) there was an
equivalent probability for each of the 19 bronchopulmonary segments to express a
ventilation defect. We assumed that each of the twins would have at least one ventilation
defect because of their longstanding clinical asthma diagnosis of asthma and their age.16
Asthma patients with MRI ventilation defects are typically older than asthma patients
without defects5 and these twins were older than the mean age of participants in this
previously reported investigation (35±11-years5). We first observed one ventilation defect
in the apico-posterior left upper lobe segment in Twin1, and the probability for this single
defect in this single bronchopulmonary segment was 1 in 19. Following this estimate, the
probability that Twin2 would have exactly one defect in the same bronchopulmonary
segment was 1 in 192 or 1 in 361.
Mathematical models of asthmatic airways predict that ventilation or gas distribution
abnormalities would be random or stochastic.8,9,17 If we assume that the occurrence of
ventilation defects in asthma was random over time such that the presence and spatial
locations of ventilation abnormalities appeared in different lung segments over time, we
could also determine the probability that two patients have the same single segmental
ventilation defect at baseline and again at seven-year follow-up to be 1 in 194 or 1 in
130,321. These odds are less likely than a single individual’s risk of being struck by
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lightning (~1 in 10,000 lifetime, 1 in 100,000 annual risk) and suggests that MRI
ventilation defects may not be randomly distributed. While MRI studies have shown that
the presence and size of specific ventilation defects may fluctuate modestly over time,7,18
MRI ventilation defects in participants with asthma are mainly spatially persistent. In both
twins, there was evidence of airways hyperreactivity and bronchodilator reversibility
through the follow-up period, so the abnormal remodeling of the apico-posterior left upper
lobe airway may stem from increased airway smooth muscle mass. However, we cannot
comment on the contribution of airway inflammation because it was not evaluated.
Longitudinal MRI and CT studies in patients with asthma have demonstrated persistent
and dynamic disease components,7,18-20 whereas here we focused on persistently abnormal
regions. For example, Twin1 exhibited ventilation heterogeneity in the right lung base that
was not present at follow-up, nor in Twin2. These regions of abnormal ventilation were
associated with abnormally remodeled airways (Twin1 RB9 and RB10 most distal
branches mean WA%=68% generation 5 versus LB2 WA%=71% generation 6). We think
that intermittent ventilation abnormalities may be due to transient inflammation in
combination with airway remodeling, although inflammatory status was not evaluated.
Limitations of our case study and analysis include the fact that the twins were only
evaluated twice and the assumption we made that there was an equal probability of
ventilation defects appearing in any of the 19 bronchopulmonary segments. In other words,
we did not take into consideration that, in twins, there might be a bias for airway and
ventilation abnormalities in specific lung regions. In addition, we did not make any
assumptions about a potential upper limit for ventilation defect number, less than the 19
potential segmental airways. However, in our experience in over 200 asthmatic patients,
there are typically fewer than five ventilation defects in participants with moderate disease,
which is consistent with previous investigations.16 Therefore, the probability of repeated
defects in space and time as we observed would be lower, so our estimates are conservative.
A more rigorous analysis could include the probability of multiple ventilation defects, the
probability of twins having asthma, or the probability of subsegmental (38 subsegments)
or sub-subsegmental (76 sub-subsegments) ventilation defects, all of which would serve to
lower the probabilities estimated here. Finally, we have assumed the persistent ventilation
defect in these patients to be related to asthma pathophysiology and/or abnormal airway
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structure. These findings could also be explained to some extent by shared genetics, epigenetics or in utero events, which we did not evaluate here and cannot rule out.
In twins with asthma, we observed a single spatially-identical MRI ventilation defect
related to abnormal airway remodeling which persisted in the same spatial location after
seven years. If ventilation defects occur randomly in asthmatics, the probability of this
occurring in both patients in the same location, twice over seven years is ~1 in 130,000.
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CHAPTER 4
4

HYPERPOLARIZED HELIUM 3 MRI IN MILD-TOMODERATE
ASTHMA:
PREDICTION
OF
POSTBRONCHODILATOR REVERSIBILITY

Building on the evidence of spatially and temporally persistent regional lung abnormalities
in twins with asthma from Chapter 3, we wanted to evaluate the long-term structurefunction relationships in unrelated asthma patients and determine the role for MRI
ventilation abnormalities in predicting longitudinal disease worsening.
In order to quantitatively evaluate ventilation abnormalities over time, we first determined
the minimal clinically important difference for MRI ventilation defects; this work is
provided in Appendix A.
The contents of this chapter were previously published in the journal Radiology: RL Eddy,
S Svenningsen, C Licskai, DG McCormack, G Parraga. Hyperpolarized Helium 3 MRI in
Mild-to-Moderate Asthma: Prediction of Postbronchodilator Reversibility. Radiology.
2019;293(1):212-20. Permission to reproduce this article was granted by the Radiological
Society of North America (RSNA) and is provided in Appendix B.

4.1 Introduction
In patients who have asthma, chronic airways disease typically results in variable airflow
obstruction that may be partially or completely reversed using bronchodilators.1 Many
people with asthma maintain stable lung function and bronchodilator reversibility over
time, while a subset of patients may experience accelerated lung function decline and
eventually lose post-bronchodilator reversibility.2-4 Recent epidemiological studies have
revealed that in up to 10% of people with asthma, airways disease may lead to chronic,
persistent airflow obstruction and chronic obstructive pulmonary disease5,6 but the
mechanisms underlying these changes are not fully understood.
Airway remodeling caused by chronic inflammation has been suggested to mediate
changes that result in airflow obstruction that is not bronchodilator-reversible.7 Asthma
involves both the small and large airways and it is difficult to measure small airway
dysfunction using spirometry measurements of the forced expiratory volume in one second
(FEV1) because it is insensitive to peripheral airway changes.
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The morphologic structure of remodeled and inflamed airways can be directly measured
using thoracic radiographic CT8-10 and airway function may also be viewed by using
expiratory CT lucency of gas trapping11,12 or parametric response mapping.13,14 Parametric
response map gas trapping was shown14 to be increased in participants with severe asthma
as compared with participants with non-severe asthma and control participants. Inhaled
hyperpolarized gas MRI directly probes ventilation as a consequence of both central and
peripheral airway function and has revealed the presence of non-random ventilation
defects15 that are the functional consequences of airway remodeling, inflammation and/or
intraluminal plugging.16-18 In patients with asthma, MRI ventilation defects are spatiallyrelated to abnormally remodeled airways,16,17 positively correlated with disease severity19
and improved in response to bronchodilators,15,20 The size and spatial locations of MRI
ventilation abnormalities persist over time21,22 and are related to asthma exacerbations23
and asthma control/quality-of-life.24
Although epidemiological studies5,6,25 suggest that asthma progression to chronic
obstructive pulmonary disease may be relatively common, it is difficult to identify patients
who are at-risk. Because hyperpolarized helium 3 (3He) and xenon 129 (129Xe) MRI
provide sensitive tools to simultaneously measure both small and large airway function,
we hypothesized that MRI ventilation abnormalities would be predictive of future FEV1
bronchodilator reversibility and, at the same time, ventilation defects would remain
spatially-persistent during follow-up. Accordingly, the purpose of this study was to
investigate six-year longitudinal changes in hyperpolarized 3He MRI ventilation defects in
study participants with mild-moderate asthma and identify predictors of longitudinal
changes in post-bronchodilator FEV1 reversibility.

4.2 Materials and Methods
4.2.1 Study Participants and Design
Between January 2010 and April 2011, we consecutively recruited study participants from
a tertiary care pulmonary clinic who had mild-to-moderate asthma (ie, prescribed mediumhigh dose inhaled corticosteroid with long-acting beta-agonist LABA or less treatment for
asthma controller medication) according to the Global Initiative for Asthma treatment step
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criteria,1 and were aged 18−70 years with less than 1 pack-year smoking history.
Participants provided written informed consent to an ethics-board-approved, Health
Insurance Portability and Accountability Act-compliant, registered (ClinicalTrials.gov:
NCT02351141) protocol for baseline and 6-year follow-up visits (November 2016−June
2017).

Exclusion criteria included the following: FEV1 greater than 80%pred and

concentration of methacholine required to decrease FEV1 by 20% from baseline (PC20)
greater than 8 mg/mL, claustrophobia, inability to undergo spirometry, body mass index
greater than 40 kg/m2, and contraindications to MRI (ie, metal, electronic, or magnetic
implants). Baseline measurements were previously reported17 and focused on the crosssectional analyses; in our study, we reported the longitudinal follow-up measurements after
6 years and compared them with baseline measurements. Data generated during our study
are available from the corresponding author.
Spirometry, plethysmography, CT and MRI were performed at both study visits. At
baseline, participants underwent a methacholine challenge, with MRI and spirometry
performed before methacholine, after methacholine and after bronchodilator recovery, and
plethysmography and CT before methacholine. At follow-up, participants underwent all
tests before and after bronchodilator only (no methacholine challenge at follow-up), with
CT performed after bronchodilator. We used electronic health records and participant selfreports to measure exacerbations and changes in medication during the study visit
interval.26

4.2.2 Pulmonary Function Tests and Methacholine Challenge
Spirometry was performed according to American Thoracic Society guidelines27 by using
a spirometer (ndd EasyOne; ndd Medizintechnik AG, Zurich, Switzerland).
Plethysmography was performed by using a plethysmograph (MedGraphics Elite Series;
MGC Diagnostics Corporation, St. Paul, MN) to measure lung volumes and airways
resistance.

Methacholine challenge was performed according to American Thoracic

Society guidelines28 with the two-minute tidal breathing method up to and including PC20
by using a breath-actuated nebulizer (AeroEclipse II; Trudell Medical International,
London, ON, Canada). Bronchodilation was achieved following four separate doses of
100 μg of novo-salbutamol hydrofluoroalkane (Teva Novopharm Ltd., Toronto, ON,
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Canada) through a pressurized metred-dose inhaler using a spacer (AeroChamber Plus;
Trudell Medical International). Bronchodilator reversibility of FEV1 was defined as a postbronchodilator increase of 200 mL and 12%29; participants were dichotomized as reversible
or not reversible FEV1 at follow-up. The minimal clinically important difference for FEV1
was used to determine changes in FEV1 between visits as previously described.29,30
Participants withheld asthma medications according to American Thoracic Society
guidelines28 before both visits as follows: short-acting β-agonists were withheld for 8
hours, long-acting β-agonists were withheld for 48 hours and long-acting muscarinic agents
were withheld for 24 hours.

4.2.3 MRI Parameters and Analysis
We performed anatomical proton (hydrogen 1 [1H]) and 3He static ventilation MRI at the
coronal plane within 5 minutes by using a whole-body 3.0-T imager (Discovery MR750;
General Electric Healthcare, Milwaukee, WI) with broadband capability as previously
described.31 Participants were instructed to inhale a gas mixture from a 1.0-L bag (Tedlar®;
Jensen Inert Products, Coral Springs, FL) from functional residual capacity, and 15 coronal
sections were acquired in 8-15 seconds at breath-hold. We performed 1H MRI before
hyperpolarized 3He during 1.0-L breath-hold of high purity, medical-grade nitrogen (N2;
Spectra Gases, Alpha, NJ) by using the whole-body radiofrequency coil and a fast-spoiled
gradient-recalled echo sequence (partial echo acquisition; total acquisition time, 8 seconds;
repetition time msec/echo time msec, 4.7/1.2; flip angle, 30º; field of view, 40x40cm2;
bandwidth, 24.4kHz; 128x80 matrix zero-padded to 128x128; partial echo percentage,
62.5%, 15-17 sections; slice section thickness, 15mm; no gap). 3He gas was polarized to
30−40% by using a commercial turn-key polarizer (HeliSpin; Polarean, Durham, NC). We
performed 3He static ventilation MRI during 1.0-L breath-hold of hyperpolarized 3He
diluted to 25% by volume with N2 by using a single-channel rigid elliptical transmit-receive
chest coil (RAPID Biomedical, Wuerzburg, Germany) and a two-dimensional multisection
fast-gradient-recalled echo sequence (partial echo acquisition; total acquisition time, 11
seconds; repetition time msec/echo time msec, 3.8/1.0; flip angle, 7º; field of view,
40x40cm2; bandwidth, 48.8kHz; 128x80 matrix zero-padded to 128x128; partial echo
percentage, 62.5%, 15-17 sections; section thickness, 15mm; no gap).
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Quantitative MRI analysis was performed by a single observer (R.L.E., with four-years
experience) who was blinded to baseline and follow-up visits by using in-house
segmentation software (smallest detectable difference32 and minimal clinically important
difference33) in MATLAB R2016a (Mathworks, Natick, MA) as previously described.32
Static ventilation images were segmented by using three-dimensional k-means clustering
that classified voxel intensities into five clusters ranging from signal void or ventilation
defects (cluster 1) to hyperintense signal (cluster 5; all ventilated volume clusters 2-5).
Ventilation abnormalities were quantified as the ventilation defect volume (VDV) and as
the ventilation defect percent (VDV normalized to the MRI-measured volume of the
thoracic cavity). Repeatability of MRI VDV and ventilation defect percent in this study
was evaluated by a single observer (R.L.E., blinded for segmentation) in five randomly
selected participants. Blinded participant selection and randomization between repeated
segmentation rounds was provided by an additional observer who did not participate in the
data analysis. Quantitative, clinically-relevant MRI changes were evaluated by using the
following equation: ΔVDV>|110| mL, which is the published minimal clinically important
difference for VDV,33 where ΔVDV is the change in VDV. The spatial locations of
ventilation defects were visually and qualitatively compared between visits (R.L.E.).

4.2.4 CT Parameters and Analysis
Thoracic CT was performed within 10 minutes of MRI using a 64-section system
(LightSpeed VCT; GE Healthcare) at breath-hold after inhalation of 1.0 L of N2 from
functional residual capacity to volume match to MRI. Participants were transported from
MRI to CT by wheelchair to avoid exercise-induced changes. At baseline, CT was
performed in a 4−10 cm axial region of interest with visually obvious ventilation defects
as previously described17 to reduce radiation dose. At follow-up, a full CT image of the
thorax was acquired by using a low-dose protocol as previously described.34
Thoracic CT images were analyzed by using a commercial workstation (Pulmonary
Workstation 2.0; VIDA Diagnostics Inc., Coralville, IA) to segment and measure the threedimensional airway tree. The measurements between visits were compared within the
region of the partial CT acquired at baseline.
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4.2.5 Statistical Analysis
Data were tested for normality by using Shapiro-Wilk tests with commercially-available
software (SPSS Statistics 25.0; IBM Corporation, Armonk, NJ). When data were not
normally distributed, they were log transformed. Measurements for each visit were
compared by using paired t-tests, and bronchodilator-reversible and bronchodilator-notreversible subgroup measurements were compared by using unpaired t-tests (SPSS; IBM).
MRI VDV and ventilation defect percent repeatability were determined by using the
coefficient of variation and two-way mixed effects intraclass correlation coefficient (SPSS;
IBM). Univariable relationships were evaluated by using Pearson correlation coefficients
(r) in commercially-available software (GraphPad Prism 7.00; GraphPad Software, La
Jolla, CA) for follow-up post-bronchodilator change in FEV1 with baseline measurements
related to the methacholine challenge.

These included FEV1 and VDV before

methacholine with differences between challenge states (ie, post-methacholine minus premethacholine) and PC20. On the basis of univariable relationships, multivariable models
were generated (SPSS; IBM) by using the enter approach to determine the largest influence
for predicting FEV1 bronchodilator reversibility (post-bronchodilator change in FEV1 in
milliliters) at follow-up for the following two models: a) baseline variables that had
significant univariable relationships with post-bronchodilator change in FEV1 at followup, and b) age, FEV1, and PC20 at baseline which have been shown2,4,35 to predict future
bronchodilator reversibility, along with baseline VDV. The regression coefficients for the
variables in the multivariable models were expressed as standardized β. Results were
considered statistically significant when the probability of making a Type I error was less
than 5% (p < 0.05).

4.3 Results
4.3.1 Study Participants
The study flow chart is provided in Figure 4-1; 26 participants were enrolled17 but two
participants (2/26, 8%) did not have asthma and were excluded. Of 24 participants who
completed the baseline visit, nine participants (35%) were lost to follow-up because they
moved farther than 500 km away or could not be contacted, and four participants (15%)
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participants declined the follow-up visit. In total, 11 participants (seven men and 4 women)
with mild-moderate asthma (Global Initiative for Asthma treatment steps 1-41) were
evaluated twice within mean 78 months ± 7 (standard deviation; median, 79 months; range,
68-87). Mean participant age was 42 years ± 9 at baseline (men, 41 years ± 10; women,
44 years ± 6, p=.63) and 49 years ± 9 at follow-up (men, 48 years ± 10; women, 51 years
± 7, p=.62). Table 4-5 in the supplement shows the baseline measurements for participants
who completed longitudinal follow-up (11 participants; 42%) and those who were lost to
follow-up (15 participants, 58%). Participants who completed longitudinal follow-up were
older (mean age 42 years ± 9 vs 28 years ± 9, respectively; p<.01) with worse lung function
overall (all p<.05 except forced vital capacity and total lung capacity) and ventilation defect
percent (5% ± 4 vs 2% ± 1, respectively; p<.01).

Figure 4-1 Study flowchart of patient inclusion and exclusion
Two participants were excluded because they did not have current asthma.
*Enrolled per Svenningsen et al17
Table 4-1 provides demographic, pulmonary function test, and MRI measurements. A
participant listing is provided in Table 4-6 and a detailed list of asthma medications is
provided in Table 4-7, both in the supplement. Between the baseline and follow-up visits,
mean body mass index (27 kg/m2 ± 4 vs 28 kg/m2 ± 4, respectively; p=.03) and mean
residual volume (126%pred ± 20 vs 136%pred ± 26, respectively; p=.02) were different; all
other measurements were not different (p>.05). All participants were never-smokers (0
pack-year) and none reported an asthma exacerbation between study visits. All participants
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except one (participant S06) were prescribed inhaled corticosteroids and/or inhaled
corticosteroids with long-acting β-agonist at baseline. During the interval between visits,
nine participants (82%) remained on the same type and dose of medication whereas a single
participant (participant S03) changed the type of inhaled corticosteroid and long-acting βagonist controller while administered the same daily inhaled corticosteroid dose. Against
medical advice, a single participant (participant S11) refused to self-administer prescribed
asthma medications during the interval between the baseline and follow-up visits.
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Table 4-1 Participant and MRI measurements at baseline and follow-up
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4.3.2 3He MRI Ventilation at Baseline and Follow-up
MRI measurements were highly repeatable with coefficient of variation of 5% (95%
confidence interval: 3%, 7%) and intraclass correlation coefficient of 1.00 (95% confidence
interval 0.98, 1.00) for both VDV and ventilation defect percent. For eight study
participants (of 11 participants, 73%), MRI ventilation defects remained in the same
location at the 6-year follow-up MRI and were similar in size (change in VDV between
visits, <110 mL). Figure 4-2 shows 3He MRI ventilation at baseline and follow-up and
airway corresponding to a persistent defect for a representative participant with stable VDV
(participant S03). A subsegmental bifurcation in the RB8 bronchus showed narrowing in
the inferior daughter branch compared with the superior daughter branch.

For the

remaining three participants (of 11; 27%), follow-up pre-bronchodilator ventilation defects
were visually and quantitatively larger than baseline defects (change in VDV between
visits, ≥110 mL) and were in the same lung regions as baseline post-methacholine
ventilation defects. Figure 4-3 shows 3He MRI ventilation and airway corresponding to
worsened follow-up defect for a representative participant with worse VDV at follow-up
(participant S01). The LB8 bronchus leading to the worsened follow-up defect was
abruptly truncated.
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Figure 4-2 3He MRI ventilation in a representative participant with stable ventilation
between baseline and follow-up
A, Centre coronal section 3He ventilation MRI (cyan, administered as an inhaled contrast
agent) coregistered to anatomic hydrogen 1 (1H) MRI (gray scale) for baseline
premethacholine challenge (pre-MCh) and follow-up before and after bronchodilator (preBD and post-BD, respectively). Persistent defects between visits are shown (arrows).
B, Follow-up three-dimensional 3He MRI shows ventilation coregistered to CT with threedimensional airway tree at oblique angle. Inset (coronal view) shows RB8 bronchus
subsegmental bifurcation. Inferior daughter branch leading to persistent defect between
baseline and follow-up appears narrowed compared with superior daughter branch.
Participant S03 was a man with mild-to-moderate asthma (baseline and follow-up,
respectively: age, 28 years and 35 years; forced expiratory volume in 1 second, 3.97 L and
4.19 L; ventilation defect volume, 340 mL and 260 mL).
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Figure 4-3 3He MRI ventilation in a representative participant with worse ventilation at 6year follow-up
A, Centre coronal section 3He ventilation MRI (cyan, administered as an inhaled contrast
agent) coregistered anatomic hydrogen 1 MRI (gray scale) for baseline premethacholine
challenge (pre) and after methacholine challenge (post), and follow-up before (pre) and
after (post) bronchodilator. Worsened defects were shown between visits (arrows).
B, Follow-up three-dimensional 3He MRI shows ventilation coregistered to CT with threedimensional airway tree at oblique angle. Inset on top (coronal view) shows LB8 bronchus
leading to worsened follow-up defect. Lumen appears clear and open but is abruptly
truncated within three sections anteriorly (inset on bottom). Participant S01 was a woman
with mild-to-moderate asthma (baseline and follow-up, respectively: age, 36 and 41 years;
forced expiratory volume in 1 second, 2.28 L and 1.71 L; ventilation defect volume, 270
mL and 780 mL).
Table 4-2 shows CT airway measurements including airway wall area percent, lumen area,
wall thickness, and number of mucus plugs at baseline and follow-up, and total airway
count at follow-up. For all participants at baseline versus follow-up, mean wall area
percent (70% ± 2 vs 69% ± 1, respectively; p=.14) and wall thickness (28.3 mm ± 2.1 vs
27.8 mm ± 3.3, respectively; p=.66) were not different, whereas mean lumen area was
greater at follow-up (baseline vs follow-up, 5.4 mm2 ± 1.9 vs 6.9 mm2 ± 1.6, respectively;
p<.001). Airway measurements were not different between subgroups (p>.05). One
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participant (participant S01) had three subsegmental mucus plugs at follow-up in the LB4,
RB2 and RB10 bronchi, which did not correspond to ventilation defects.
Table 4-2 CT measurements
Baseline (n=11)
LA
WT
WA%
Participant
(mm2)
(mm)
Stable VDV at follow-up (n=8)
S02
69
6.7
28.3
S03
72
4.8
28.5
S04
72
3.5
25.7
S06
72
5.7
28.7
S07
72
4.9
27.0
S08
69
3.0
24.5
S09
74
4.3
31.6
S10
69
6.7
28.3
Mean (±SD) 71 (2) 5.0 (1.4) 27.8 (2.1)
Worse VDV at follow-up (n=3)
S01
70
3.4
27.6
S05
66
3.8
29.3
S11
69
6.8
28.6
Mean (±SD) 68 (2) 4.7 (1.9) 28.5 (0.9)
Group differences (n=11)
p
.12
.87
.72
ALL (±SD)
70 (2) 5.4 (1.9) 28.3 (2.1)
(n=11)
Difference from baseline (p)

Follow-up (n=11)
LA
WT
M
(mm2)
(mm)

M

WA%

TAC

0
0
0
0
0
0
0
0
-

69
70
69
67
69
69
71
68
69 (1)

8.8
5.9
6.0
7.8
7.1
4.5
6.5
7.8
6.8 (1.4)

24.5
27.2
25.3
23.6
27.3
25.3
29.3
29.7
26.5 (2.2)

0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/0
-

170
130
166
145
180
202
165
141
162 (23)

0
0
0
-

72
71
67
70 (3)

4.5
5.7
8.2
6.1 (1.9)

26.3
31.5
31.1
29.7 (2.9)

1/3
0/0
0/0
-

114
224
196
178 (57)

-

.66
69 (1)

.30
6.9 (1.6)

.59
27.8 (3.3)

-

.51
167 (33)

.14

<.001

.66

-

-

WA%=wall area percent; LA=lumen area; WT=wall thickness; M=mucus; TAC=total airway
count; VDV=ventilation defect volume; SD=standard deviation.
Mucus indicates mucus plugging.
Measurements are matched for segments within partial CT images acquired at baseline, except
mucus plugging at follow-up shown as matched partial CT/whole thoracic CT.
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4.3.3 FEV1 and Ventilation Defect Postbronchodilator Reversibility
Measurements
Table 4-3 shows FEV1 and ventilation defect post-bronchodilator reversibility
measurements for each participant by groups with stable and worse VDV at follow-up. At
follow-up, six participants were not FEV1 bronchodilator reversible and eight participants
had marginal MRI ventilation defect (change in VDV was greater than -110 mL)
bronchodilator reversibility (grey-shaded cells). We compared measurements between
FEV1 reversible and not reversible participant groups and, as shown in Figure 4-4, PC20
was greater (ie, more normal) in participants who were not reversible (Figure 4-4A;
p=.01), whereas the ratio of residual volume to total lung capacity (RV/TLC) was greater
in participants who were bronchodilator reversible (Figure 4-4B; p<.001). All other
measurements were not different between reversible and not reversible participant groups
(supplement Table 4-8; p>.05). We also plotted baseline measurements against postbronchodilator ΔFEV1 at follow-up and univariable relationships are shown in Figure
4-4C and D. PC20 (r=-.61, p=.049), and pre-methacholine challenge VDV (r=.67, p=.02)
at baseline were related to post-bronchodilator change in FEV1. All other measurements
were not correlated with post-bronchodilator change in FEV1 (supplement Table 4-9,
p>.05).
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Table 4-3 Changes in forced expiratory volume in 1 second and ventilation defects
Baseline
PostBD−PreMCh
ΔFEV1
ΔVD
(mL, %) (mL, %)
Stable VDV at follow-up (n=8)
S02
-520, -15
-190, -3
S03
+380, +10 -120, -2
S04
+30, +2
-10, 0
S06
+70, +3
+10, 0
S07
-90, -2
-210, -4
S08
+470, +26
-30, -1
S09
-350, -9
-70, -2
S10
-30, -1
+10, 0
Mean
-10, +2
-80, -1
SD
330, 12
120, 3
Worse VDV at follow-up (n=3)
S01
-110, -5
+190, +5
S05
+200, +7
-60, 0
S11
-140, -6
+40, +1
Mean
-20, -1
+60, +2
SD
190, 7
130, 3
ALL (n=11)
Mean
-10, +1
-30, 0
SD
270, 10
100, 2

Baseline
PostBD−PostMCh
ΔFEV1
ΔVD
(mL, %)
(mL, %)

Follow-up
PostBD−PreBD
ΔFEV1
ΔVD
(mL, %)
(mL, %)

+780, +35
+1360, +45
+360, +37
+810, +43
+1080, +53
+1010, +81
+650, +21
+580, +29
+830, +43
310, 18

-420, -7
-1710, -25
-80, -2
-1150, -19
-870, -11
-230, -4
-340, -5
-630, -9
-680, -10
480, 7

+680, +24
+220, +5
+220, +15
+150, +5
+950, +37
+260, +14
+400, +11
+60, +2
+370, +14
300, 11

-200, -4
-90, -2
-20, 0
-10, 0
-250, -2
-10, 0
-50, -2
+20, 0
-80, -1
100, 2

+800, +58
+600, +23
+740, +48
+710, +42
100, 18

-1040, -19
-430, -6
-340, -7
-600, -10
380, 7

+1030, +60
+160, +5
+110, +5
+430, +23
520, 32

-580, -11
-100, -1
-40, -1
-240, -4
300, 6

+760, +40
270, 18

-570, -9
500, 8

+300, +14
370, 18

-100, -2
160, 3

BD=bronchodilator; MCh=methacholine challenge; FEV1=forced expiratory volume in
one second; VD=ventilation defects; VDV=ventilation defect volume; SD=standard
deviation.
ΔFEV1 shown as absolute difference in mL and as a percent of baseline.
ΔVD shown as absolute ventilation defect volume (VDV) difference in mL and as
absolute ventilation defect percent (VDP) difference.
Grey shaded cells indicate not reversible FEV1 and VDV (n=6 not reversible FEV1, n=8
not reversible VDV).
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Figure 4-4 Group differences and univariable relationships for postBD FEV1 reversibility
A, Baseline concentration of methacholine required to decrease FEV1 by 20% (PC20; log
scale) was lower (ie, worse) in FEV1-reversible participants (p=.01) and, B, baseline
residual volume (RV)-to-total lung capacity (TLC) ratio (RV/TLC) was greater in
reversible participants (p<.001).
C, Natural logarithm of PC20 (lnPC20; r=0.61; p=.049) and, D, premethacholine challenge
(preMCh) VDV (r=0.67; p=.02) were related to BD change in FEV1 (ΔFEV1) at followup.
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4.3.4 Multivariable Analysis
We generated multivariable models to explore potential predictors of post-bronchodilator
FEV1 reversibility at follow-up (Table 4-4). Baseline pre-methacholine challenge VDV
(standardized β=0.89; p=.01) and pre-methacholine challenge to post-bronchodilator
change in VDV (standardized β=0.58; p=.03) predicted post-bronchodilator change in
FEV1 (model 1: R2=.80; p=.01). A second model including FEV1, age and PC20 did not
predict post-bronchodilator change in FEV1 (model 2: R2=.63; p=.15).
Table 4-4 Multivariable model to predict bronchodilator reversibility
Unstandardized
Parameter
B
Standard Error
MODEL 1: FEV1 reversibility at follow-up, n=11 (R2=.80, p<.01)
1.86
0.47
Baseline PreMCh VDV✝
✝
1.80
0.67
Baseline PostBD−PreMCh ΔVDV
2
PC20 mL /mg*
-0.11
0.05
MODEL 2: FEV1 reversibility at follow-up n=11 (R2=.63, p=.15)
1.15
0.67
Baseline PreMCh VDV✝
✝
-0.01
0.01
Baseline PreMCh FEV1
Age mL/year
-0.01
0.02
PC20 mL2/mg*
-0.08
0.10

Standardized
β

p

0.89
0.58
-0.41

.01
.03
.052

0.55
-0.14
-0.26
-0.29

.14
.72
.54
.48

B=regression coefficient; β=standardized regression coefficient; FEV1=forced expiratory
volume in one second; MCh=methacholine challenge; VDV=ventilation defect volume;
BD= bronchodilator; PC20=concentration of methacholine causing 20% decrease in FEV1.
*log transformed PC20. For all models, dependent variable being predicted was
bronchodilator ΔFEV1 in mL at follow-up (FEV1,post-FEV1,pre). Percent predicted (%pred)
was used for pre-MCh FEV1 to account for age, sex, height and race differences, and
absolute differences in mL were used for ΔFEV1.
✝
Unitless because independent and dependent variables have the same units.
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4.4 Discussion
Recent epidemiological studies have revealed that in up to 10% of asthmatics, airways
disease may lead to chronic, persistent airflow obstruction and chronic obstructive
pulmonary disease, but the mechanisms underlying these changes are not fully understood.
In this study, we investigated six-year longitudinal changes in hyperpolarized 3He MRI
ventilation defects in individuals with mild-to-moderate asthma and sought to identify
predictors of longitudinal changes in post-bronchodilator FEV1-reversibility. We showed
that MRI ventilation predicts long-term post-bronchodilator FEV1 reversibility in mild-tomoderate asthma. We observed: 1) negligible post-bronchodilator reversibility in six of 11
participants at follow-up, 2) baseline MRI ventilation defects predicted follow-up postbronchodilator reversibility (R2=.80, p=.01), 3) MRI ventilation defects persisted in the
same spatial locations 6.5-years later, and, 4) ventilation defects worsened in three of 11
participants, in the same lung regions they previously worsened during methacholine
challenge, 6.5-years prior.
MRI ventilation defects persisted in the same spatial locations at follow-up. For three
participants (S01, S05, S11), ventilation defects also worsened in the same spatial regions
that worsened during a methacholine challenge, approximately 6.5 years prior. Previous
studies have evaluated MRI ventilation defects for up to approximately 1.5 years21,22 and
revealed spatially persistent defects,21 suggesting that fixed asthma airway abnormalities
are spatially heterogeneous. We also evaluated CT airway measurements to investigate the
underlying pathophysiology of persistent and worsening ventilation defects which revealed
inter-individual differences and mucus plugs in a single participant who worsened.
However, there was no spatial relationship between ventilation worsening and mucus plugs
in this participant with mild-moderate asthma.
The prevalence of negligible bronchodilator reversibility in our participant cohort (6/11,
55%) was higher than previously reported in epidemiological studies.5,6 In all but one of
these participants, there were no changes in medication (except for S11 who refused
prescribed ICS/LABA) or exacerbations. Moreover, at follow-up, two participants in this
subgroup (S06, S10) met the criteria for fixed airflow obstruction consistent with COPD36
and two others (S05, S11) had worse VDV at follow-up. Airway remodeling caused by
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chronic inflammation has been suggested to mediate changes that result in airflow
obstruction not reversed by bronchodilators7 and patients with asthma not using regular
treatment may progress to irreversible obstruction.4

We did not test for airway

inflammation, so it is possible that inadequately controlled inflammation was responsible
for the lack of reversibility which is consistent with the CT finding here of mucus plugs in
only one participant.
For two participants (S04, S08) there was poorly reversible post-bronchodilator VDV
alongside physiologically-relevant FEV1 reversibility, and in participant S11 who
apparently stopped all asthma medications, there was neither FEV1 nor VDV postbronchodilator reversibility and ventilation defects worsened at follow-up. These findings
are consistent with unresolved small airway abnormalities or mucus plugs37 leading to
persistent ventilation defects that are not reversed using salbutamol, which mainly has
receptors in the central airways. This could also be consistent with airway inflammation18
and suggests that irreversible FEV1 and worsening ventilation defects may result from
inadequate treatment and/or poor adherence to prescribed asthma medication.
MRI ventilation defect volume at baseline predicted bronchodilator reversibility at followup whereas age, PC20 and FEV1 did not predict bronchodilator reversibility. Although
baseline VDV had the greatest relative influence, the difference between pre-methacholine
and post-challenge recovery ventilation defects (PostBD−PreMCh ΔVDV) also
significantly contributed.

Abnormal FEV1 and reduced post-bronchodilator FEV1

reversibility were previously shown to predict post-bronchodilator FEV1 reversibility.4
Both diminished4 and augmented2,35 airway hyper-responsiveness were also shown to
predict FEV1 decline and irreversible airflow obstruction in asthmatics. Severe airway
hyper-responsiveness was previously suggested to have a protective effect on the airways
by preventing airway narrowing, thereby preserving bronchodilator reversibility.4 Whilst
post-bronchodilator FEV1 changes following methacholine have been evaluated,38 to our
knowledge, this is the first exploration of the potential longitudinal consequence of
ventilation defects induced using methacholine. It is somewhat counterintuitive that
diminished ventilation at baseline predicted post-bronchodilator reversibility six years
later. MRI ventilation defects can be due to large and small airway abnormalities,
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inflammation and/or intraluminal mucus plugging;17,18,37 the fact that baseline ventilation
defects and the post-bronchodilator change in ventilation defects following a methacholine
challenge predict future FEV1 reversibility suggests that it is airway abnormalities and not
inflammation or mucus plugging that drive MRI predictions of future post-bronchodilator
reversibility. However, the near complete lack of mucus plugs in the participants studied
here means we cannot test the role of mucus in our longitudinal findings. Nevertheless,
we think these results highlight the utility and sensitivity of MRI ventilation measurements
for hypothesis-driven, mechanistic studies, especially when combined with pulmonary
function tests and thoracic CT. We think it is important to point out that MRI and CT are
highly complementary. In other words, MRI in combination with CT provides a way to
discern the airway structural and luminal determinants of ventilation abnormalities in
asthma.
We acknowledge the small sample size and the fact that this study was limited to two time
points, both of which limit the generalizability of the multivariable models. Baseline and
follow-up MRI evaluations were also different, but this allowed us to explore different
relationships between airway hyper-responsiveness, ventilation defects and bronchodilator
reversibility. Finally, we recognize that compared to 3He MRI, 129Xe MRI offers a much
less costly and highly sensitive alternative to measure small airway function,20 so with
129

Xe MRI, we would expect similar if not more sensitive detection of ventilation defects.

In study participants with mild to moderate asthma, MRI ventilation defect volume
predicted reversibility of post-bronchodilator FEV1, six years later, suggesting that
pulmonary functional MRI may help identify patients at risk for the transition from asthma
to fixed airflow obstruction and chronic obstructive pulmonary disease.
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4.6 Supplement
Table 4-5 Baseline measurements for participants who completed longitudinal follow-up
and lost to follow-up
Completed
Lost to
All
Sig Diff*
Parameter
Follow-up
Follow-up
(n=26)
(p)
(±SD)
(n=11)
(n=15)
Age years
35 (11)
42 (9)
28 (9)
<.01
Female Sex n
14
4
10
.23
BMI kg/m2
25 (5)
27 (4)
25 (5)
.32
FVC %pred
93 (11)
87 (13)
96 (10)
.06
FEV1 %pred
84 (15)
76 (12)
93 (12)
<.01
FEV1/FVC %
74 (11)
70 (7)
81 (10)
<.01
RV %pred
113 (24)
126 (20)
104 (24)
.02
TLC %pred
101 (9)
103 (9)
100 (9)
.28
RV/TLC %pred
113 (20)
123 (18)
106 (19)
.03
Raw %pred
124 (69)
172 (68)
91 (49)
<.01
PC20 mg/mL
5.87 (12.28)
0.50 (0.72)
9.80 (15.15)
<.01
VDP %
3 (3)
5 (4)
2 (1)
<.01
SD=standard deviation; BMI=body mass index; FVC=forced vital capacity;
%pred=percent predicted; FEV1=forced expiratory volume in one second; RV=residual
volume; TLC=total lung capacity; Raw=airways resistance; PC20=concentration of
methacholine causing a 20% decrease in FEV1; VDP=ventilation defect percent.
*Significance of difference between participants included and excluded for longitudinal
follow-up.
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Table 4-6 Participant listing of demographic characteristics and pulmonary function and
MRI measurements at baseline and follow-up.
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Table 4-7 Medication use at both visits
Baseline
Follow-up
Corticosteroid use, n (%)
None
1 (9)
2 (18)
Low-medium dose ICS
10 (91)
9 (82)
High-dose ICS
0
0
OCS
0
0
Types of controllers, n (%)
ICS only
1 (10)
1 (11)
ICS/LABA only
8 (80)
7 (78)
ICS/LABA + ICS
1 (10)
1 (11)
ICS=inhaled corticosteroid; OCS=oral corticosteroid; LABA=long-acting β-agonist.
Participants were prescribed budesonide alone or in combination with formoterol,
except for one participant prescribed fluticasone furoate in combination with
vilanterol and another prescribed budesonide alone and in combination with
formoterol. No participants were prescribed leukotriene receptor antagonists (LTRA)
or tiotropium.
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Table 4-8 Baseline measurement differences between reversible and not reversible
participant groups
Reversible
Not Reversible
Sig Diff
(n=5)
(n=6)
(p)
Parameter (±SD)
Age years
42 (6)
42 (11)
>.99
Female Sex n
3
1
.24
2
BMI kg/m
26 (4)
27 (4)
.89
FVC %pred
83 (10)
91 (15)
.39
FEV1 %pred
72 (12)
79 (13)
.43
PostMCh−PreMCh ΔFEV1 L
-0.85 (0.41)
-0.77 (0.23)
.69
PostBD−PreMCh ΔFEV1 L
-0.04 (0.35)
0.02 (0.26)
.73
PostBD−PostMCh ΔFEV1 L
0.81 (0.28)
0.79 (0.29)
.93
FEV1/FVC %
70 (6)
70 (8)
.98
RV %pred
144 (13)
111 (8)
<.01*
TLC %pred
105 (8)
102 (10)
.64
RV/TLC %pred
139 (7)
109 (8)
<.001
Raw %pred
209 (36)
109 (8)
.17
PC20 mg/mL
0.08 (0.01)
0.84 (0.86)
.01
VDV mL
310 (230)
190 (120)
.27
PostMCh−PreMCh ΔVDV mL
0.48 (0.48)
0.74 (0.53)
.42
PostBD−PreMCh ΔVDV mL
-0.05 (0.16)
-0.04 (0.06)
.80
PostBD−PostMCh ΔVDV mL
-0.53 (0.41)
-0.77 (0.55)
.45
VDP %
6 (4)
4 (2)
.36
SD=standard deviation; BMI=body mass index; FVC=forced vital capacity;
%pred=percent predicted; FEV1=forced expiratory volume in one second;
MCh=methacholine challenge; VD=bronchodilator; RV=residual volume; TLC=total
lung capacity; Raw=airways resistance; PC20=concentration of methacholine causing a
20% decrease in FEV1; VDV=ventilation defect volume; VDP=ventilation defect
percent. *Highly collinear with RV/TLC therefore only reported RV.
NOTE: subgroups defined by bronchodilator reversibility at follow-up.

131

Table 4-9 Correlation coefficients for univariable relationships with postbronchodilator ΔFEV1 at follow-up
Pearson Coeff
Sig
(r)
(p)
Parameter
FEV1 %pred
.23
.50
PostMCh−PreMCh ΔFEV1 L
.16
.65
PostBD−PreMCh ΔFEV1 L
-.08
.81
PostBD−PostMCh ΔFEV1 L
-.18
.60
VDV mL
.67
.02
PostMCh−PreMCh ΔVDV mL
-.61
.048
PostBD−PreMCh ΔVDV mL
-.42
.20
PostBD−PostMCh ΔVDV mL
.25
.46
lnPC20 mg/mL
-.61
.049
FEV1=forced expiratory volume in one second; %pred=percent predicted;
MCh=methacholine challenge; BD=bronchodilator; VDV=ventilation defect
volume; PC20=concentration of methacholine causing a 20% decrease in
FEV1; VDV=ventilation defect volume.
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CHAPTER 5
5

IS COMPUTED TOMOGRAPHY TOTAL AIRWAY
COUNT RELATED TO ASTHMA SEVERITY AND
AIRWAY STRUCTURE-FUNCTION?

To better understand regional and whole-lung airway abnormalities in asthma, we
evaluated CT total airway count in participants with asthma over a range of severities and
compared these results with previously published results for COPD. We determined the
relationship between CT total airway count with airway morphology, pulmonary function
and MRI ventilation.
The contents of this chapter were previously published in the journal American Journal of
Respiratory and Critical Care Medicine: RL Eddy, S Svenningsen, M Kirby, D Knipping,
DG McCormack, C Licskai, P Nair, G Parraga. Is Computed Tomography Total Airway
Count Related to Asthma Severity and Airway Structure-function? Am J Respir Crit Care
Med. 2020. [Epub ahead of print] Permission to reproduce this article was granted by the
American Thoracic Society (ATS) and is provided in Appendix B.

5.1 Introduction
In asthma, airways disease caused by smooth muscle abnormalities, inflammation and/or
mucus hypersecretion leads to variable airflow obstruction that is reversible or improves
post-bronchodilator.1 Airway abnormalities in asthma are believed to encompass the entire
tracheobronchial tree from the large to the small airways2 and small airways disease is
recognized as a distinct phenotype of asthma.2-4 While small airway abnormalities remain
difficult to directly measure, the large airways have been extensively investigated in vivo,
using x-ray computed tomography (CT). Airway walls in asthmatics are thicker as
compared to healthy controls5-12 and this thickening tends to worsen with increasing asthma
severity.

Until now, CT studies of asthma have focused on morphological airway

measurements and their relationships with clinical measurements, however the total
number of CT-visible airways in patients with asthma has not been investigated.
Landmark studies of airways disease in COPD were performed using micro-CT13-15 and
more recently, in vivo CT total airway count (TAC) revealed missing distal airways that
were associated with thinning airway walls in patients with mild COPD.16 We think this
finding may have implications for airways disease in asthma and hypothesized that in
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severe asthma, thickened airways are concomitant with airway obstruction and/or
occlusion, which could be quantified using TAC.
Accordingly, our objective was to measure and evaluate CT total airway count in patients
with asthma across a range of severities and explore potential relationships of TAC with
asthma severity, airway measurements, pulmonary function and pulmonary functional
magnetic resonance imaging (MRI). A preliminary description of these results was
previously reported in abstract form.17

5.2 Materials and Methods
5.2.1 Study Participants and Design
Study participants with asthma according to the Global Initiative for Asthma (GINA)
treatment step criteria1 were recruited as a convenience sample between ages 18 to 70 years
with <1 pack year smoking history from two tertiary care respirology clinics (Asthma
Centre, St Joseph’s Health Care London, Western University, London, Ontario, Canada;
Firestone Institute for Respiratory Health, St Joseph’s Health Care Hamilton, McMaster
University, Hamilton, Ontario, Canada). Participants provided written informed consent
to an ethics board and Health Canada-approved, registered (www.clinicaltrials.gov,
NCT02351141) protocol for a single study visit (Robarts Research Institute, Western
University, London Canada). Participants performed spirometry, plethysmography and
MRI before and after bronchodilator and completed a single post-bronchodilator thoracic
CT as well as the asthma control (ACQ-6)18 and quality of life questionnaires (AQLQ).19
Participants were stratified by asthma severity according to GINA treatment steps1 as:
GINA1-3, GINA4, and GINA5.

5.2.2 Pulmonary Function Tests
Spirometry and plethysmography were performed using a MedGraphics Elite Series
plethysmograph (MGC Diagnostics Corporation, St. Paul, MN, USA). Spirometry was
performed according to ATS guidelines20 to measure FEV1 and FVC, and plethysmography
was performed to measure lung volumes and airways resistance. Post-bronchodilator
measurements were acquired after four separate doses of 100 μg of Novo-Salbutamol HFA
(Teva Novopharm Ltd., Toronto, ON, Canada) through a pressurized metred-dose inhaler
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using an AeroChamber Plus spacer (Trudell Medical International, London, ON, Canada).
Participants withheld asthma medications before the study visit according to ATS
guidelines20: short-acting β-agonists for ≥6 hours, long-acting β-agonists for ≥12 hours and
long-acting muscarinic agents for ≥24 hours.

5.2.3 CT
Thoracic CT was acquired post-bronchodilator using a 64-slice LightSpeed VCT system
(General Electric Healthcare, Milwaukee, WI, USA) as previously described21 from apex
to base under breath-hold conditions after inhalation of 1.0 L of N2 gas from functional
residual capacity. CT parameters were as follows: 64 x 0.625 collimation, 120 kVp, 100
mA, tube rotation time 500 ms, pitch 1.25, standard reconstruction kernel, 1.25 mm slice
thickness and field of view (FOV) 36-40 cm2. The total effective dose for each CT scan
was 1.8 mSv, calculated using the manufacturer’s settings and the ImPACT patient
dosimetry calculator (based on the UK Health Protection Agency NRPB-SR250 software).
Thoracic CT images were analyzed by a single observer with four-years experience (RLE)
using Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., Coralville, IA, USA) to
segment and label the airway tree and lung lobes. All airway segments in the segmented
tree were summed to quantify total airway count (TAC),16 and airway counts were also
generated by tree generation from the trachea (generation 0) to generation 11.
We utilized a combination of automated airway segmentation and manual segmentation in
the presence of complete airway lumen occlusions (possible mucus, cellular debris or its
combination22).

These were also recorded by manual inspection during airway

segmentation as follows: 1) if there was completely visible lumen on both proximal and
distal sides of an occlusion, the airway was manually segmented to its terminus and TAC
was recorded at the distal terminus beyond the occlusion, and, 2) if there was lumen visible
only on the proximal side of an occlusion which terminated the airway, TAC was recorded
at the proximal end of the occlusion and not beyond the occlusion.

Anatomically

equivalent segmental, subsegmental and sub-subsegmental airways for five airway paths
(RB1, RB4, RB10, LB1, LB10; third to fifth generation)23 were used to generate airway
wall area percent (WA%) and lumen area (LA). We determined if subsegmental and sub-
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subsegmental daughter branches were missing for the five airway paths using the output
file exported from Pulmonary Workstation 2.0. All airway segments were assigned a
unique identifier that linked each parent airway to its corresponding daughter branches,
and we defined participants with missing subsegments (generation 4) and sub-subsegments
(generation 5) if one or more daughter branches were missing in the report. Airways were
qualitatively assessed for segmental branch variants similar to previously published
results.24

5.2.4 MRI
Anatomical proton (1H) and 3He static ventilation MRI were acquired within five minutes
of each other using a whole-body 3.0 T Discovery MR750 (General Electric Healthcare,
Milwaukee, WI, USA) system with broadband imaging capability as previously
described.25 Participants were instructed to inhale a gas mixture from a 1.0 L Tedlar® bag
(Jensen Inert Products, Coral Springs, FL, USA) from functional residual capacity, and 15
coronal slices were acquired in 8-15 seconds under breath-hold conditions. 1H MRI was
performed before hyperpolarized 3He during 1.0 L breath-hold of ultra-high purity,
medical-grade nitrogen (N2; Spectra Gases, Alpha, NJ, USA). 3He gas was polarized to
30−40% (HeliSpin; Polarean, Durham, NC, USA) and static ventilation imaging was
performed during 1.0 L breath-hold of hyperpolarized 3He diluted to 25% by volume with
N2.
Quantitative MRI analysis was performed by a single observer with four-years experience
(RLE) using in-house segmentation software as previously described26 and MRI ventilation
abnormalities were quantified as the ventilation defect percent (VDP; ventilation defect
volume normalized to the MRI-measured thoracic cavity volume).

VDP was also

generated for each lung lobe by registering MRI to CT and normalizing the ventilation
defect volume within each lobe to the corresponding lobe volume.27

5.2.5 Statistical Analysis
All statistical analysis was performed using SPSS Statistics 25.0 (IBM Corporation,
Armonk, NJ, USA). Data were tested for normality using Shapiro-Wilk tests and when not
normally distributed, non-parametric tests were performed. Demographic, pulmonary
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function test and imaging measurements between treatment step groups were compared
using one-way analysis of variance (ANOVA) or Kruskal-Wallis tests with post-hoc HolmBonferroni correction for multiple comparisons. An analysis of covariance (ANCOVA)
was used to compare TAC by treatment step group adjusted by age, sex and body mass
index (BMI) as potential covariates, with post-hoc Holm-Bonferroni correction for
multiple comparisons.

The number of participants with missing sub-subsegmental

branches was plotted in a histogram for the number of missing sub-subsegments, and the
mode from the histogram was used to dichotomize participants; groups were compared
using unpaired t-tests. Receiver operator characteristic (ROC) curves were generated to
determine thresholds for TAC and the number of missing sub-subsegments for
differentiating mild (GINA1-3) from severe asthma (GINA4-5). Univariate relationships
were evaluated using Pearson (r) or Spearman (ρ) correlation coefficients. Multivariable
models were generated using the enter approach to determine the relative influence of
significant univariate parameters on FEV1 and WA%, with age, sex and BMI entered in
the first step as potential covariates. All results were considered statistically significant
when the probability of making a Type I error was less than 5% (p < 0.05).

5.3 Results
5.3.1 Participant Demographics, Pulmonary Function and Imaging
Measurements
We evaluated 70 participants with a clinical diagnosis of asthma as shown in Table 5-1.
There were 15 participants in the GINA1-3 subgroup (6 females/9 males, 45±12 years), 19
participants in the GINA4 subgroup (10 females/9 males, 51±12 years) and 36 participants
in the GINA5 subgroup (24 females/12 males, 48±13 years). Participants in the GINA4
group had worse FEV1 (64±19%pred vs. 88±20%pred, p=0.003) and FEV1/FVC (58±17% vs.
74±11%, p=0.006) as compared to participants in the GINA1-3 subgroup. Participants in
the GINA5 subgroup had worse FEV1 (65±22%pred vs. 88±20%pred, p=0.004) and FVC
(80±18%pred vs. 94±14%pred, p=0.03), WA% (68.2±1.7% vs. 66.7±1.5%, p=0.006) and
VDP (10±8% vs. 3±2%, p=0.02) compared with participants in the GINA1-3 subgroup.
There were no differences between the GINA4 and GINA5 subgroups. CT FOV differed
to a small extent among study participants such that FOV=36x36 cm2 for 47 participants,
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FOV=40x40 cm2 for 20 participants, FOV=39x39 cm2 for 2 participants and FOV=41x41
cm2 for a single participant. Importantly, TAC was not significantly different between
subgroups based on FOV (p=0.7) and FOV was not significantly different between GINA
subgroups (p=0.1).
Table 5-1 Participant demographics, pulmonary function and imaging measurements
Parameter (±SD)
ALL
GINA1-3
GINA4
GINA5
(n=70)
(n=15)
(n=19)
(n=36)
Age years
48 (12)
45 (12)
51 (12)
48 (13)
Female n (%)
40 (57)
6 (40)
10 (53)
24 (67)
2
BMI kg/m
29 (5)
28 (5)
28 (6)
30 (5)
ACQ-6 Score
1.6 (1.2)
1.6 (0.9)
1.3 (1.3)
1.7 (1.3)
AQLQ Score
5.0 (1.4)
5.1 (1.1)
5.5 (1.3)
4.7 (1.4)
FEV1 %pred
70 (22)
88 (20)
64 (19)*
65 (22)*
BD ΔFEV1 %
17 (20)
8 (11)
16 (21)
20 (22)
FVC %pred
85 (17)
94 (14)
86 (14)
80 (18)*
FEV1/FVC %
65 (14)
74 (11)
58 (17)*
64 (12)
RV L
2.41 (0.67)
2.29 (0.55)
2.67 (0.53)
2.32 (0.77)
RV %pred
131 (35)
125 (35)
144 (24)
128 (39)
TLC L
5.98 (1.18)
6.47 (0.89)
6.19 (1.10)
5.63 (1.27)
TLC %pred
104 (14)
105 (11)
110 (10)*
100 (15)
RV/TLC %pred
127 (26)
118 (25)
131 (19)
128 (30)
Raw %pred
195 (118)
167 (93)
190 (80)
210 (244)
CT FOV cm2
37 (2)
37 (2)
38 (2)
37 (2)
TAC n
154 (45)
183 (49)
148 (36)*
146 (47)*
WA%
67.7 (1.6)
66.7 (1.5)
67.5 (1.1)
68.2 (1.7)*
LA mm2
10.5 (2.4)
11.5 (2.0)
10.4 (2.4)
9.7 (2.7)
VDP %†
9 (8)
3 (2)
10 (10)
10 (8)*
ACQ=asthma control questionnaire; AQLQ=asthma quality of life questionnaire;
BD=bronchodilator; BMI=body mass index; FEV1=forced expiratory volume in one
second; FOV=field of view; FVC=forced vital capacity; GINA=Global Initiative for
Asthma; LA=lumen area; Raw=airways resistance; RV=residual volume; SD=standard
deviation; TAC=total airway count; TLC=total lung capacity; VDP=ventilation defect
percent; WA%=wall area percent; %pred=percent predicted.
*Significantly different from GINA Steps 1-3 (p<0.05) using one-way ANOVA for
parametric variables or Kruskal Wallis tests for non-parametric variables, both with posthoc Holm Bonferroni corrections. †n=60

5.3.2 Is TAC Reduced with Increasing Asthma Severity?
In Figure 5-1, representative 3D reconstructed CT airway trees show that with greater
asthma severity, the airway tree has fewer segmented airways. TAC was significantly
lower in the GINA4 (145±10, p=0.03) and GINA5 (148±7, p=0.045) subgroups as
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compared to GINA1-3 subgroup (182±11) when adjusting for covariates (age, sex, BMI).
BMI was the only significant covariate (p=0.003), whereas age and sex were not significant
(p=0.05 and p=0.06, respectively). We performed an additional ANCOVA to include
RV/TLC as a covariate, however RV/TLC was not significant (p=0.07) and TAC and
GINA subgroup remained a significant interaction (p=0.03). TAC was not different
between males and females (males TAC=155±42 vs. females TAC=155±50, p=1.0), and
there was no significant interaction between sex and GINA status for TAC (p=0.2). Figure
5-1 also shows that TAC was significantly reduced for generations 6 (p=0.04) and 7
(p=0.01) for the GINA4 subgroup and generations 6 (p=0.04), 7 (p=0.01), 10 (p=0.01) and
11 (p=0.02) for the GINA5 subgroup as compared to the GINA1-3 subgroup. The values
for airway count by generation are shown in supplementary Table 5-6, as well as those
previously published for healthy never-smokers16 for comparison.

Figure 5-1 CT airway count by airway tree generation
Three-dimensional reconstruction of the segmented airway tree for representative
participants with asthma by Global Initiative for Asthma (GINA) treatment steps for
asthma severity shows reduced airways as asthma severity increases (top). Total airway
count was significantly less for GINA4 (p=0.03) and GINA5 (p=0.045) participants
compared with GINA1-3 participants. GINA4 participants had significantly less airways
at airway tree generations 6 and 7 compared with GINA1-3, whereas GINA5 participants
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had significantly less airways at generations 6, 7, 10 and 11 compared with GINA1-3. Stars
(*) indicate significantly different from GINA1-3.

5.3.3 Is TAC Associated with Abnormal Airway Structure and Function?
Table 5-2 shows the number of participants with CT invisible or missing subsegmental
(generation 4) and sub-subsegmental (generation 5) daughter branches. A total of 19
participants (27%) were missing subsegmental branches, which was most common in the
right middle lobe (RB4; 13/19). A total of 69 participants (99%) were missing subsubsegmental branches, and this was most common in the left lower lobe (LB10; 54/69)
and right middle lobe (RB4; 48/69). The distribution of participants with missing subsubsegments provided in Figure 5-2 shows that the most common number of missing subsubsegments (mode) was 10; 34/70 participants or 49% were missing ≥10 (or ≥50%) of 20
potential total sub-subsegmental airways. Figure 5-2 also shows that asthma participants
with ≥10 missing sub-subsegments (n=34) had increased WA% (68.6±1.4% vs.
66.8±1.3%, p<0.0001) and reduced LA (9.1±1.9 mm2 vs. 11.8±2.2 mm2, p<0.0001)
compared with participants with <10 missing sub-subsegments (n=36). Participants with
≥10 missing sub-subsegments also had greater pre-bronchodilator VDP compared with
participants with <10 missing sub-subsegments (7±7% vs. 11±9%, p=0.03), but not postbronchodilator VDP (5±7% vs. 7±6%, p=0.053). VDP improved post-bronchodilator in
both subgroups dichotomized by missing sub-subsegments (both p<0.001). ROC curves
showed an area under the curve of 0.71 (p=0.01) for TAC. A TAC threshold of 165
discriminated between subgroups with a sensitivity of 60% and specificity of 67%.
Table 5-2 Participants with missing subsegmental and sub-subsegmental
daughter branches by whole-lung and lung lobe
Number of Participants
Parameter
n=70
n (%)
Subsegments
Sub-subsegments
Whole-lung
19 (27)
69 (99)
RUL (RB1)
2 (3)
21 (30)
RML (RB4)
13 (19)
48 (69)
RLL (RB10)
2 (3)
45 (64)
LUL (LB1)
5 (7)
42 (60)
LLL (LB10)
4 (6)
54 (77)
LLL=left lower lobe; LUL=left upper lobe; RLL=right lower lobe; RML=right
middle lobe; RUL=right upper lobe. All percentages shown as fraction of total n=70.
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Figure 5-2 Airway morphology and VDP by number of missing sub-subsegmental airways
Participants were dichotomized by the number of missing sub-subsegmental airways less
than and greater than the mode of the number of missing sub-subsegmental airways
(mode=10); 36 participants had <10 missing sub-subsegmental airways and 34 had ≥10
missing sub-subsegmental airways. For participants with ≥10 missing sub-subsegmental
airways, wall area percent (WA%) was significantly greater and lumen area (LA) was
significantly less (both p<0.0001), compared with participants with ≥10 missing subsubsegmental airways. Pre-bronchodilator (BD) ventilation defect percent (VDP) was
significantly worse in participants with ≥10 missing sub-subsegments (p=0.03) but postBD VDP was not different (p=0.053).
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The relationship between missing sub-subsegmental airways and VDP on a lobar level is
shown in Figure 5-3. MRI ventilation defect percent (VDP) was significantly greater in
the right middle lobe (RML, p=0.04), right lower lobe (RLL, p<0.0001) and left lower lobe
(LLL, p<0.0001) as compared to the right upper lobe (RUL), and VDP was significantly
greater in the RLL (p<0.0001) and LLL (p<0.0001) as compared to the left upper lobe
(LUL). We also classified participants by the number of missing sub-subsegments on each
of the five airway paths; as compared to participants with 0 missing sub-subsegments,
participants with 3-4 missing on RB10 and LB1 had significantly greater VDP in the RLL
and LUL, respectively (both p=0.04), whereas participants with 1-2 missing had
significantly greater VDP in the LUL (p=0.02). Groups were not different for the RML
(p=0.7), LLL (p=0.3), nor RUL (p=0.5; not shown).
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Figure 5-3 MRI VDP by lung lobe
MRI ventilation defect percent (VDP) was significantly greater in the right middle lobe
(RML), right lower lobe (RLL) and left lower lobe (LLL) as compared to the right upper
lobe (RUL; *p<0.05); VDP was significantly greater in the RLL and LLL as compared to
the left upper lobe (LUL; †p<0.05). As compared to participants with 0 missing subsubsegments, participants with 3-4 missing sub-subsegments on RB10 and LB1 had
significantly greater VDP in the RLL and LUL, respectively (both p=0.04), whereas
participants with 1-2 missing sub-subsegments had significantly greater VDP in the LUL
(p=0.02). Groups were not different for the RML nor LLL.
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As shown in Table 5-3, we also investigated airway branch variants at the segmental level.
Airway branch variants were observed in 18 of 70 participants (26%). The most common
branch variants were the accessory sub-superior segment (n=10, 14%) and the accessory
left-medial basal segment (n=4, 6%). Other variants included an absent right-medial basal,
accessory right anterior, accessory right-medial basal and accessory airway off the left
main bronchus, before the left upper lobe bronchus. Participants with airway variants had
significantly diminished pre-bronchodilator RV (117±28%pred vs. 137±36%pred, p=0.03),
TLC (99±14%pred vs. 105±13%pred, p=0.04) and RV/TLC (117±24%pred vs. 130±26%pred,
p=0.050), significantly diminished post-bronchodilator MRI VDP (5±6% vs. 7±7%,
p=0.048), and significantly greater LA (11.6±2.4 mm2 vs. 10.1±2.4 mm2), compared with
participants without airway variants.

TAC was not significantly different between

participants with and without airway variants (164±33 vs. 152±50, p=0.4).
Table 5-3 Segmental airway branch variants
Parameter
Number of Participants
n (%)
n=70
None
52 (74)
Any
18 (26)
Accessory sub-superior (RB6)*
10 (14)
Absent right-medial basal (RB7)
1 (1)
Accessory left-medial basal (LB7)
4 (6)
Accessory right anterior (RB3)
1 (1)
Accessory right-medial basal (RB7)
1 (1)
Accessory left main bronchus†
1 (1)
*Accessory right sub-superior (RB6) observed in 10 of 70
participants, 2 of which also had accessory left sub-superior (LB6),
and 1 of which also had absent right-medial basal (RB7).
†
Accessory branch off left main bronchus, before left upper lobe
bronchus.
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Table 5-4 summarizes the number of participants with CT evidence of airway occlusions
that either terminated or did not terminate airways and the total number of airway
occlusions observed during the segmentation process. Intraluminal airway occlusions were
identified in 20 of the 70 (29%) participants; five (7%) participants had occlusions that
terminated the airway (11 total occlusions) and 15 participants (22%) had occlusions that
did not terminate the airway segmentation distal to the plug (31 total occlusions). Of the
five participants with occlusions terminating airways, two were GINA4 (2/19, 11%) and
three were GINA5 (3/36, 8%). Of the 15 participants with occlusions that did not terminate
the airways, one was GINA3 (1/15, 7%), four were GINA4 (4/19, 21%) and ten were
GINA5 (10/36, 28%).
Table 5-4 CT airway count and airway occlusion
ALL
GINA1-3
Parameter
(n=70)
(n=15)
Occlusions terminating airways
Participants n (%)
5 (7)
0
Occlusions n
11
0
Occlusions not terminating airway
Participants n (%)
Occlusions n

15 (22)
31

No occlusions
Participants n (%)
50 (71)
GINA=Global Initiative for Asthma.

GINA4
(n=19)

GINA5
(n=36)

2 (11)
3

3 (8)
8

1 (7)
1

4 (21)
10

10 (28)
20

14 (93)

13 (68)

23 (64)

5.3.4 Is TAC Related to FEV1 and Airway Wall Area?
Figure 5-4 shows that TAC was moderately related to post-bronchodilator FEV1 (r=0.39,
p=0.001; post-bronchodilator ΔFEV1 r=-0.38, p=0.002 [not shown]), WA% (r=-0.55,
p<0.0001) and LA (r=0.52, p<0.0001). In a subset of 60 participants who underwent
hyperpolarized 3He MRI (two did not fit the MRI coil and eight were consented to
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MRI only), TAC was also related to post-bronchodilator VDP (ρ=-0.34, p=0.008). TAC
was weakly related to RV/TLC (r=-0.28, p=0.02), but not FVC (r=0.24, p=0.051), RV (r=0.21, p=0.09), TLC (r=-0.02, p=0.9) nor FOV (r=0.03, p=0.8; data not shown).
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Figure 5-4 CT total airway count relationships
Total airway count was significantly related to post-bronchodilator FEV1 (r=0.39, p=0.001)
and MRI ventilation defect percent (VDP; ρ=-0.34, p=0.008), as well as CT wall area
percent (WA%; r=-0.55, p<0.0001) and lumen area (LA; r=0.52, p<0.0001).
Multivariable models to determine the relative influence of TAC on FEV1 and WA%,
adjusted for covariates, are shown in Table 5-5. First, we determined the relative influence
of CT imaging measurements on FEV1 (Model 1: R2=0.27, p=0.003), for which TAC was
the only predictor (β=0.50, p=0.001). Next, we determined the relative influence of CT
and MRI on FEV1 (Model 2: R2=0.49, p<0.0001), and both CT TAC (β=0.27, p=0.03) and
MRI VDP (β=-0.53, p<0.0001) significantly contributed. Finally, in a model for WA%
(Model 3: R2=0.32, p=0.0001), only TAC was a significant predictor (β=-0.53, p<0.0001).
Some of these important relationships can be demonstrated in Figure 5-5 where 3D
reconstructed airway trees are shown co-registered to 3He MRI static ventilation.
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Table 5-5 Multivariable models
Unstandardized
Standardized
p
Parameter
B
Standard Error
β
MODEL 1: FEV1 %pred (R2=0.27, p=0.003)
TAC
0.22
0.07
0.50
0.001
WA%
-0.58
2.44
-0.05
0.8
LA
-0.62
1.62
-0.07
0.7
2
MODEL 2: FEV1 %pred (R =0.49, p<0.0001)
TAC
0.13
0.06
0.27
0.03
WA%
-0.25
2.25
-0.02
0.9
LA
-0.18
1.45
-0.02
0.9
VDP
-1.34
0.28
-0.53
<0.0001
MODEL 3: WA% (R2=0.32, p=0.0001)
TAC
-0.02
0.01
-0.53
<0.0001
FEV1
-0.01
0.01
-0.07
0.7
VDP
-0.02
0.04
-0.09
0.5
B=regression coefficient; β=standardized regression coefficient; FEV1=forced
expiratory volume in one second; LA=lumen area; TAC=total airway count;
VDP=ventilation defect percent; WA%=wall area percent; %pred=percent predicted.
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Figure 5-5 Airway count and wall area relationship with MRI ventilation defects and FEV1
Three-dimensional reconstruction of the segmented airway tree co-registered to twodimensional coronal centre slice 3He MRI static ventilation (cyan) and anatomical 1H
(grey-scale) for participants with <10 (left) and ≥10 (right) missing sub-subsegments. The
participant with <10 missing sub-subsegments (45-year-old female) has greater TAC, less
MRI ventilation defects and greater FEV1 than the participant with ≥10 missing subsubsegments (31-year-old female). The two-dimensional airway paths to RB1 (below)
show the CT-visible sub-subsegmental daughter branch (RB1ai) with less abnormal airway
wall thickening at the subsegmental level (RB1a) for the participant with <10 missing subsubsegments, versus the missing sub-segmental daughter branch with marked airway wall
thickening at the segmental level for a participant with ≥10 missing sub-subsegments.
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5.4 Discussion
Recent work has shown that CT total airway count decreases with increasing severity in
COPD16 and based on these findings, we wondered whether airways also appear missing
on CT in asthma and about the potential relationship of CT TAC with asthma severity. We
evaluated 70 participants with asthma and made the following observations: 1) TAC was
diminished in GINA4 and GINA5 participants compared with GINA1-3, 2) asthma
participants with ≥10 missing sub-subsegmental airways had thicker airway walls,
narrower airway lumens and worse MRI ventilation defects than asthma participants with
<10 missing sub-subsegmental airways, and 3) TAC was moderately related to FEV1, MRI
VDP, airway wall thickness and lumen area, and in multivariate models, TAC
independently predicted FEV1 and WA%.

5.4.1 TAC is Reduced with Increasing Asthma Severity
To our knowledge, this is the first time the relationship between CT airway count and
asthma severity has been directly measured and we were surprised to observe that the total
number of CT-visible airways was reduced in GINA4-5 participants. Moreover, mean
TAC for all asthma participants in this study (154±45) was less than mean TAC previously
reported for never-smoker healthy participants in the CanCOLD cohort (221±73),16
suggesting the reduced number of airways may be linked to asthma susceptibility or
pathogenesis. In fact, TAC reported for GINA1-3 (183±49) and GINA4-5 (148±36,
146±47, respectively) were qualitatively similar to TAC measurements previously reported
in GOLD 1 (190±66) and GOLD II COPD (152±53), respectively.16 We note that BMI
was the only significant covariate when comparing TAC between treatment steps; age, sex
and RV/TLC were not significant covariates. To the best of our knowledge, there are no
previously published TAC values for patients with asthma. Missing or CT-invisible
airways started to be obvious at generation 6 in asthma which is similar to previous findings
(generation 5) in COPD16 and could be due to airway narrowing, obstruction and/or
obliteration. We note that four participants with the lowest FEV1/FVC were GINA4, which
may dictate a need for treatment step-up.1 The GINA4 subgroup sample size was about
half the GINA5 subgroup and the small sample size may have also influenced this result.
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5.4.2 TAC is Associated with Abnormal Airway Structure and Function
For asthmatics with ≥10 missing sub-subsegmental airways, airway walls were thicker and
airway lumens were narrower; this is in agreement with extensive CT studies
demonstrating thickened airway walls in patients with asthma.5-12 COPD participants were
previously dichotomized using the presence or absence of sub-subsegmental branches.16
However, we were alarmed that all but one participant had missing sub-subsegments and
the dichotomization scheme previously described was not possible. In fact, approximately
50% of the 70 participants we evaluated were missing half or more (≥10) of the total 20
possible sub-subsegmental airways. We note that the mean number of missing subsubsegments was 9, the median=8, and the mode=10 and that using any of these thresholds
resulted in the same subgroup composition. Similar to previous work in COPD,16 our
results suggest that in asthma, CT-invisible airways may be related to abnormal airway
structure, which may be a combination of airway remodeling28 and/or intraluminal
occlusion.22 Intraluminal airway occlusion (mucus, cellular debris or their combination)
was identified in 20 participants, although such occlusions terminated the airways in a
quarter of those with occlusions (5 of 20) which is 7% (5 of 70) of all participants evaluated.
All but one participant with occlusions reported severe asthma, which is similar to previous
reports,22 although we observed fewer occlusions or plugs in fewer participants overall than
previously reported. Together, this suggests that intraluminal occlusions did not have a
large impact on TAC in this study. The presence of thicker airway walls and narrowed
lumens in subsegmental airways that were missing daughter branches suggest that it is
obstruction (via airway wall remodeling or collapse), rather than airway destruction that is
responsible for our findings in participants with asthma. Quantitative CT phenotypes have
been identified in patients with asthma29 largely based on proximal airway morphology
including airway luminal narrowing and wall thickness. TAC provides a complementary
quantitative CT measurement that reflects the architecture of the airway tree and may help
to further enrich imaging-based phenotypes of asthma. We also investigated the functional
consequences of reduced TAC and observed worse MRI ventilation defects in participants
with more missing sub-subsegments on the whole-lung level and worse MRI VDP in lung
lobes with greater prevalence of missing sub-subsegments. Previous work30 demonstrated
a relationship between thickened airway walls and MRI ventilation defects in asthma,
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which is congruent with our finding that TAC and abnormal airway structure contribute to
abnormal MRI ventilation on whole-lung and regional lobar levels.
Similar to recently published findings in COPD,24 we observed airway variants in 18 of 70
or 26% of participants. The most common variant was an accessory sub-superior segment
which was observed 14% of participants. These results are in good agreement with
published results in 3,000 COPD participants,24 with very similar prevalence of airway
variants and the presence of the accessory sub-superior segment. Interestingly, MRI VDP
was worse in participants with conventional segmental airway anatomy compared with
participants with airway variants, which may be explained by the smaller airway lumens
also observed in participants with conventional airway tree architecture. We were not
powered to investigate relationships for individual airway variants which should be
investigated in larger-scale studies.

5.4.3 TAC is Related to FEV1 and Airway Wall Area
TAC was significantly, albeit weakly to moderately, related to FEV1, VDP, WA% and LA.
In addition, TAC was inversely and positively correlated with WA% and LA, respectively.
This suggests that thickened airway walls and narrow airway lumens help explain
diminished TAC in asthma, in contrast to COPD where missing airways were related to
thinning airway walls.16 The relationship between TAC and VDP was especially weak,
possibly because a large proportion of participants reported VDP<5%. We note that VDP
values here were similar to previously reported values in mild-moderate (3-4%30,31) and
severe asthma (6-10%31,32). Univariate relationships were used to drive multivariable
models to investigate these relationships and showed that among the CT measurements
investigated, TAC was the only independent predictor of FEV1. In a separate model, CT
TAC and MRI VDP together explained a greater proportion of FEV1 variability. Hence,
CT airway count provided unique information related to FEV1, independent of airway
morphology. Previous work in COPD16 also showed that TAC and lumen area both helped
to explain FEV1. To more deeply explore this finding and our own results, we generated
an additional multivariable model using only CT wall area percent (β=-0.24, p=0.2) and
CT lumen area (β=0.04, p=0.8), neither of which was significant (model R2=0.13, p=0.1).
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It is important to note that airway wall and lumen measurements were generated for
anatomically equivalent segmental, subsegmental and sub-subsegmental airways in five
airway paths.23 BMI was a significant covariate in the multivariable models (participant
age and sex were not) which may help explain the weak to moderate univariate
relationships. CT in combination with MRI offers highly complementary information
about lung structure and function in patients with asthma and generates an understanding
of the functional consequences of structural abnormalities. TAC also uniquely explained
airway wall morphology (WA%) which suggests there is some form of interaction between
airway thickening and apparently lost/missing or CT invisible airways.

5.4.4 Limitations and Unanswered Questions
Limitations of our study include the fact that the study was based on a convenience sample
dominated by more severe disease, such that we were underpowered to individually
evaluate GINA1-3 (GINA1 n=4, GINA2 n=2 and GINA3 n=9). A population-based
sample would provide more participants with milder disease which would allow for the
detection of differences between all GINA subgroups. It is important to note that CT
images were acquired at functional residual capacity plus 1.0 L to volume-match CT and
MRI datasets. We pondered the relationship between CT/MRI lung volume and airway
count and the fact that most studies acquire CT close to TLC.16 CT lung volume acquisition
differences could impact participants with larger lung volumes because at a lower fraction
of vital capacity, the elastic forces tethering the airways open would also be lowered which
would impact lumen diameters and potentially contribute to reduced TAC. We note
however that TAC was not significantly related to the fraction of lung volume for imaging
normalized to vital capacity (r=0.04, p=0.7) or total lung capacity (r=0.045, p=0.7). We
did not acquire expiratory CT and therefore we have no CT measurements of air
trapping33,34 so it is not possible to compare parametric response map or expiratory CT
lucency measures with TAC in this study. Although CT FOV differed to a small extent
among study participants, we confirmed that CT FOV was not different between treatment
step groups and was not correlated with TAC, nor was TAC different between participant
groups with different FOV. We also acknowledge the lack of repeat and longitudinal
follow-up CT imaging at this time. Future work will be needed evaluate the reproducibility
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of TAC in participants with asthma and potential changes in TAC over time. Whereas
repeat and sometimes longitudinal CT in patients with asthma is not common due to
radiation burden, MRI allows for repeat evaluations without added risk to patients. Missing
airways on CT were related to worse MRI ventilation defects on whole-lung and lobar
levels, and previous work has demonstrated spatial relationships between focal ventilation
defects and abnormally remodeled airways.30,35 Although MRI and CT measure different
but complimentary information, this supports the notion that ventilation defects are
indicative of abnormal airways in severe asthma and can be used to guide treatment
decisions or localized therapies with the goal of resolving ventilation defects and thus,
airway abnormalities and asthma control.
This study raises more questions than it answers. What are the underlying
pathophysiological processes that drive airway drop-out in severe asthma? Do mucus or
other types of occlusions play a role and were these more dominant at airway termini at a
timepoint prior to our evaluation? In other words, is the relative lack of mucus at most
airway termini definitive for the process underlying missing airways? Are some patients
preprogrammed for low TAC which may be coincident to, or predictive of the development
of asthma? Is TAC a missing link between asthma-COPD overlap or the asthma transition
to loss of post-bronchodilator reversibility and COPD? How does TAC change over time,
with and without treatment? Future studies ought to investigate histologic airway wall
remodeling,28 inflammatory markers including sputum cell counts or exhaled nitric
oxide32,36 and/or CT scores for intraluminal obstructions22,37 to elucidate the underlying
mechanisms for missing airways.
genome-wide

association

studies

Integration of TAC with ‘omic investigations or
(GWAS)38,39

may

help

determine

possible

predispositions for reduced TAC and development of obstructive lung disease. Finally,
longitudinal studies are also required to understand the stability of TAC over time and how
it may help monitor disease progression or changes in response to therapy.
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5.4.5 Conclusions
Whilst chronic airflow obstruction and airway obliteration have been described in
COPD,13-15 airways disease in asthma is regarded as temporally variable and reversible
within an entire tracheobronchial tree. Here we show that the airway tree is truncated in
patients with severe asthma and the reduced number of terminal airways is similar in
magnitude to what was previously reported in moderate COPD.16 The reduced number of
airways detected using CT in asthma may be related to airway obstruction (luminal
plugging, airway collapse or wall thickening) rather than destruction or obliteration. How
TAC may change with treatment or over time in patients with asthma remains to be
determined. In severe asthma, MRI ventilation heterogeneity was recently likened to a
canary in the coal mine40 because MRI ventilation abnormalities uniquely explained
asthma control40 and also predicted the transition of asthma to fixed obstruction.41 In a
similar manner, the airway tree may represent the tunneling shafts that support the coal
mining operation; once blocked or destroyed, the entire enterprise is threatened and
sometimes doomed.
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5.6 Supplement
Table 5-6 Total airway count by airway generation
Generation
Never-smokers1
GINA1-3
GINA4
GINA5
Count (±SD)
(n=15)
(n=19)
(n=36)
0
1.0 (0.0)
1.0 (0.0)
1.0 (0.0)
1.0 (0.0)
1
2.0 (0.1)
2.0 (0.0)
2.0 (0.0)
2.0 (0.0)
2
4.0 (0.1)
4.3 (0.8)
4.5 (1.4)
4.2 (0.5)
3
13.0 (0.8)
13.4 (0.6)
13.9 (1.1)
13.5 (1.0)
4
24.2 (1.3)
25.0 (2.2)
24.9 (1.7)
25.0 (2.5)
5
43.5 (6.2)
45.3 (6.2)
39.4 (7.3)
38.8 (10.1)
6
52.3 (17.4)
46.9 (16.3)
32.0 (15.4)*
34.9 (17.3)
7
42.1 (22.9)
27.5 (16.3)
14.8 (8.8)*
13.8 (12.1)*
8
23.3 (16.4)
10.1 (10.5)
5.3 (4.7)
5.8 (5.5)
9
10.8 (9.8)
2.5 (3.3)
2.2 (2.7)
1.3 (2.0)
10
3.8 (4.6)
1.1 (1.8)
0.3 (0.6)
0.2 (0.6)*
11
0.3 (0.7)
0.0 (0.0)
0.0 (0.0)*
1
GINA=Global Initiative for Asthma. From Kirby et al., 2018. *Significantly different
from treatment steps 1-3, p<0.05.
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CHAPTER 6
6

CONCLUSIONS AND FUTURE DIRECTIONS

In this final chapter, I provide a summary and overview of the important findings and
conclusions presented in Chapters 2-5. The limitations specific to each study and general
limitations are also provided with some potential solutions. Finally, I end my thesis with
future directions based on what we observed using hyperpolarized 3He MRI, CT and
oscillometry.

6.1 Overview and Research Questions
Asthma has long been idealized as a diffuse airways disease with variable symptoms and
airflow limitation despite evidence of ventilation heterogeneity that was first identified
over six decades ago.1-4 Structure and function of asthma are still clinically characterized
using the forced expiratory volume in one second (FEV1) – although FEV1 is a simple and
inexpensive measurement, it only provides a global measurement of lung function that
cannot capture the regional heterogeneity of airway abnormalities that may be responsible
for symptoms and disease worsening. In an effort to better understand the mechanisms of
ventilation heterogeneity, computational models have been generated and suggest that the
regional heterogeneity observed in asthma can only be described by randomly distributed
airway abnormalities throughout the whole lung.5,6 The in vivo mechanisms however have
been challenging to measure using current clinical tools such as FEV1. As a result, asthma
is still regarded as a random disease and treatments are geared towards all airways and not
individualized.
Quantitative pulmonary imaging methods have been developed to directly visualize and
quantify regional abnormalities in patients with lung disease. In particular, hyperpolarized
gas MRI provides in vivo images of regional gas distribution in high resolution. As
expected, MRI ventilation in young healthy volunteers is homogeneously distributed,7,8
whereas in asthmatics, characteristic ventilation heterogeneity is observed.9,10

In

conjunction with CT and oscillometry, the underlying structure of ventilation heterogeneity
may be ascertained; focal ventilation abnormalities, known as ventilation defects, are
spatially and quantitatively related to abnormal large11 and small airways.12,13

The

physiological relevance of ventilation defects has been anchored to important clinical
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measures including FEV1,11,12,14,15 asthma control16 and airway inflammation.17
Preliminary longitudinal studies in asthma demonstrate that defects are spatially and
temporally persistent for up to 1.5 years,15,18 importantly contradicting in silico results.
These early disruptive MRI results suggest that asthmatic airway and corresponding
ventilation abnormalities are not random. Despite this evidence and support for clinical
use, pulmonary imaging has played a limited role in asthma research and clinical care
because the physiological mechanisms, long-term nature and clinical relevance of regional
ventilation heterogeneity in asthma are poorly understood.
The overarching objective of this thesis was to exploit sensitive pulmonary imaging
measurements to better understand the structure and function of the asthmatic lung that
drive ventilation heterogeneity and provide a foundation for imaging to guide disease
phenotyping for personalized asthma treatment and predict disease worsening.
The specific research questions addressed were: 1) Are the biomechanical impacts of
ventilation heterogeneity in asthma different from those of COPD and can these differences
be explained using oscillometry and MRI ventilation defects? (Chapter 2); 2) Are
ventilation defects similar between twins with asthma and spatially and temporally
persistent over long periods of time? (Chapter 3); 3) Are ventilation defects spatially and
quantitatively persistent over long periods of time in unrelated asthma patients, and can
ventilation defects predict future bronchodilator reversibility? (Chapter 4); and 4) Is the
airway tree truncated in severe asthma and are truncated airways to thickened airway walls
and worse airway function? (Chapter 5)

6.2 Summary and Conclusions
In Chapter 2, we evaluated the relationships between hyperpolarized 3He MRI ventilation
defects and oscillometry measurements of lung biomechanics in a total of 175 participants
including 49 with asthma, 56 with COPD, 28 ex-smokers without COPD and 42 neversmokers without lung disease. In both asthma and COPD, VDP was significantly related
to R5-19 (asthma: ρ=0.48, p=0.0005; COPD: ρ=0.45, p=0.0004), X5 (asthma: ρ=-0.41,
p=0.004; COPD: ρ=-0.38, p=0.004) and AX (asthma: ρ=0.47, p=0.0007; COPD: ρ=0.43,
p=0.0009). When COPD participants were dichotomized by the presence of emphysema
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(RA950≥6.8%), VDP was sig`nificantly related to X5 in those with emphysema (ρ=-0.36,
p=0.04) whereas in those without emphysema, VDP was related to R5-19 (ρ=0.54, p=0.008).
VDP was significantly related to AX in participants with (ρ=0.39, p=0.02) and without
(ρ=0.43, p=0.04) emphysema. These results suggest that MRI VDP and oscillometrymeasured R5-19 and X5 may reflect disease-specific airway and parenchymal biomechanical
abnormalities that lead to ventilation defects.
In Chapter 3, we evaluated the spatial and temporal nature of CT airway and
hyperpolarized 3He MRI ventilation abnormalities over the course of seven years in adult
female nonidentical twins with asthma.

Both twins showed a spatially-matched

subsegmental MRI ventilation defect in the left upper lobe corresponding to the LB2
apicoposterior bronchopulmonary segment. At 7-year follow-up, the LB2 WA% was 71%
and 75% for twin 1 and twin 2, respectively. Based on the 19 anatomically and functionally
distinct bronchopulmonary segments, and under the assumptions of no more than one
defect per segment and an equivalent probability for each of the 19 segments to express a
defect, we estimated the probability that two patients have the same single defect at two
timepoints to be 1 in 130,321. These findings suggest that ventilation abnormalities may
not be randomly distributed within patients with asthma and persist distal to airway
abnormalities for long periods of time.
In Chapter 4, we investigated 6-year longitudinal changes in hyperpolarized 3He
ventilation defects in 11 participants with mild-to-moderate and aimed to determine
predictors of longitudinal post-bronchodilator FEV1 reversibility.

There were no

differences between FEV1 (76%pred vs 76%pred, p=0.9) and MRI VDV (240 mL vs 250 mL,
p=0.9) between baseline and follow-up and no participants experienced any medication
changes or exacerbations during the time between study visits. For 8 of 11 participants,
MRI ventilation defects were spatially and quantitatively persistent between study visits.
For the remaining 3 participants, ventilation defects worsened in the same locations
previously induced by methacholine at the baseline visit. At follow-up, FEV1 was not
reversible in 6 of 11 participants; baseline PC20 was significantly worse in FEV1-reversible
compared with nonreversible participants (0.08±0.01 mg/mL vs 0.84±0.86 mg/mL,
p=0.01). No other measurements were significantly different between FEV1 reversible and
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FEV1 non-reversible groups. In multivariable models including MRI VDV, FEV1, PC20
and participant age, only VDV significantly predicted post-bronchodilator FEV1
reversibility at follow-up (R2=0.80, p<0.01). These results suggest that MRI ventilation
defects are spatially persistent over 6.5 years, and are uniquely predictive of future
bronchodilator reversibility in patients with asthma.
In Chapter 5, we measured CT TAC in 70 participants with asthma across a range of
severities including 15 GINA1-3, 19 GINA4 and 36 GINA5, and evaluated relationships
for TAC with asthma severity, airway morphology, pulmonary function and MRI
ventilation. TAC was significantly diminished in GINA4 (145±10, p=0.03) and GINA5
(148±7, p=0.045) compared with GINA1-3 (182±11). Sub-subsegmental airways were
CT-invisible or missing in 69 of 70 participants. The most common number of missing
sub-subsegments was 10, and participants with ≥10 missing sub-subsegments had worse
WA% (68.6±1.4% vs 66.8±1.3±, p<0.0001), LA (9.1±1.9 mm2 vs 11.8±2.2 mm2,
p<0.0001) and VDP (7±7% vs 11±9%, p=0.03) than those with <10 missing subsubsegments. In a multivariable model including all CT parameters, TAC (β=0.50,
p=0.001) independently predicted FEV1 (R2=0.27, p=0.003). In a separate model including
VDP, TAC (β=0.27, p=0.03) and VDP (β=-0.53, p<0.0001) combined to explain FEV1
(R2=0.49, p<0.0001). In severe asthma, TAC was reduced to a similar degree as previously
published results in moderate COPD, and these results challenge our understanding of
airways disease in asthma as temporally variable and reversible.
In summary, we have provided: 1) an understanding of biomechanical lung abnormalities
specifically related to asthma compared with COPD with and without emphysema; 2)
evidence of a spatially-matched MRI ventilation defect in twins with asthma that is
spatially and temporally persistent for seven years; 3) evidence that MRI ventilation defects
are spatially and temporally persistent for over six years in a group of participants with
mild-to-moderate asthma, and that ventilation defects are predictive of future
bronchodilator reversibility; 4) evidence that airway wall thickening is related to reduced
total number of CT-visible airways in severe asthma that is similar in magnitude to
moderate COPD and related to worse MRI VDP.
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6.3 Limitations
The most significant limitations from Chapters 2-5 are presented here. The study specific
limitations are also provided within the Discussion section of each respective chapter.
Following the study specific limitations, general limitations common to all chapters are
addressed.

6.3.1 Study Specific Limitations
Chapter 2: Oscillometry and Pulmonary Magnetic Resonance Imaging in Asthma and
COPD
In the study presented in Chapter 2, the oscillometry-derived results were limited by the
use of raw values without correction for age or anthropometric factors. It is wellestablished that pulmonary function measurements vary with age, sex, height and
ethnicity.19 Although our participant cohort was well-matched for sex and consisted only
of Caucasian adults, impedance differences between groups, or lack of differences, may
have been influenced by participant age and height. This may also partially explain the
weak correlations observed between oscillometry measurements and MRI VDP. Diverse,
global reference equations are currently under development for oscillometry, and future
investigations should employ normalized values where possible.
Another limitation of this study derives from the fact R5-19 may not capture the largest
influence of ventilation heterogeneity on the frequency dependence of resistance.
Experimental studies in animal models and humans have shown that heterogeneity has the
largest influence on respiratory system resistance between 0.1-5 Hz.20-22 We therefore only
captured a small portion of the impact of heterogeneities using R5-19 and this may explain
the weak correlations observed. It is important to note though that all commercially
available oscillometry devices approved for use in humans employ broadband signals with
lower bounds of 4-5 Hz.23 Future studies could investigate the relationships between
respiratory system resistance at frequencies <5 Hz and MRI ventilation heterogeneity,
however this would require custom-built oscillometry systems.
As a technical limitation, shunting of the oscillatory waves to the upper airways reduces
sensitivity of oscillometry measurements to obstruction.24 This means that in patients with
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severe airflow obstruction, impedance may be underestimated and this may also have
influenced correlation strengths observed in this study. To mitigate the effects of upper
airway shunt, we perform extensive coaching and instruct participants to firmly hold their
cheeks with their hands.
Finally, we acknowledge that oscillometry and MRI measurements were acquired in
different positions, introducing the potential for postural effects.

Oscillometry was

performed in the upright position whereas MRI was performed supine and this may have
had an additional impact on the strength of the relationships between MRI and oscillometry
measurements of ventilation heterogeneity. Previous work has demonstrated that R5 is
increased in the supine position compared to upright25,26 and the presence of emphysema
may also cause large upright-to-supine AX variability.27 Regardless, we took steps to
mitigate and minimize potential postural effects in this study by completing imaging within
five minutes to limit the time that patients are supine, which has been shown to minimize
atelectasis.28
Chapter 3: Nonidentical Twins with Asthma: Spatially-matched CT Airway and MRI
Ventilation Abnormalities
In the study presented in Chapter 3, we only evaluated one set of twins. Our results are
thus difficult to generalize to all patients or twins with asthma. We assumed the persistent
ventilation defect in these participants to be related to asthma pathophysiology and/or
abnormal airway structure. It is possible that these findings could also be explained to
some extent by shared genetics, epi-genetics or in utero events, which we did not evaluate
here and could not rule out. Future investigations would benefit from a more complete
clinical history incorporating these factors.
Based on the assumptions we made, our probability estimate for a repeated ventilation
abnormality in space and time was conservative. In twins, there may be a bias for airway
and ventilation abnormalities in specific lung regions which we did not account for.
Moreover, we did not make any assumptions about an upper limit of number of ventilation
defects that might be less than one for each of the 19 potential segmental airways. In the
literature, participants with moderate disease typically have fewer than five ventilation
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defects.14 A more rigorous analysis could include the probability of twins having asthma,
the probability of multiple ventilation defects, or the probability of subsegmental (38
subsegments) or sub-subsegmental (76 sub-subsegments) ventilation defects. However,
accounting for these factors would only serve to lower the estimated probability and would
likely more strongly support our conclusions.
Chapter 4: Hyperpolarized Helium 3 MRI in Mild-to-Moderate Asthma: Prediction of
Postbronchodilator Reversibility
The longitudinal study presented in Chapter 4 was limited by the small sample size of
only mild-to-moderate participants and this limits the generalizability of the multivariable
model results to the broader asthma population. Importantly however, hyperpolarized gas
MRI measurements are extremely sensitive; as demonstrated in this study and others in the
literature, significant group differences and relationships may be detected using small
sample sizes. Nonetheless, this study generated pilot data that can motivate large imaging
cohort studies of asthma over a range of asthma severities to further confirm the results
observed here.
Another limitation of this study was the partial thoracic CT images that were acquired at
the baseline timepoint which limited the regional airway comparisons between study visits.
Low-dose research CT protocols similar to that used at the time of follow-up are now
widely available and may be employed in future studies to longitudinally investigate
morphological airway changes. Further development of ultra-low dose CT methods29,30
may also facilitate the broader use of longitudinal CT imaging in patients with asthma. In
spite of the partial CT volume, we were able to demonstrate persistent structure-function
relationships in specific lung regions.
Chapter 5: Is Computed Tomography Total Airway Count Related to Asthma Severity and
Airway Structure-function?
The study presented in Chapter 5 was based on a convenience sample of asthmatics
recruited from local tertiary care centres, thus our participant population was dominated by
more severe disease. We were underpowered to individually compare GINA treatment
steps 1-3 to tease out differences between all levels of asthma severity. The strength of the

165

study could have been improved using a population-based sample which would have better
facilitated recruitment of participants with milder disease.
Another limitation was the acquisition of CT images at FRC+1.0 L. While this facilitates
comparison and registration to MRI by volume-matching the acquisitions, most studies
acquire CT close to TLC and this may limit our comparisons to previous work.31 The lung
volume acquisition differences could especially impact participants with larger lung
volumes because at a lower fraction of vital capacity, the elastic forces tethering the
airways open would be reduced; this would impact lumen diameters and potentially
contribute to decreased TAC. We determined that TAC was however not significantly
related to the CT lung volume normalized to vital capacity (r=0.04, p=0.7) or total lung
capacity (r=0.05, p=0.7), therefore we suspect lung inflation at imaging to have minimally
impacted our results. We also did not acquire expiratory CT and therefore could not
evaluate the regional nor whole-lung relationships between imaging measurements of gas
trapping32,33 and TAC. Future large cohort studies could benefit from paired inspiratoryexpiratory CT imaging to contemporaneously evaluate and compare TAC and gas trapping.

6.3.2 General Limitations
A general limitation to the studies presented in Chapters 2-5 is the lack of measurements
of airway inflammation.

Asthma is characterized by chronic airway inflammation,

however we were unable to ascertain the role of inflammation within our findings.
Previous work has demonstrated a direct relationship between MRI VDP and sputum
eosinophils and suggested that ventilation defects which persist following bronchodilator
are indicative of unresolved airway inflammation.17 To our advantage in the absence of
inflammatory biomarkers in Chapters 4 and 5, we used pre- and post-bronchodilator MRI
evaluations to infer the role of smooth muscle dysfunction.

In future work, direct

comparison of oscillometry, CT airway and MRI ventilation abnormalities to airways
inflammation will be important towards guiding clinical treatment decisions and for
personalized therapy. Ongoing studies at our centre are now prospectively evaluating noninvasive biomarkers of inflammation from exhaled breath, sputum and blood in
conjunction with MRI study visits.
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Another general limitation to all chapters was our focus only on ventilation defects (as a
volume and percent of total lung volume), though it is obvious that hyperpolarized gas MRI
ventilation is not binary. In addition to ventilation defects, four distinct intensities of MR
gas signal can be visualized by expert readers ranging from hypo- to hyper-intense signal.34
The heterogeneity of the gas signal itself is evident in Figure 1-10 in the introduction for
both 3He and

129

Xe in asthma and COPD. The well-established clinical relevance of

ventilation defects in asthma supported their investigation in this thesis,11,16 however the
clinical relevance of the MRI signal distribution and its spatial and temporal behaviour are
unknown. The semi-automated MR image segmentation method employed in this thesis
quantifies each of the four respective intensities34 that can subsequently be investigated
individually to determine their underlying mechanisms and clinical relevance.
Alternatively, coefficients of variation35 or texture features36 of the signal intensity may be
investigated to directly probe heterogeneity. Oscillometry-MRI comparisons like those in
Chapter 2 may particularly benefit from direct comparison of signal intensity
measurements because these are likely the regions actually probed by the oscillatory waves.
In future work, it will be important to evaluate the signal intensity and its heterogeneity in
space and time in conjunction with ventilation defects.
Pertinent to Chapters 3-4, we acknowledge the limited longitudinal analysis of two
timepoints. Including a third timepoint, especially one at an interim point between the two
study visits would add strength to these studies as well as to our conclusions of nonrandom, spatially and temporally persistent CT airway and MRI ventilation abnormalities.
Moreover, we acknowledge the lack of longitudinal timepoints altogether in Chapters 2
and 5. We think that reduced CT TAC in severe has important implications for airways
disease in asthma, however future work will be needed evaluate the reproducibility of TAC
in participants with asthma and potential changes in TAC over time.

Moreover,

oscillometry has excellent intra-patient reproducibility37 that could make it a sensitive tool
for detecting changes in ventilation heterogeneity over long periods of time.
An important limitation through Chapters 2-5 is the limited worldwide supply and
subsequent high cost of 3He that has inhibited its clinical translation.38 3He MRI has played
an important role in our developing understanding of asthma in previous work and the work
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presented in this thesis, however novel prospective research studies using 3He are unlikely.
In contrast,

129

Xe is less costly and poised for clinical translation; clinical approval

currently exists in the United Kingdom and approval is pending in the United States.

129

Xe

MRI is more sensitive to airway obstruction and exhibits significantly greater ventilation
defects than 3He in both asthma39 and COPD.40

This increased sensitivity will be

advantageous in future research and clinical studies, but could have implications for the
conclusions in this thesis. For example, only 27% of participants in Chapter 4 showed
spatially persistent but quantitatively larger or worsened ventilation defects at follow-up.
If this study were repeated using

129

Xe MRI, it is plausible that more participants would

show worsening defects that were undetected with 3He. Moreover, one might hypothesize
that there are stronger relationships between

129

Xe VDP and oscillometry measurements

compared to those in Chapter 2 due to systematically greater VDP or possible wider
dynamic range of VDP compared with 3He. Speculations aside, future 129Xe MRI studies
are required to validate the results presented here using 3He MRI.

129

Xe is additionally

advantageous because it can provide regional measurements of gas exchange.

All

prospective studies currently ongoing or upcoming at Western University in London,
Canada are now employing

129

Xe for ventilation and gas exchange measurements in

patients with asthma and COPD.

6.4 Future Directions
6.4.1 Between-participant Probability Maps of MRI Ventilation Defects in
Asthma
The work presented in Chapters 3 and 4 of this thesis demonstrated spatially and
temporally persistent CT airway abnormalities and MRI ventilation defects within
participants with mild-to-moderate asthma. The results in Chapter 3 also demonstrated a
spatially-matched ventilation abnormality between twins with asthma, and this promotes
speculation about a spatial preference for airway and ventilation abnormalities between
participants with asthma. As a result, we now pose the following research questions:
1) Are there more likely regional locations for airway and ventilation abnormalities
between different participants with asthma?
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2) Does inhaled methacholine act on particular airways between different
participants with asthma?
To answer these questions, we retrospectively evaluated 31 participants with asthma,
including 12 with mild-to-moderate and 19 with severe asthma, to describe a proof-ofconcept spatial probability distribution of MRI ventilation defects between patients with
asthma. Participants underwent hyperpolarized 3He MRI before and after methacholine
and images were segmented using a semi-automated method.34

Each image in the

respective groups of mild-to-moderate and severe asthma, before and after methacholine,
were deformably co-registered using the modality-independent neighbourhood descriptor
method (MIND)41 in MATLAB R2015a (Mathworks, Natick, MA, USA) as previously
described.42 The ventilation mask for one participant was selected as the fixed reference
image and the 3He images for all participants in each group were registered to the one mask
to enable direct comparisons.
Figure 6-1 shows preliminary probability maps for mild-to-moderate and severe asthma
participants at baseline and post-methacholine. These maps describe the probability that a
voxel was ventilated across the group of asthma patients included in each model; brighter
blue regions represent higher likelihood of that voxel being ventilated whereas dark blue
regions represent lower likelihood of that voxel being ventilated (ie, ventilation defects).
Qualitatively comparing baseline and post-methacholine maps, the ventilation distribution
is visually more heterogeneous following methacholine for both mild-moderate and severe
asthmatics. At baseline, there is a visual superior-inferior gradient in both mild-moderate
and severe participants, such that superior regions showed a greater likelihood of being
ventilated. Post-methacholine, a posterior-anterior ventilation gradient becomes more
evident. In severe asthma specifically, two locations can be visually identified in the postmethacholine posterior slice that appear as ventilation defects in roughly 50% or more of
the sample, in the upper left and right lung lobes.
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Figure 6-1 Ventilation defect probability maps for mild-moderate and severe asthma
Posterior, centre and anterior slices pre- and post-methacholine showing regional
probability of ventilation defects between participants with asthma. Colour map represents
no ventilation in black (0%) to complete ventilation in cyan (100%) throughout the patients
included in the model.
These results point towards a regional preference for the location of ventilation defects and
abnormally remodeled airways between participants with asthma. These results may be
important for the development of novel therapies that can be targeted towards regions with
the highest likelihood to be abnormal. The registration pipeline and maps generated here
provide a framework for development and application of a probability model of the
distribution of ventilation in patients with asthma. Towards generating a functional atlas
of the asthmatic lung that is generalizable to the broader asthma population, it will be
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important to continue to build this model by continuously including data from more
research participants.

6.4.2 Contributions of Large versus Small Airways to Ventilation
Heterogeneity in Asthma
With the understanding that ventilation defects in asthma are spatially persistent for long
periods of time, ventilation defects may serve as important targets for novel asthma
therapies, including image-guided and targeted small airway approaches. Ventilation
defects in asthma may be driven by large11 or small12 airway abnormalities, however the
relative contribution of large versus small airway obstruction to ventilation heterogeneity
in a given patient is not well-understood.
With this in mind, we hypothesize that CT airway tree geometries can be used to
differentiate the contributions of large versus small airways to ventilation heterogeneity in
a patient-specific approach using CT airway tree geometries. In a preliminary study, we
aimed to develop a pipeline to calculate VDP related to the small or large airways using
paired MRI ventilation and CT image sets. MR ventilation images were segmented using
a semi-automated method34 and CT airway trees were segmented up to the 10th generation
using commercial software (Pulmonary Workstation 2.0; VIDA Diagnostics Inc.,
Coralville, IA, USA). Airways that could be segmented were assumed to be all large
airways, and those that could not be segmented were considered the small airways. MR
static ventilation images were co-registered to the thoracic CT volume and airway tree
using the MIND method41 in MATLAB R2015a (Mathworks, Natick, MA, USA). The
trachea was manually removed from the airway tree and the remaining airways were dilated
on a voxel-wise basis using a 20x3 ellipsoid in order to account for the volume around the
large airways. This volume was subsequently used to separate the 3He ventilation into
relative contributions of the small and large airways, and VDP was calculated as the
volume of defects within each region normalized to the total volume of that region. This
pipeline is outlined in Figure 6-2.
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Figure 6-2 Small versus large airways image analysis pipeline
MRI ventilation was deformably co-registered to the thoracic CT and airway tree volumes
(A) and the registered airway tree (B) was dilated in 3D on a voxel-wise basis (C). The
dilated airway tree volume was registered to the segmented ventilation clusters (D) to
generate the ventilation volume corresponding to the large and small airways.
As a proof-of-concept, the pipeline was evaluated in 20 participants with asthma, 10 each
with mild-to-moderate and severe asthma. Whole-lung (5±4% vs 8±4%, p=0.1), large
airway (2±2% vs 3±3%, p=0.3) and small airway VDP (6±5% vs 10±3%, p=0.055) were
not significantly different between mild-to-moderate and severe asthma groups. In both
mild-to-moderate and severe asthma, small airways VDP was significantly greater than
large airways VDP (p=0.002 and p=0.0001, respectively). Relationships for FEV1 with
whole-lung and large and small airway VDP are shown in Figure 6-3. Whole-lung (r=0.6, p=0.008) and large airway (r=-0.6, p=0.01) VDP were significantly related to FEV1,
whereas small airway VDP was not (r=-0.3, p=0.2). Because FEV1 is known to be
dominated by airflow in the large airways,43 the relationship between FEV1 and large
airways VDP provides initial validation of our pipeline. This pipeline provides a first step
towards distinguishing the large versus small airway contributions to ventilation
heterogeneity in asthma.
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Figure 6-3 Relationships between FEV1 and whole-lung, large and small airway VDP
In 20 participants with asthma, whole-lung and large airway VDP were significantly related
to FEV1 whereas small airways VDP was not.
Our results in Chapter 5 however suggest that the assumption that the airways in the
segmented tree represent all large airways may be invalid, especially in severe asthma.
This pipeline can be extended to account for a priori spatial relationships between large
airways and ventilation defects. Alternatively, a computational three-dimensional airway
tree model consisting of 64,895 airways44 could be used to simulate large versus small
airway narrowing in asthma related to ventilation defects. Although this approach is not
patient-specific, it provides a controlled environment to model both the large and small
airways and eliminates the impact of airways that appear missing on CT. Previous work
has generated image-functional models using this airway tree in conjunction with MRI
ventilation in participants with asthma to simulate respiratory system impedance by
narrowing the small airways that were spatially related to ventilation defects.13,45 When
directly compared with experimental oscillometry impedance measurements, the simulated
results did not completely explain the experimental impedance,13 which may suggest an
interplay between both large and small airways to generate ventilation defects that differs
between patients. In contrast to the previous computational models with promote random
airway abnormalities using a model of a single terminus,5,46 models generated using a
three-dimensional airway tree with patient-specific MRI ventilation and experimental
oscillometry measurements can provide a way to generate models of the large versus small
airways abnormalities in patients with asthma.
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6.4.3 Imaging Phenotypes of Asthma
Quantitative imaging biomarkers provide novel ways to generate imaging-based
phenotyping or clustering of patients with respiratory disease. Imaging plays a large role
in COPD clinical care owing to multiple large cohort studies that have established imaging
phenotypes of COPD47,48 using x-ray computed tomography (CT)49-52 and inhaled gas
MRI.53 In contrast, pulmonary imaging has played a limited role in asthma research and
clinical care because the mechanisms and physiological relevance of regional ventilation
heterogeneity have been poorly understood. In the Severe Asthma Research Program
cohort, one study used CT measurements of proximal airway structure, tissue biomechanics
and gas trapping to identify for the first time imaging phenotypes of asthma.54 Pulmonary
functional MRI measurements have never been evaluated independently or in conjunction
with CT for the generation of imaging phenotypes of asthma. The results in this thesis
have provided an understanding of the pulmonary imaging structure-function determinants
of ventilation heterogeneity in asthma and support the use of MRI results to phenotype
asthma.
The AIM-IT cohort study at Western University in London, Canada is the largest known
cohort study with paired CT and inhaled gas MRI in participants with asthma and provides
a unique platform to explore imaging phenotypes of asthma using both CT and MRI. As
a first step, we used MRI VDP and CT airway measurements to drive imaging-based
clusters of asthma in 60 participants with asthma, including 16 mild-moderate and 44
severe. CT TAC and morphological airway measurements were generated as they were in
Chapter 5. Univariate relationships were assessed between VDP and CT TAC, WA%,
WT, LA and Pi10, with age, sex and BMI included as covariates. These relationships
suggested VDP, TAC, Pi10, age and BMI sufficiently explained the variability in the data.
Based on these five parameters, k-means clustering was used to generate clusters of
participants with similar parameters in MATLAB R2018a (Mathworks, USA). K-means
clustering and corresponding Dunn’s coefficients were used to determine the quality of the
clustering method and were evaluated for 3-6 clusters; Dunn’s coefficient was greatest for
6 clusters (3, 4, 5, 6: 0.05, 0.11, 0.16, 0.18), and the resultant 6 clusters are described in
Figure 6-4.
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Figure 6-4 MR and CT imaging-based clusters of asthma
Description of 6 imaging-based clusters of asthma with values for each variable included
in the clustering. Representative 3He MR (cyan) ventilation images co-registered to
anatomical 1H (grey-scale) and CT airway tree (yellow) are shown for each cluster.
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These results provide a first MRI-driven approach to phenotype asthma as a proof-ofconcept, however for MRI phenotypes to be clinically translated they must be driven by
129

Xe MRI. As previously addressed, 129Xe MRI is more sensitive to airway abnormalities

than 3He and it follows that 129Xe MRI may more sensitively detect different phenotypes.
Moreover, 129Xe MRI measurements of signal intensity heterogeneity may also be included
to further develop MRI phenotypes of asthma. As a final step, it will be critical for these
MRI phenotypes to be anchored to important clinical characteristics of asthma54 such as
age at onset, sex, obesity, severity, disease control, presence and nature of inflammation,
and bronchodilator reversibility. We expect that MRI phenotypes of asthma will be related
to well-established clinical phenotypes and subsequently can be used to guide clinical
treatment decisions, regional therapies and development of novel therapies.

6.5 Significance and Impact
Even though the regional heterogeneity of asthma has been understood for over 60 years
and early MRI results suggested focal abnormalities in patients were not random,
pulmonary structure and function are still clinically characterized by FEV1 and underlying
regional structure-function abnormalities and their variation over time remained uncertain.
Today, asthma is still regarded as random and treatments are geared towards all airways
and not individualized. A better understanding of the mechanisms and physiological
relevance of regional ventilation heterogeneity in asthma is critical at this time as the
number of people in Canada and worldwide with asthma is continuously growing55,56 and
10% of these patients will progressively worsen to develop COPD.57,58
This thesis advances our understanding of asthma the spatially heterogeneous nature of
asthma.

The studies presented in this thesis provide strong evidence that airway

abnormalities and corresponding ventilation defects in asthma are not random, but are
spatially and temporally persistent for up to 7 years. We have provided for the first time,
evidence that disease worsening occurs in previously abnormal airways and that MRI
ventilation abnormalities sensitively predict longitudinal disease worsening towards
development of COPD. Ventilation abnormalities have a specific biomechanical impact
in asthma compared with COPD, however in severe asthma, the airway tree becomes
truncated to a similar degree as moderate COPD.
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The long-term spatial and temporal persistence of airway and ventilation abnormalities in
asthma makes them ideally suited for personalized treatment targets as well as targets for
novel therapy development. Although there are often differences between asthma and
COPD, a similar truncation of the airway tree in asthma and airways-disease predominant
COPD challenges our understanding of these differences. MRI ventilation abnormalities
may be the ‘red flag’ to identify patients at risk for asthma worsening to COPD and provide
a means to stratify these patients for more rigorous treatment.

Armed with these

understandings of regional airway and ventilation abnormalities in asthma, there is
increased potential to guide treatment decisions and regional therapies, predict disease
worsening and ultimately, improve patient outcomes.
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APPENDICES
Appendix A – What is the Minimal Clinically Important Difference for Helium-3
Magnetic Resonance Imaging Ventilation Defects?
In this article, we determined the minimal clinically important difference for MRI
ventilation defects which accounts for both patient-reported asthma control and the
ventilation defect measurement error. This work was a necessary first step in order to
evaluate longitudinal changes in ventilation defects in Chapter 4.
The contents of this appendix were previously published in the European Respiratory
Journal as a research letter: RL Eddy, S Svenningsen, DG McCormack, G Parraga. What
is the minimal clinically important difference for helium-3 magnetic resonance imaging
ventilation defects? Eur Respir J. 2018;51(6). Permission to reproduce this article was
granted by the European Respiratory Society (ERS) and is provided in Appendix B.
To the Editor:
Pulmonary magnetic resonance imaging (MRI) using inhaled polarised gases provides a
way to directly visualise and sensitively measure lung ventilation abnormalities or
ventilation defects;1 the burden in individual patients may be directly quantified as the
percent ventilation volume,2 ventilation defect volume (VDV)3 or ventilation defect
percent (VDP)4 which is VDV normalised to the total lung volume. In patients with
asthma, MRI ventilation defects worsen during methacholine5 and exercise challenge5,6
and respond to bronchodilation.5,6 However, it is still unknown if quantitative changes in
MRI ventilation abnormalities directly reflect changes in patient-related outcomes like
symptoms; this is important when considering MRI for clinical and research studies in
asthma patients which requires an understanding of the minimal clinically important
difference (MCID).
First described in 1989,7 the MCID reflects the smallest measurement difference that
patients perceive as beneficial. MCID estimations typically involve patient perception but
up to nine methods have been reported,8 and no standard for calculating MCID has been
established. For example, changes in clinical parameters provide the foundation for the socalled anchor-based MCID approach,9 in which patient- or clinician-reported metrics serve
as ‘anchors’. On the other hand, distribution-based or data-driven approaches reflect
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instrument error and precision, including the standard error of measurement (SEM)10 which
has been validated as a proxy for the MCID.
Here we estimate the MCID of MRI VDV and VDP using distribution- and anchor-based
approaches.

We used both approaches because MRI VDV and VDP measurement

precision are heavily dependent on the algorithm used and the reproducibility of the
quantification. First, we used the SEM to estimate the distribution-based MCID for VDV
based on algorithm precision previously published.3 As previously described,3 pulmonary
MRI VDV is quantified using a semi-automated algorithm in units of mL while VDP is
measured as a percentage of the thoracic cavity volume in units of %. Based on five
repeated segmentation rounds in 15 subjects, the SEM for VDP was calculated as the
square root of the repeated measures intra-observer VDP variance and was 40 mL.3 We
also consider the smallest detectable difference (SDD) which generates confidence about
measurement uncertainty. The previously calculated SDD for VDV was 110 mL,3 and
because this is larger than the SEM, it is possible that an observed change less than the
SEM would be due to measurement error. In contrast, if the SDD is smaller than the MCID,
it is possible to distinguish a clinically important change with adequate measurement
precision. To be certain that a clinically important change is not due to measurement error,
we propose to conservatively use the MCID of 110 mL which reflects measurement
precision, instead of 40 mL which was the measured SEM.
For the anchor-based method, we used the patient-reported and validated asthma control
questionnaire (ACQ) score11 as the anchor and the significant relationship between ACQ
score and MRI VDP previously published in 18 asthmatic patients.12 In these asthmatics,
the relationship between ACQ score and VDP was determined by equation of their linear
relationship as VDP=7.5ACQ – 5.0.12

The MCID for ACQ score was previously

determined to be 0.511 and therefore based on the linear relationship, a 0.5 change in ACQ
would result in a 4% VDP difference. Therefore, using ACQ score as an anchor, the VDP
MCID is 4%.
While ACQ score and exacerbations may be used in asthma clinical trials, the most
commonly-used objective endpoint is the forced expiratory volume in one second (FEV1);
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the MCID for FEV1 is often described as a range which for asthmatics is 100–200 mL.13
In contrast with FEV1 which is dominated by the large airways,14 MRI is sensitive to all
airways and the MCID is 110 mL for VDV (distribution-based) and 4% for VDP (anchorbased). The 4% VDP MCID can be translated to a VDV of 200 mL based on the mean
thoracic cavity volume segmented from MRI which was reported to be 5.0 L.3 In a similar
manner, the VDV MCID of 110 mL is equivalent to approximately 2%. Thus, we report a
range of 110–200 mL for VDV and 2–4% for VDP as MCID ranges. To illustrate the
quantitative meaning of the MCID of VDP in individual patients, Figure 1 shows MRI for
three patients with asthma with visually and quantitatively improved ventilation following
bronchodilation (increasing VDP improvement shown from left to right). For subject S1
there was a change in VDV/VDP equivalent to the distribution-based MCID or SDD. For
subjects S2 and S3, there were post-bronchodilator changes in VDV/VDP that were similar
in magnitude to the anchor-based MCID estimate. Notably, S1 and S3 showed clinically
significant post-bronchodilator FEV1 changes (≥ 200 mL and ≥ 12%), while S2 did not.
The sensitivity of MRI to post-bronchodilator changes highlights a unique opportunity for
pulmonary MRI to help explain subjective or patient-perceived improvements (i.e. ACQ
or quality of life improvements) that are not reflected by FEV1. The number of experts
using hyperpolarised gas MRI in asthma clinical trials is still very small so it is important
to consider the MRI VDP MCID in the context of the MCID of other established asthma
biomarkers. The MCID we calculated for MRI VDP is similar to the MCID for FEV1 in
asthma at 110-200 mL. Moreover, we have used the ACQ MCID of 0.511 to determine the
upper limit of this range at 200 mL and therefore these are already intrinsically related.
The MCID for the asthma quality of life questionnaire (AQLQ) is also 0.515 and though
the relationship between VDP and AQLQ has not been directly established, we previously
showed that VDP is significantly worse in patients with lower quality of life (AQLQ<5).12
MRI VDP directly detects early changes in clinically important pathologies with high
reproducibility.16 Taken together, this means that MRI has both the sensitivity and
precision needed for clinical studies, although the complexity and cost of the acquisition
of these measurements compared to other tests is still a limitation.
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Figure 1. Change in asthmatic magnetic resonance imaging (MRI) ventilation after
bronchodilator (BD) for three representative subjects. Three asthmatic subjects exhibited
visual changes in MR ventilation post-BD. A 45-year-old male (S1) underwent an
improvement in ventilation equal to the smallest detectable difference and distributionbased minimal clinically important difference (MCID), while a 28-year-old-female (S2)
and a 31-year-old female (S3) underwent improvements at least as large as the anchorbased MCID. Notably, S1 and S3 also exhibited clinically significant changes in forced
expiratory volume in 1 s (FEV1) (≥200 mL and 12%) but S2 did not. VDV: ventilation
defect volume; VDP: ventilation defect percent.
It is important to consider the 3He MRI results in the context of future development of
129

Xe MRI which is much less costly to acquire. In this regard, we previously directly

compared 3He and

129

Xe MRI and showed that

129

Xe VDP was greater than 3He VDP in

asthmatics;17 this suggested that there was enhanced sensitivity to airway abnormalities
using 129Xe gas which we speculated was due to the viscosity and diffusivity of the gas, so
that

129

Xe VDP was systematically larger than 3He VDP in asthmatics. Based on this

important information, we speculate that the slope of the linear relationship between ACQ
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and

129

Xe VDP, and thus the MCID, would be similar to 3He MRI VDP, but these

calculations still need to be undertaken in a prospective

129

Xe MRI study. It is also

important to note that, though there is no standard for calculating MCID values, the anchorbased estimation we generated here was based on cross-sectional data and did not reflect
within-subject variability or response to therapy. Considering the original definition of
MCID,7 “within-subject” differences in response to therapy will be important to investigate
in prospectively designed clinical trials.
In summary, pulmonary MRI biomarkers of ventilation have already provided some
intriguing results in patients with asthma, but to our knowledge, MRI biomarkers have not
been used in large-scale clinical trials of potential new therapies. Other considerations
aside (i.e. technological and financial), this lack of uptake may reflect the lack of a deep
understanding of the relationship between MRI biomarkers with how patients perceive
symptoms. We provide calculations of MCID for 3He MRI VDV and VDP to support the
use of MRI in the research and development of novel therapies, as well as therapy decisions
or n=1 trials, towards more precise decision making in individual patients.
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Ventilation Heterogeneity in Severe Asthma by Dupilumab. Thorax. 2019;74(11):10878.
FEATURED ON JOURNAL COVER
RL Eddy, S Svenningsen, C Licskai, DG McCormack, G Parraga. Hyperpolarized
Helium 3 MRI in Mild-to-Moderate Asthma: Prediction of Postbronchodilator
Reversibility. Radiology. 2019;293(1):212-20.
EDITORIAL HIGHLIGHT, FEATURED ON JOURNAL COVER
S Svenningsen, E Haider, C Boylan, M Mukherjee, RL Eddy, DPI Capaldi, G Parraga,
P Nair. CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma. Chest.
2019;155(6):1178-89.
RL Eddy, A Westcott, GN Maksym, G Parraga, RJ Dandurand. Oscillometry and
Pulmonary Magnetic Resonance Imaging in Asthma and COPD. Physiol Rep.
2019;7(1):e13955.
RL Eddy, S Svenningsen, DG McCormack, G Parraga. What is the Minimal Clinically
Important Difference for Helium-3 Magnetic Resonance Imaging Ventilation Defects?
Eur Respir J. 2018;51(6).
HM Young, F Guo, RL Eddy, GN Maksym, G Parraga. Oscillometry and Pulmonary
MRI of Ventilation Heterogeneity in Obstructive Lung Disease: Relationship to Quality
of Life and Disease Control. J Appl Physiol. 2018;125(1):73-85.
S Svenningsen, RL Eddy, HF Lim, PG Cox, P Nair, G Parraga. Sputum Eosinophilia
and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma. Am J
Respir Crit Care Med. 2018;197(7):876-84.
EDITORIAL HIGHLIGHT
DPI Capaldi, RL Eddy, S Svenningsen, F Guo, JSH Baxter, AJ McLeod, P Nair, DG
McCormack, G Parraga for the Canadian Respiratory Research Network. Free-breathing

204

15.

16.
17.

18.

19.

20.

21.

Pulmonary MR Imaging to Quantify Regional Ventilation. Radiology. 2018;287(2):693704.
RL Eddy, S Svenningsen, A Kassay, DG McCormack, P Nair, G Parraga for the
Canadian Respiratory Research Network. This is what Asthma Looks Like: Review of
New and Emerging Functional Imaging Methods and Results. Canadian Journal of
Respiratory, Critical Care and Sleep Medicine. 2018;2(1):27-40.
HM Young, RL Eddy, G Parraga. MRI and CT Lung Biomarkers: Towards an In Vivo
Understanding of Lung Biomechanics. Clin Biomech. 2019;66:107-122.
DPI Capaldi, K Sheikh, RL Eddy, F Guo, S Svenningsen, P Nair, DG McCormack, G
Parraga for the Canadian Respiratory Research Network. Free-breathing Pulmonary
MRI: Response to Bronchodilator and Bronchoprovocation in Severe Asthma. Acad
Radiol. 2017;24(10):1268-76.
M Kirby, RL Eddy, D Pike, S Svenningsen, DD Sin, HO Coxson, DG McCormack, G
Parraga for the Canadian Respiratory Research Network. MRI Ventilation
Abnormalities Predict Quality-of-Life and Lung Function Changes in Mild-to-Moderate
COPD: Longitudinal TINCan Study. Thorax. 2017;72(5):475-7.
K Sheikh, F Guo, DPI Capaldi, A Ouriadov, RL Eddy, S Svenningsen, G Parraga for
the Canadian Respiratory Research Network. Ultra-short Echo Time MRI Biomarkers
of Asthma. J Magn Reson Imaging. 2016;45(4):1204-15.
F Guo, S Svenningsen, RL Eddy, DPI Capaldi, K Sheikh, A Fenster, G Parraga.
Anatomical Pulmonary Magnetic Resonance Imaging Segmentation for Regional
Structure-Function Measurements of Asthma. Med Phys. 2016;43(6):2911-26.
D Pike, M Kirby, RL Eddy, F Guo, DPI Capaldi, A Ouriadov, DG McCormack, G
Parraga. Regional Heterogeneity of Chronic Obstructive Pulmonary Disease
Phenotypes: Pulmonary 3He Magnetic Resonance Imaging and Computed Tomography.
COPD. 2016;13(5):601-9.

In Revision (1)
1.

B
1.

2.

S Svenningsen, MJ McIntosh, A Ouriadov, NB Konyer, RL Eddy, DG McCormack,
MD Noseworthy, P Nair, G Parraga. Reproducibility of Hyperpolarized 129Xe MRI in
Severe Asthma to Evaluate Clinical Trial Feasibility. Manuscript ID ARAD-S-1901476.R1.
Book Chapters (2)
AL Barker, RL Eddy, H Yaremko, M Kirby, G Parraga. Structure-Function Imaging
of Asthma: Airways and Ventilation Biomarkers. In: Pulmonary Functional Imaging –
Basics and Clinical Applications. Ohno Y, Hatabu H and Kauczor HU (Eds). Springer
2018. Submitted September 1, 2018.
DPI Capaldi, RL Eddy, G Parraga. Pulmonary MRI in Clinical Trials. In: MRI of the
Lung Second Edition. p. 453-478. Kauczor HU and Wielpütz MO (Eds). ISBN: 978-3319-42616-7. Medical Radiology. Springer, Cham 2016.
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C

Peer-Reviewed Published Conference Proceedings (2)

1.

AM Matheson, DPI Capaldi, F Guo, RL Eddy, DG McCormack, G Parraga. Fourier
Decomposition Free-breathing 1H MRI Perfusion Maps in Asthma. Proc. SPIE 10949,
Medical Imaging 2019: Image Processing, 1094912 (15 March 2019).
JL MacNeil, DPI Capaldi, RL Eddy, AR Westcott, AM Matheson, AL Barker, C Ong
Ly, DG McCormack, G Parraga. Development and Evaluation of Pulmonary Imaging
Multi-Parametric Response Maps for Deep Phenotyping of Chronic Obstructive
Pulmonary Disease. Proc. SPIE 10953, Medical Imaging 2019: Biomedical
Applications in Molecular, Structural, and Functional Imaging, 109530J (15 March
2019).

2.

ABSTRACTS AND PRESENTATIONS
A
1.

2.

3.

4.

5.

6.

7.

Submitted Abstracts (9)
MJ McIntosh, RL Eddy, JL MacNeil, AM Matheson, G Parraga. Automated
Quantification of Spatially Abnormal 129-Xe MRI Ventilation and Perfusion:
Implications for Lung Cancer, Asthma and COPD. Joint American Association of
Physicists in Medicine – Canadian Organization of Medical Physicists Meeting
Vancouver, Canada July 12-16, 2020.
FR Salerno, TJ Lindenmaier, AM Matheson, RL Eddy, MJ McIntosh, J Dorie, G
Parraga, CW McIntyre. Noninvasive assessment of pulmonary hypertension using
quantitative imaging in hemodialysis patients. European Renal Association – European
Dialysis and Transplant Association 2020 Milan, Italy June 6-9, 2020.
RL Eddy, C Licskai, DG McCormack, G Parraga. Novel MRI-based Clusters of
Asthma: Pulmonary Functional MRI and CT. International Society of Magnetic
Resonance in Medicine Annual Scientific Meeting 2020 Sydney, Australia April 18-23,
2020. Accepted oral presentation
AM Matheson, RL Eddy, JL MacNeil, MJ McIntosh, G Parraga. Fully-automated 1H
Thoracic Cavity Segmentation for Hyperpolarized Gas Imaging Using a Convolutional
Neural Network. International Society of Magnetic Resonance in Medicine Annual
Scientific Meeting 2020 Sydney, Australia April 18-23, 2020. Accepted oral
presentation
MJ McIntosh, RL Eddy, D Knipping, T Lindenmaier, DG McCormack, C Licskai, C
Yamashita, G Parraga. Supervised Shallow Learning of 129Xe MRI Texture Features to
Predict Response to Anti-IL5 Biologic Therapy in Severe Asthma. International Society
of Magnetic Resonance in Medicine Annual Scientific Meeting 2020 Sydney, Australia
April 18-23, 2020. Accepted oral presentation
RL Eddy, MJ McIntosh, AM Matheson, D Knipping, C Licksai, DG McCormack, G
Parraga. 129Xe MRI Ventilation Heterogeneity Phenotypes of Asthma. American
Thoracic Society Annual Scientific Meeting 2020 Philadelphia, PA May 15-20, 2020.
Accepted oral presentation
MJ McIntosh, RL Eddy, D Knipping, AL Barker, T Lindenmaier, C Yamashita, G
Parraga. Response to Benralizumab in Severe Asthma: 129Xe MRI, Oscillometry and
Clinical Measurements. American Thoracic Society Annual Scientific Meeting 2020
Philadelphia, PA May 15-20, 2020. Accepted oral presentation
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8.

9.

B
1.
2.
3.
4.

5.
6.

7.

C
1.

2.

3.

4.

AM Matheson, RL Eddy, AL Barker, DG McCormack, G Parraga. Perfusion
Abnormalities in COPD: How do Emphysema and Airways Contribute? American
Thoracic Society Annual Scientific Meeting 2020 Philadelphia, PA May 15-20, 2020.
Accepted poster discussion presentation
H Serajeddini, RL Eddy, D Knipping, T Lindenmaier, KJ Bosma, I Dhaliwal, G
Parraga. Longitudinal 129Xe MRI in a Survivor of Respiratory Failure Related to Ecigarette Use. American Thoracic Society Annual Scientific Meeting 2020 Philadelphia,
PA May 15-20, 2020. Accepted thematic poster presentation
Invited Oral Presentations (7)
Y Habis, RL Eddy (co-presenters). Airway Remodeling: A Clinical and Imaging
Review. London, ON March 3, 2020.
RL Eddy. MRI Ventilation Heterogeneity and Oscillometry: Where Do We Go Next?
Montreal Oscillometry Summer Seminar Montreal, QC July 25-26, 2019.
RL Eddy. Undergrad to Grad School to Post-PhD: Polarizing Perspectives. Summer
Student Lunch Seminar Series, Robarts Research Institute, London, ON July 9, 2019.
RL Eddy. Pulmonary MRI of Airways Disease: Space-time Explorations. Centre for
Heart Lung Innovation Seminar, University of British Columbia and St. Paul’s Hospital
Vancouver, BC June 28, 2019.
RL Eddy. Pulmonary MRI: Polarizing Perspectives. Department of Radiology Grand
Rounds, University of British Columbia Vancouver, BC June 26, 2019.
RL Eddy, G Parraga. Oscillometry and Pulmonary MRI Measurements of Ventilation
Heterogeneity in Obstructive Lung Disease: Relationship to Quality of Life and Disease
Control. American Thoracic Society Respiratory Structure and Function Assembly
Journal Club Webinar. February 26, 2019.
RL Eddy, RJ Dandurand, HM Young, GN Maksym, G Parraga. Relationship Between
Pulmonary Functional MRI and Oscillometry. Montreal Oscillometry Summer Seminar
Montreal, QC August 2, 2018.
Proffered Oral Presentations (18) *presenter
RL Eddy,* C Licskai, G Parraga. Severe Asthma: Where do the Airways Go and Does
it Matter? 9th International Workshop on Pulmonary Functional Imaging New Orleans,
LA October 18-20, 2019. Selected for Top 3 Young Investigator Finalist
RL Eddy,* A Westcott, GN Maksym, DG McCormack, G Parraga. Differences
Between 3He and 129Xe Ventilation Heterogeneity Explained Using Oscillometry.
International Society of Magnetic Resonance in Medicine Annual Scientific Meeting
2019 Montreal, Canada May 11-16, 2019.
RL Eddy,* A Westcott, GN Maksym, DG McCormack, G Parraga. Can Oscillometry
Explain Differences Between 3He and 129Xe Ventilation Heterogeneity? 17th Annual
Imaging Network Ontario Symposium London, ON, Canada, March 28-29, 2019.
AL Barker,* RL Eddy, AM Matheson, A Westcott, GR Washko, G Parraga. Are MRI
Ventilation Defects and CT Vascular Pruning Related in Bronchiectasis and COPD
Patients? 17th Annual Imaging Network Ontario Symposium London, ON, Canada,
March 28-29, 2019.
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5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

AM Matheson,* RL Eddy, DPI Capaldi, F Guo, DG McCormack, G Parraga. Multiscalar Perfusion and Ventilation Defects in Asthma. 17th Annual Imaging Network
Ontario Symposium London, ON, Canada, March 28-29, 2019.
HM Young, F Guo, RL Eddy,* GN Maksym, G Parraga. Pulmonary MRI
Measurements of Ventilation Heterogeneity in Obstructive Lung Disease: Relationships
to Oscillometry, Quality of Life and Disease Control. International Society of Magnetic
Resonance in Medicine Annual Scientific Meeting 2018 Paris, France June 16-21, 2018.
RL Eddy*, S Svenningsen, DG McCormack, G Parraga. What is the Minimal Clinically
Important Difference for MRI Ventilation Defects? London Imaging Discovery Day
2018 London ON, June 14, 2018.
RL Eddy,* S Svenningsen, DG McCormack, G Parraga. What is the MCID for MRI
Ventilation Heterogeneity? Canadian Respiratory Research Network 2018 Annual
General Meeting Ottawa, ON January 18-19, 2018.
DPI Capaldi,* JSH Baxter, AJ McLeod, RL Eddy, S Svenningsen, F Guo, DG
McCormack, G Parraga. Measuring Specific Ventilation using Four-dimensional
Magnetic Resonance Imaging: A Novel Physiological Biomarker of Asthma. 103rd
Scientific Assembly and Annual Meeting of the Radiological Society of North America
Chicago, IL November 26-December 1, 2017.
RL Eddy,* K Sheikh, DPI Capaldi, S Svenningsen, DG McCormack, G Parraga.
Ventilation Heterogeneity Reversibility: Asthma, COPD or ACOS? European
Respiratory Society International Congress 2017 Milan, Italy September 9-13, 2017.
S Svenningsen,* RL Eddy, HF Lim, P Nair, G Parraga. Inflammatory and NonInflammatory Contributions to Ventilation Heterogeneity in Severe, Poorly-controlled
Asthmatics. American Thoracic Society Annual Scientific Meeting 2017 Washington
DC May 19-24, 2017.
RL Eddy, DPI Capaldi, K Sheikh, S Svenningsen, DG McCormack, G Parraga.
Pulmonary MRI Ventilation Defects in Asthma: Stochastic or Deterministic?
International Society of Magnetic Resonance in Medicine Annual Scientific Meeting
2017 Honolulu, HI April 22-27, 2017.
RL Eddy,* DPI Capaldi, K Sheikh, S Svenningsen, DG McCormack, G Parraga.
Pulmonary MRI Ventilation Defects in Asthma: Stochastic or Deterministic? 8th
International Workshop on Pulmonary Functional Imaging Seoul, South Korea March
24-26, 2017.
RL Eddy,* DPI Capaldi, K Sheikh, S Svenningsen, DG McCormack, G Parraga.
Pulmonary MRI Ventilation Defects in Asthma: Stochastic or Deterministic? 15th
Annual Imaging Network Ontario Symposium London, ON, Canada, March 15-16,
2017.
RL Eddy,* S Svenningsen, DG McCormack, G Parraga. MRI Ventilation Defects in
Asthma: Space and Time Explorations of Non-randomness. Canadian Respiratory
Research Network 2017 Annual General Meeting Ottawa, ON January 12-13, 2017.
RL Eddy, D Pike, K Sheikh, GA Paulin, M Kirby,* DG McCormack, G Parraga,
Testing the Fletcher-Peto Assumptions using Pulmonary Imaging Biomarker
Longitudinal Measurements. American Thoracic Society Annual Scientific Meeting
2016 San Francisco, CA May 13-18, 2016.
K Sheikh,* F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG
McCormack, G Parraga. What does Magnetic Resonance Imaging Signal-Intensity
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mean in Asthma? American Thoracic Society Annual Scientific Meeting 2016 San
Francisco, CA May 13-18, 2016.
18. K Sheikh,* F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG
McCormack, G Parraga. What does Magnetic Resonance Imaging Signal-Intensity
mean in Asthma? London Health Research Day 2016, London, Ontario, Canada. March
29, 2016.
D

Proffered Poster Presentations (31) *presenter

1.

FR Salerno,* RL Eddy, AM Matheson, G Parraga, CW McIntrye. Lung Ventilation
Abnormalities in Chronic Hemodialysis Patients with Hyperpolarized 129Xe Gas
Magnetic Resonance Imaging. American Society of Nephrology Kidney Week 2019
Washington DC November 5-10, 2019.
2. RL Eddy, A Westcott, M Kirby, DG McCormack, G Parraga. CT Pulmonary Vessel
Volume in Ex-smokers with Normal FEV1. European Respiratory Society International
Congress 2019 Madrid, Spain September 28-October 2, 2019. Traditional poster.
3. RL Eddy,* GN Maksym, RJ Dandurand, G Parraga. Oscillometry Detects Different
Airway Abnormalities that Manifest as MRI Ventilation Heterogeneity in Asthma and
COPD. American Thoracic Society Annual Scientific Meeting 2019 Dallas, TX May
17-22, 2019. Poster discussion.
4. RL Eddy,* DG McCormack, M Kirby, G Parraga. CT Airway Count as a Biomarker of
Asthma Pathogenesis: Severe Asthma and ACOS in Never-smokers. American Thoracic
Society Annual Scientific Meeting 2019 Dallas, TX May 17-22, 2019. Poster
discussion. *Selected for Canadian Thoracic Society Annual Poster Competition
5. AL Barker,* RL Eddy, AM Matheson, AR Westcott, GR Washko, G Parraga.
Bronchiectasis, Vascular Pruning and Ventilation Defects in COPD and Bronchiectatic
Patients: Are They Related? American Thoracic Society Annual Scientific Meeting
2019 Dallas, TX May 17-22, 2019. Poster discussion.
6. AM Matheson,* RL Eddy, DPI Capaldi, F Guo, DG McCormack, G Parraga. Perfusion
Abnormalities and Ventilation Heterogeneity in Asthma. American Thoracic Society
Annual Scientific Meeting 2019 Dallas, TX May 17-22, 2019. Poster discussion.
7. S Svenningsen,* E Haider, C Boylan, M Mukherjee, RL Eddy, DPI Capaldi, G Parraga,
P Nair. Airway Luminal Contributors to MRI Ventilation Heterogeneity in Severe
Asthma. American Thoracic Society Annual Scientific Meeting 2019 Dallas, TX May
17-22, 2019. Poster discussion.
8. A Westcott,* A Ouriadov, RL Eddy, DG McCormack, M Kirby, G Parraga.
Compressed Sensing Hyperpolarized Gas Ventilation MRI: Towards a Maximal
Clinically Acceptable Acceleration Factor. International Society of Magnetic
Resonance in Medicine Annual Scientific Meeting 2019 Montreal, Canada May 11-16,
2019. Digital poster.
9. AL Barker,* A Westcott, RL Eddy, DG McCormack, G Parraga, A Ouriadov.
Feasibility of Single Breath-hold Isotropic Voxel 129Xe in Patients. International Society
of Magnetic Resonance in Medicine Annual Scientific Meeting 2019 Montreal, Canada
May 11-16, 2019. Digital poster.
10. S Svenningsen,* A Ouriadov, NB Konyer, RL Eddy, A Westcott, DG McCormack, M
Kjarsgaard, MD Noseworthy, P Nair, G Parraga. Two-site Reproducibility of
Hyperpolarized 129Xe MRI Ventilation in Severe Asthma: Implications for Multicenter
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11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

Clinical Studies. International Society of Magnetic Resonance in Medicine Annual
Scientific Meeting 2019 Montreal, Canada May 11-16, 2019. Digital poster.
RL Eddy,* HM Young, A Kassay, DPI Capaldi, S Svenningsen, DG McCormack, G
Parraga. Contributions of Large Versus Small Airways to MRI Ventilation
Heterogeneity in Asthmatics. International Society of Magnetic Resonance in Medicine
Annual Scientific Meeting 2018 Paris, France June 16-21, 2018. Traditional Poster.
S Svenningsen,* N Zha, RL Eddy, DPI Capaldi, M Kjarsgaard, K Radford, P Nair, G
Parraga. MRI Ventilation Texture Features Discriminate Severe Asthmatics with and
without Eosinophilic Airway Inflammation. International Society of Magnetic
Resonance in Medicine Annual Scientific Meeting 2018 Paris, France June 16-21, 2018.
Traditional Poster.
A Westcott,* RL Eddy, DPI Capaldi, HM Young, DG McCormack, G Parraga. Novel
Quantification of Ventilation Heterogeneity Patterns in Hyperpolarized 3He MRI.
International Society of Magnetic Resonance in Medicine Annual Scientific Meeting
2018 Paris, France June 16-21, 2018. E-poster.
RL Eddy,* S Svenningsen, DG McCormack, G Parraga. Determining the Minimal
Clinically Important Difference: MRI Ventilation Defect Percent in Asthmatics.
American Thoracic Society Annual Scientific Meeting 2018 San Diego, CA May 1723, 2018. Poster Discussion.
S Svenningsen,* RL Eddy, DPI Capaldi, M Kjarsgaard, K Radford, G Parraga, P Nair.
Effect of anti-Th2 Therapy on MRI Ventilation Heterogeneity in Prednisone-dependent
Asthma. American Thoracic Society Annual Scientific Meeting 2018 San Diego, CA
May 17-23, 2018. Poster Discussion.
RL Eddy,* S Svenningsen, DG McCormack, G Parraga. What is the Minimal Clinically
Important Difference for MRI Ventilation Defects? London Health Research Day 2018,
London, Ontario, Canada. May 10, 2018. Traditional Poster.
RL Eddy,* S Svenningsen, DG McCormack, G Parraga. Five-year MRI Study of
Ventilation Heterogeneity in Asthma. European Respiratory Society International
Congress 2017 Milan, Italy. September 9-13, 2017. Thematic Poster.
HM Young, F Guo, RL Eddy,* C Church, G Maksym, G Parraga. Forced Oscillation
Technique and MRI Predictions of Airway Reactance in Moderate-Severe Asthma.
European Respiratory Society International Congress 2017 Milan, Italy. September 913, 2017. Poster Discussion.
DPI Capaldi, K Sheikh, RL Eddy,* S Svenningsen, DG McCormack, G Parraga.
Fourier-decomposition of Free-breathing Pulmonary Proton MRI in Asthma. European
Respiratory Society International Congress 2017 Milan, Italy. September 9-13, 2017.
Thematic Poster.
RL Eddy, S Svenningsen, DG McCormack, G Parraga. Five-year MRI Study of
Ventilation Heterogeneity in Asthmatics: Where Do the Defects Go? American
Thoracic Society Annual Scientific Meeting 2017 Washington DC May 19-24, 2017.
Thematic Poster.
RL Eddy, K Sheikh, DPI Capaldi, S Svenningsen, C Licskai, DG McCormack, G
Parraga. Ventilation Heterogeneity Reversibility: Asthma, COPD or ACOS? American
Thoracic Society Annual Scientific Meeting 2017 Washington DC May 19-24, 2017.
Poster Discussion.
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22. RL Eddy, DPI Capaldi, K Sheikh, S Svenningsen, DG McCormack, G Parraga.
Probability Mapping of Lung Functional Abnormalities in Asthma using MRI: Lung
Atlas Explorations of Non-randomness. American Thoracic Society Annual Scientific
Meeting 2017 Washington DC May 19-24, 2017. Poster Discussion.
23. A Bhalla,* K Sheikh, HM Young, RL Eddy, DG McCormack, TM Luu, S Katz, G
Parraga. Asthma Phenotypes in Adult Survivors of Premature Birth Using Functional
Magnetic Resonance Imaging. American Thoracic Society Annual Scientific Meeting
2017 Washington DC May 19-24, 2017. Poster Discussion.
24. DPI Capaldi, K Sheikh, RL Eddy, S Svenningsen, M Kirby, DG McCormack, G
Parraga. Asthma Ventilation Abnormalities Measured using Fourier-Decomposition
Free-breathing Pulmonary 1H MRI. International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 201 Honolulu, HI April 22-27, 2017. E-poster.
25. RL Eddy,* K Sheikh, DPI Capaldi, S Svenningsen, C Licskai, DG McCormack, G
Parraga. Ventilation Heterogeneity Reversibility: Asthma, COPD or ACOS? London
Health Research Day 2016, London, Ontario, Canada. March 28, 2017. Thematic
Poster.
26. M Fennema, RL Eddy,* DPI Capaldi, K Sheikh, S Svenningsen, C Licskai, DG
McCormack, G Parraga. The Abnormal Airways that Dominate Asthma Attack: New
clues using ventilation MRI during Exercise- and Methacholine-Challenge. American
Thoracic Society Annual Scientific Meeting 2016 San Francisco, CA May 13-18, 2016.
Poster Discussion.
27. F Guo, S Svenningsen, RL Eddy, M Fennema, DG McCormack, G Parraga. Towards
Image-guided Asthma Therapy: A clinical pipeline to generate MRI Sub-segmental
Ventilation Measurements. American Thoracic Society Annual Scientific Meeting 2016
San Francisco, CA May 13-18, 2016. Poster Discussion.
28. F Guo, K Sheikh, RL Eddy, DPI Capaldi,* DG McCormack, A Fenster, G Parraga. A
Segmentation Pipeline for Measuring Pulmonary Ventilation Suitable for Clinical
Workflows and Decision-making. International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 2016 Suntec City, Singapore May 7-13, 2016. Eposter.
29. M Fennema, S Svenningsen, RL Eddy, D Leary, G Maksym, G Parraga. Can the Forced
Oscillation Technique and a Computational Model of Respiratory System Mechanics
Explain Asthma Ventilation Defects? International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 2016 Suntec City, Singapore May 7-13, 2016.
Thematic Poster.
30. RL Eddy,* M Kirby, D Pike, K Sheikh, GA Paulin, DG McCormack, G Parraga.
Testing the Fletcher-Peto Assumptions using Pulmonary Imaging Biomarker
Longitudinal Measurements. London Health Research Day 2016, London, Ontario,
Canada. March 29, 2016. Thematic Poster.
31. RL Eddy,* M Doughty, I Hegazzi. Breast Imaging Using Electrical Impedance
Tomography. McMaster University Electrical and Computer Engineering (ECE) Expo
2015 Hamilton, Ontario, Canada. April 7, 2015 (Engineering Design Project poster).
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POST-GRADUATE EDUCATION DEVELOPMENT AND EXPERIENCES
04/2019

Poster Judge
Medical Biophysics Undergraduate Research Day, Western
University

03/2019

Biotechnology Debate Judge
Western Advancement in Medicine Society (AIMS) Club
Role: Judge 20-minute debate by presenting feedback to
debate teams on validity and strength of arguments and
determine a winning side.

09/2018-04/2019

Career Profile Advisor
The Student Success Centre, Western University
Role: Deliver career and employment support to Western
University students as part of the Career Counselling team
with extensive training on resume, cover letter, CV and
LinkedIn Profile development

05/2018-

Oscillometry Standardization Project
Oscillometry Unit, Centre for Innovative Medicine, Montreal,
Canada
Objective: Standardization of oscillometry results across five
commercially marketed devices and a wave tube
Role: Attend meetings, and read and edit draft manuscript(s)

10/2017-12/2019

Deep Learning Club Co-coordinator
Co-coordinators: Andrew Westcott, Wenyao Xia, Patricia Johnson
Goal: Monthly seminar for introductory deep learning with specific
applications in medical imaging and health information science, for
multi-disciplinary trainees
Role: meeting scheduling and organization, preparation of
meeting content, presentations during meetings

06/2017/-04/2018

Graduate Student Mentor/Supervisor
Undergraduate Student: Robert DiCesare, BSc Candidate Physiology
and Pharmacology
Project: “Resting State Brain Connectivity & Lung Function
in Healthy Volunteers during Methacholine-induced
Bronchoconstriction Mimicking Asthma Attack”

01/2017-03/2018

Graduate Student Mentor/Supervisor
Undergraduate Student: Andrea Kassay, BSc Candidate Medical
Biophysics
Project: “Intraobserver Repeatability of CT Airway
Measurements in Patients with Asthma”
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04/2016-03/2017

Volunteer Research Assistant
Study: Canadian Alliance for Healthy Hearts and Minds, Robarts
Research Institute
Role: Calling and scheduling study visit appointments for
participants, performing participant study visits including
physical measurements, cognitive assessments (Montreal
Cognitive Assessment, Digital Symbol Substitution) and
preparation for MRI and completing appropriate study forms
and paperwork

RESEARCH FUNDING APPLICATIONS
Lawson Health Research Institute Spring 2016 Internal Research Fund (Successful)
MRI-guided Endobronchial Thermoplasty for Severe Uncontrolled Asthma
June 2016
PROFESSIONAL SOCIETIES
2017European Respiratory Society (ERS)
Student Member
2016Canadian Respiratory Research Network (CRRN)
Trainee Member
2015International Society for Magnetic Resonance in Medicine (ISMRM)
Student Member
2015American Thoracic Society (ATS)
Trainee Member
2015Canadian Thoracic Society (CTS)
PhD Student Member
2015Canadian Organization of Medical Physicists (COMP)
Student Member
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